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1 Summary 
The different functions of RNA have led to great and increasing interest in the field of 
synthetic biology. One such example of versatile RNA molecules used in synthetic biology is 
aptamers. Aptamers are able to bind to a wide range of target molecules with a high affinity 
and specificity, which is why they are often compared to antibodies. Using the SELEX 
method, they can be generated in vitro against target molecules for a broad range of possible 
applications. In nature, they work as the sensing domain of riboswitches and regulate gene 
expression by binding their cognate target molecule. Riboswitches can also be generated 
synthetically from in vitro generated aptamers.  
In the course of this work, a novel RNA aptamer which selectively binds to one of two light-
induced isoforms of a specific small molecule ligand (azoCm) was developed. The potential 
function of such an aptamer as a riboswitch was evaluated. 
A previously carried out SELEX experiment against azoCm yielded a specifically binding 
aptamer (aptamer 42). At the beginning of this work, its secondary structure was analyzed 
using in-line probing. As it was previously shown aptamer 42 could not work as a riboswitch 
regulating GFP expression in the model organisms Saccharomyces cerevisiae, other aptamers 
from the same SELEX were tested under the same conditions using in vivo screening. As no 
functional riboswitch could be identified, a new SELEX experiment using a new aptamer 
library was started.  
The new affinity SELEX yielded aptamers specifically binding to azoCm. However, in vivo 
screening of aptamers from this SELEX did not result in an azoCm dependent riboswitch. 
Therefore, a novel light SELEX method was developed and established. This light SELEX 
protocol enriched isoform selective aptamers by a light-induced conformational change of 
azoCm during the SELEX process. As in vivo screening of light SELEX aptamers did not 
yield a riboswitch again, in vitro binding studies of aptamers from the light SELEX were 
performed. Comparing three aptamers which showed the highest discrimination between the 
two isoforms of azoCm to each other led to the discovery of a 13 nt sequence motif that only 
these aptamers shared. A next-generation sequencing experiment performed with the SELEX 
and light SELEX rounds revealed that this sequence motif (“light motif”) was specifically 
enriched during light SELEX rounds, but was gradually depleted during the later, more 
stringent affinity SELEX. Based on this discovery, a new library for SELEX was designed, 
containing the partially randomized light motif, as well as entirely randomized flanking 
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regions. SELEX performed with this light motif doped library led to a fast enrichment within 
five rounds, and aptamers from this SELEX were tested regarding their in vivo functionality. 
From the aptamers tested in vivo, four showed gene regulatory function, however with a low 
regulatory factor of 1.25- to 1.35-fold. Based on the best functional aptamer B2, partially 
randomized aptamer libraries were generated for further in vivo screenings. While the 
regulatory factor of B2 could not be improved using this approach, a modified version of it 
called B2-1 could be shown to regulate gene expression in yeast cells in an azoCm dose-
dependent manner. To learn more about the aptamer B2-1, its binding affinity was analyzed 
using isothermal calorimetry. The kD of B2-1 was determined to be 23 nM, depending on the 
calculation model used. A truncated version of B2-1 showed a low micromolar binding to 
azoCm, indicating that structurally relevant parts of B2-1 had been deleted during the 
truncation. However, both B2-1 and its truncated version did selectively bind to only one 
isoform of azoCm, while binding to the other isoform could not be detected. 
The aptamer developed in this work shows a much stronger discrimination between the two 
isoforms of its light-switchable ligand than previously reported isoform-selective aptamers. It 
also shows the highest binding affinity to its ligand compared to the isoform-selective 
aptamers in literature to date. While a riboswitch based on this aptamer shows only slight 
regulatory function, dose dependent regulation of gene expression could be shown. This work 
therefore constitutes the first steps towards the generation of a light dependent riboswitch. 
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1.1 Deutsche Zusammenfassung 
Die verschiedenen Funktionen von RNA haben zu einem großen und zunehmenden Interesse 
für das Feld der synthetischen Biologie geführt. Ein Beispiel für vielseitige RNA-Moleküle in 
der synthetischen Biologie sind Aptamere. Aptamere sind in der Lage, an ein breites 
Spektrum von Zielmolekülen mit hoher Affinität und Spezifität zu binden, weshalb sie oft mit 
Antikörpern verglichen werden. Mit der SELEX-Methode können Aptamere für bestimmte 
Zielmoleküle in vitro für ein breites Anwendungsspektrum generiert werden. In der Natur 
fungieren sie als Sensordomäne von Riboswitchen und regulieren die Genexpression, indem 
sie an ihr Zielmolekül binden. Riboswitche können mittels synthetischer Biologie auch aus in 
vitro selektierten Aptameren erzeugt werden.  
Im Rahmen dieser Arbeit wurde ein neuartiges RNA-Aptamer entwickelt, welches selektiv an 
eine von zwei lichtinduzierten Isoformen eines bestimmten niedermolekularen Liganden 
(azoCm) bindet. Die potenzielle Funktion eines solchen Aptamers als Riboswitch wurde 
untersucht. 
Ein zuvor durchgeführtes SELEX-Experiment gegen azoCm ergab ein spezifisch bindendes 
Aptamer (Aptamer 42). Zu Beginn dieser Arbeit wurde dessen Sekundärstruktur mit Hilfe 
von In-Line Probing analysiert. Wie vorhergehende Untersuchungen zeigten, besaß Aptamer 
42 keine Riboswitch-Funktion zur Regulation der GFP-Expression im Modellorganismus 
Saccharomyces cerevisiae. Daher wurden andere Aptamere aus der gleichen SELEX unter 
gleichen Bedingungen mittels in vivo Screening getestet. Da kein funktionsfähiger Riboswitch 
identifiziert werden konnte, wurde ein neues SELEX-Experiment mit einer neuen Aptamer 
Bibliothek durchgeführt.  
Die neue SELEX ergab Aptamere, die spezifisch an azoCm binden. Das in vivo Screening 
von Aptameren aus dieser SELEX führte jedoch nicht zu einem funktionsfähigen azoCm 
abhängigen Riboswitch. Darum wurde eine neuartige Licht-SELEX Methode entwickelt und 
durchgeführt. Aptamere aus dieser Licht-SELEX wurden durch eine lichtinduzierte 
Konformationsänderung von azoCm während des SELEX-Prozesses erzeugt. Dies führte zu 
einer Anreicherung von Isoform-selektiven Aptameren. Da in vivo Screening der Aptamere 
aus der Licht-SELEX wiederum keine Riboswitch-Funktion zeigte, wurden in vitro 
Bindungsstudien durchgeführt. Der Vergleich von drei Aptameren, die die unterschiedlichste 
Bindungsspezifität zwischen den beiden Isoformen von azoCm zeigten, führte zur 
Entdeckung eines 13 nt Sequenzmotivs, das nur diesen Aptameren gemeinsam war. Next 
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Generation Sequencing der SELEX und Licht-SELEX Runden ergab, dass dieses 
Sequenzmotiv ("Lichtmotiv") während der Licht-SELEX Runden spezifisch angereichert 
wurde, während es sich in den Runden der klassischen SELEX mit hoher Stringenz 
stufenweise verringerte. Basierend auf dieser Entdeckung wurde eine neue Aptamer 
Bibliothek für SELEX entworfen, die sowohl das teilweise randomisierte Lichtmotiv als auch 
vollständig randomisierte Randbereiche enthielt. Eine SELEX mit dieser das Lichtmotiv 
enthaltenden Bibliothek führte zu einer schnellen Anreicherung innerhalb von fünf Runden. 
Aptamere aus dieser SELEX wurden auf ihre in vivo Funktionalität getestet. Von den 
getesteten Aptameren zeigten vier eine genregulatorische Funktion in S. cerevisiae, allerdings 
mit einem niedrigen Regulationsfaktor von 1,25- bis 1,35-fach. Basierend auf dem am 
stärksten regulierenden Aptamer B2 wurden teilweise randomisierte Aptamer-Bibliotheken 
für weitere in vivo Screenings generiert. Während der regulatorische Faktor von B2 mit 
diesem Ansatz nicht verbessert werden konnte, konnte eine modifizierte Version namens B2-
1 entwickelt werden, die die Genexpression in S. cerevisiae dosisabhängig reguliert. Um mehr 
über das Aptamer B2-1 zu erfahren, wurde seine Bindungsaffinität mittels Isothermer 
Titrationskalorimetrie analysiert. Die Dissoziationskonstante von B2-1 lag im niedrigen 
nanomolaren Bereich (23 nM). Eine verkürzte Version von B2-1 zeigte eine niedrige 
mikromolare Bindung an azoCm, was darauf hindeutete, dass strukturell relevante Teile von 
B2-1 während der Verkürzung wegfielen. Sowohl B2-1 als auch seine verkürzte Version 
banden jedoch selektiv nur an eine Isoform von azoCm, während eine Bindung an die andere 
Isoform nicht festgestellt werden konnte. 
Das in dieser Arbeit entwickelte Aptamer zeigt eine viel stärkere Diskriminierung zwischen 
den beiden Isoformen seines lichtschaltbaren Liganden als andere bisher publizierte 
Isoform-selektive Aptamere. Es zeigt auch die höchste Bindungsaffinität zu seinem Liganden 
als Isoform-selektive Aptameren in der bisherigen Literatur. Während ein auf diesem 
Aptamer basierender Riboswitch nur eine geringe regulatorische Funktion aufweist, konnte 
eine dosisabhängige Regulation der Genexpression nachgewiesen werden. Diese Arbeit 
beinhaltet daher die ersten Schritte zur Erzeugung eines lichtabhängigen Riboswitches. 
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2 Introduction 
2.1 Theoretical background 
2.1.1 Synthetic biology 
Cells are the smallest functional units that make up organisms [1]. In the case of 
microorganisms as most bacteria and yeasts, they actually represent the entire organism 
(unicellular organisms). In multicellular organisms they can be highly specialized and can 
provide one crucial function in organisms (e.g. different cells within the islets of Langerhans 
are producing insulin or hormones depending on blood sugar levels [2]). Some can also be 
able to move, proliferate and communicate on their own [3]. Cells are composed out of 
cytoplasm which contains many biomolecules such as proteins and nucleic acids, as well as 
more complex structures like organelles [3]. Today, researchers in cell biology and related 
fields often use tools generated by synthetic biology to analyze gene regulation and cellular 
functions. Synthetic biology is an emerging field of interdisciplinary research, rooted in 
biology. While the term “synthetic biology” was coined as early as 1910 by Stéphane Leduc 
[4-6], the field of synthetic biology has been taking up speed with the advent of fast and cost-
efficient molecular cloning techniques, such as PCR (3.2.6), easily accessible restriction 
enzymes (3.2.4), as well as sequencing methods (3.2.10). Today, the interdisciplinary research 
together with fields like electrical and chemical engineering push the boundaries of 
understanding and designing new artificial biological pathways, entire synthetic organisms or 
abstract devices isolating cellular functions, such as cell-free protein expression systems [7-9].  
A bottom-up approach to synthetic biology is the construction of novel genetic circuits. DNA 
sequences not naturally occurring together are combined into an engineered and optimized 
network, in which the DNA sequences, their RNA transcripts or their protein products can 
influence and modulate each other. For example, elements like DNA-binding proteins able to 
recruit or block RNA polymerases [10], and RNA translational repressors can modulate gene 
expression in these circuits [11, 12]. Riboswitches play an increasingly important role in this 
“genetic toolbox” [13], as they allow an RNA-based regulation, independent of protein 
factors. In a hypothetical “plug-and-play” toolbox, all of these elements could be combined at 
will and would function like the parts of a mechanically engineered machine [14]. 
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2.1.2 Genetic engineering 
Today, function and regulation of genes are studied using molecular biology techniques. 
Genes are found on chromosomes, which consist of a tightly coiled DNA (deoxyribonucleic 
acid) strand, wrapped around packaging proteins called histones [15]. A gene is a section of 
DNA coding for a protein. In order to generate these proteins from DNA, first DNA is 
transcribed to RNA (ribonucleic acid), using a cell’s internal RNA polymerase enzymes. This 
transcript is called messenger RNA (mRNA) and serves as the blueprint for protein synthesis. 
The mRNA is processed by a set of ribosomes, which decode the information stored in 
nucleotide triplets in order to generate a specific amino acid chain, the protein. The process of 
transcription and translation, called protein biosynthesis, is very similar in prokaryotes and 
eukaryotes, however differences exist [15, 16].  
While DNA (Deoxyribonucleic acid), the carrier of all genetic information, is typically 
composed of two complementary nucleotide strands, RNA is a single stranded polynucleotide 
tasked with various functions within the cell (see Figure 1). 
 
 
Figure 1: Typical process of protein biosynthesis in cells DNA (blue, left) is a double stranded molecule in the 
cell, which is transcribed to the single stranded mRNA (green, middle) by the enzyme RNA polymerase. mRNA 
is then translated into a protein (purple, right) by the ribosomes. The two steps, transcription and translation, are 
called protein biosynthesis. 
 
In order to analyze the function or regulation of genes of interest (GOI), new recombinant 
DNA is artificially constructed. The process of generating recombinant DNA is often referred 
to as cloning [17]. In general, its goal is the construction of new genetic element 
combinations, which would not exist like that in nature [18]. The desired genetic elements are 
assembled in a plasmid (also called backbone-plasmid or vector), a circular double-stranded 
DNA molecule. Plasmids typically contain replication origins (ORIs) and selection markers 
for a certain organism, so that the plasmid DNA can be transferred into it and then be 
processed and replicated like any other DNA of the host organism. This enables, for example, 
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the study of gene regulation, cell differentiation or even human disease targets in a living 
organism. To enable transfection or transformation of cells in an efficient manner, cells need 
to be made artificially “competent”, to increase their natural ability to take up foreign DNA. 
Cells are put under stress conditions (e.g. drastic temperature changes or high salt 
concentrations of surrounding media) to make their cell membrane and/or cell walls 
permeable for DNA more easily. The resulting so-called competent cells can be prepared in 
the laboratory using different methods [19]. 
 
 
2.1.3 Regulation of gene expression 
Gene regulation is a process in which a gene’s expression is modulated by DNA sequences 
located mostly up- or downstream of its DNA locus (before or after the gene), but also by 
other substances (RNA, proteins, hormones etc.). One of the most immediate interactions of a 
gene is with its promoter [20]. The promoter is typically situated immediately in front of the 
5’ end of the gene’s coding sequence and contains the transcription start site (TSS), a binding 
site for RNA polymerase, as well as transcription factor binding sites. Without it, transcription 
cannot be initiated properly. Other sequences of the DNA influencing the regulation of genes 
are enhancers, which can be as far away as ten million base pairs (bp) from the gene itself 
[21], and silencers, which act as binding sites for transcription factors such as repressors to 
silence gene expression [22]. Promoters, silencers and enhancers all work to regulate gene 
expression on the transcriptional level. Promoter regions in front of the mRNA can also 
contain binding regions for RNA binding proteins, which can regulate RNA stability and 
processing and thereby gene expression, as well. Translational control of gene expression is 
often executed by the modulation of translation initiation. Inhibitory protein binding to parts 
of the translation initiation machinery can for example prohibit its binding to mRNA [23]. A 
prominent mechanism of translational gene regulation is riboswitches, which is described in 
detail in chapter 2.1.5.  
 
 
2.1.4 RNA and regulatory RNA 
Similar to DNA, RNA is composed of a chain of nucleotides. Differences between RNA and 
DNA are the sugar components that make up their nucleobases, with RNA containing ribose 
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whereas DNA contains 2-deoxyribose. Another difference is the substitution of the 
nucleobase thymidine in DNA by uracil in RNA. RNA is typically a single-stranded 
molecule, while DNA is mostly in double-stranded form. This leads to different structural 
properties of DNA and RNA; with DNA being typically more stable and rigid, while RNA is 
more flexible, and prone to self-degradation, as well as enzymatic attacks. The structural 
flexibility of RNA provides more freedom for spatial configuration, making it a versatile tool 
for the cell to carry out different functions [24, 25]. 
Transcription and translation are the two steps of protein biosynthesis, which is the process of 
turning genetic information into a protein. Transcription describes the copying of a DNA 
nucleotide sequence into a complementary and antiparallel RNA. The synthesis of this RNA 
is performed by the enzyme RNA polymerase II. The RNA transcript should consist of a 
perfect copy of the DNA sequence. If the copied DNA contains information for the building 
of a protein, the resulting RNA (mRNA) has to be processed before being translated into a 
protein by ribosomes. A mRNA transcript includes not only a gene’s protein coding sequence, 
but regulatory sequences as well [26].  
During the processing of the freshly copied mRNA (pre-mRNA, Figure 2), so-called 
“nonsense” regions of the RNA are removed, and structures adding stability (e.g. 5’ cap and 
3’ poly(A)tail, Figure 2) are added. However, certain untranslated regions of the mRNA are 
not removed during mRNA processing, namely the 5’ and 3’ untranslated regions (UTRs). 
They are positioned before the start codon (5’, “upstream”) and after the stop codon (3’, 
“downstream”). They play a role in the stability, localization and translational regulation of 
the mRNA.  
 
 
Figure 2: Pre-mRNA and processed mRNA Shown are the unprocessed mRNA transcript of DNA 
(pre-mRNA, upper section) and the processed, translatable mRNA (lower section). Both forms of RNA contain 
the 5’ UTR on their 5’ end, followed by the start codon and the gene of interest. After the stop codon, the 
3’ UTR follows. The processed mRNA also contains a 5’ cap and a 3’ poly(A)tail, to increase its stability. 
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There are different types of RNA in an organism, with the most important being messenger 
(mRNA), ribosomal (rRNA) and transfer RNA (tRNA). While mRNA provides the ribosome 
with information about protein construction (“coding RNA”), tRNA and rRNA are non-
coding RNAs (ncRNAs) and part of the translation process in protein synthesis [26]. Other 
types of RNA play important roles in the regulation of gene expression, influencing 
transcription, translation, RNA maturation (splicing) as well as many other important 
functions in the cell. This includes, for example, micro RNAs (miRNA) and small interfering 
RNAs (siRNA), which can lead to mRNA degradation by RNA interference (RNAi) [27-31]. 
Antisense RNA (asRNA) is used by both pro- and eukarya to regulate gene expression using 
longer RNA molecules of typically more than 200 nt in length (long non-coding RNA, 
lncRNA) [32]. asRNAs can also impact transcription and RNA processing by binding 
complementary to a stretch of DNA or RNA [33]. In prokaryotes, small regulatory RNAs 
(sRNAs) control the translation initiation of genes or influence the activity of proteins by 
specifically binding to them [34]. They can also work on a post-transcriptional level by base 
pairing with the mRNA. 
ncRNAs can work in cis (encoded at the same genetic location, but on the opposite strand to 
the RNAs they act upon), but also in trans (encoded at a distance from the gene locus of the 
RNA they act upon). An example of cis-acting gene regulation is riboswitches, a stretch of 
RNA typically located in the 5’ UTR of a mRNA.  
There are several advantages when gene expression is regulated via RNA alone as opposed to 
regulation in combination with proteins. It allows (i) faster regulatory responses, (ii) easier 
transfer of a single-step genetic control element to other organisms, and (iii) flexible 
combination with different downstream readout platforms for a maximum of regulatory 
outputs [14]. 
 
 
2.1.5 Natural riboswitches 
Riboswitches are highly structured RNA sequence elements which are typically located in the 
5’ UTR of mRNAs (Figure 2). Discovered in 2002 [35-37], their study and their potential 
rapidly lead to the development of a new branch of RNA and genetic regulation research [38, 
39]. Riboswitches often regulate processes related to metabolism by interacting with a 
metabolite (or other small molecules) of the cell. Conformational changes in their three-
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dimensional structure are triggered by this interaction (“ligand binding”), and the expression 
of a gene downstream of the riboswitch is altered. Riboswitches consist of two domains, the 
so-called aptamer domain (2.1.6) and the expression platform [40]. The aptamer domain 
selectively recognizes its corresponding ligand and binds to it.  
Common regulating mechanisms are transcription termination or translation initiation, less 
frequently ribozyme-mediated mRNA degradation or the control of splicing. Figure 3 shows a 
schematic on how re-structuring of the RNA can inhibit gene expression upon ligand binding. 
 
 
Figure 3: Example of bacterial riboswitch function Shown is the structural change a riboswitch sequence can 
undergo upon ligand binding (blue circle). Without ligand present (left), the RNA structure sequesters the anti-
Shine-Dalgarno (Anti-SD) sequence, thereby leaving the Shine-Dalgarno (SD) sequence free to access by 
ribosomes, gene expression can take place. Addition of the ligand leads to a re-structuring of the RNA, bringing 
the Anti-SD and SD in close contact, so they can bind to each other. Ribosomes cannot access the SD anymore 
and gene expression is inhibited. Adapted from Lotz et al. [41]. 
 
Riboswitches are widely distributed in bacteria but are increasingly discovered in eukaryotes. 
A prominent example is the thiamine pyrophosphate (TPP) riboswitch, which is the only 
riboswitch known to date to occur in all three domains of life (Bacteria [35, 42], Archaea [43], 
and Eukarya (fungi [44, 45], plants [44, 46-49], and algae [50]). Interestingly, these examples 
of the TPP riboswitch, while composed of a highly conserved consensus core structure, can 
regulate gene expression using different mechanisms, as detailed below. 
In bacteria, transcription termination can be regulated by the presence of a terminator 
structure consisting of the aptamer domain and a sequence complementary to the 3′ part of the 
aptamer. This structure can be formed or dissolved in a ligand-dependent manner, leading to 
an activation or inhibition of transcription (e.g. the different functionalities of the purine 
riboswitch [51, 52]).  
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The process of translation initiation can be regulated as well. In the absence or presence of a 
ligand, a stem-loop structure is formed between the aptamer domain and a sequence 
complementary to the Shine-Dalgarno (SD) sequence. This sequestering or release of the SD 
sequence blocks or activates translation initiation (e.g. the SAM-III riboswitch and the 
Adenine riboswitch, resp. [53, 54]). Other, less common methods for riboswitches to regulate 
gene expression are through the formation of ribozymes (self-cleavage of RNA upon ligand 
interaction by the glmS riboswitch [55] or splicing in eukaryotes (by the TPP riboswitch [48]). 
While most riboswitches are located in the 5’ UTR of a DNA, typically between promoter and 
the gene itself (“cis”-acting riboswitches), they  can regulate also gene expression from a 
faraway DNA region (regulation in “trans”,), operating e.g. like a small RNA [56]. 
Most natural riboswitches bind selectively to second-messenger signal molecules like cyclic 
di-guanosine monophosphate (cyclic di-GMP) [57] or to coenzymes like TPP or 
S-adenosylmethionine (SAM) [58]. These molecules can both be generated from RNA 
nucleotide building blocks, which is one of the reasons that the so-called “RNA world” theory 
is widely accepted today [59]. In the so-called time of the “RNA world”, no proteins or DNA 
had evolved yet, and their current roles had to be carried out by RNA, relying on other RNA-
derived substances [36, 59, 60]. The natural riboswitches of today are considered descendants 
of these old regulatory systems, with some on the edge of extinction [61]. 
It seems feasible to make use of these natural riboswitches in a synthetic biology context. The 
study of natural riboswitches also can teach synthetic biologists how to make new, synthetic 
riboswitches (2.1.9) [62]. 
 
 
2.1.6 Aptamers 
Aptamers are small single-stranded oligonucleotides, typically consisting of ribonucleic acid 
(RNA). There are also examples of single strand DNA (ssDNA) aptamers [63], as well as 
peptide aptamers [64]. The common feature of aptamers is their ability to bind a target 
molecule (ligand) with very high affinity and specificity [65, 66]. Because of that they are 
often compared to antibodies, being described as 'chemical antibodies' [67]. Their selective 
discrimination can be so specific that they are able to differentiate even between enantiomers 
[68, 69].  
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Aptamers typically consist of 30 to 70 nucleotides and take on unique three-dimensional 
structures upon ligand recognition [70].  
The aptamer binds specifically by partially or entirely enveloping its target-molecule, coupled 
with non-covalent molecular interactions between the aptamer and its target. These 
interactions include most prominently hydrogen bonds, base-stacking and electrostatic 
interactions [71]. 
Aptamers are typically synthetically produced, mostly by using the in vitro method “SELEX” 
(systematic evolution of ligands by exponential enrichment (2.1.7) [72, 73]), which was first 
described in 1990 by two research groups in parallel (Tuerk & Gold, Ellington & Szostak [72, 
73]). In nature, they occur as the sensing domains of riboswitches, responsible for binding a 
target molecule and thereby effecting a change in gene expression (2.1.5, 2.1.9). 
Aptamers are also increasingly in the focus of researchers looking for new therapeutic 
approaches. Next to their relatively small physical size and molecular weight (Typical IgG 
antibody: 150 kDA [74]; typical aptamer size 6–30 kDa [75, 76]) they unite a flexible 
structure, with a quick, easy and reproducible production (low batch-to-batch variability), as 
well as adding the possibility of chemical modifications [77-81]. On top of that, they can be 
highly stable and show a very low immunogenicity and toxicity [60, 82, 83].  
There is evidence that many aptamers are easily internalized into cells upon binding to 
cellular receptors [67]. Next to their potential use as direct therapeutics this could make them 
useful carriers for the in-organism delivery of therapeutic small interfering RNAs (siRNAs), 
microRNAs and conventional drugs as well [67].  
The advantage of administering aptamers as medication opposed to having the organism 
produce them, lies in the possible chemical modification of specific nucleotides [81], which 
can dramatically increase the half-life of aptamers within the organism (less than 10 min 
when unmodified [80]).  
Until the conclusion of this thesis, there has been only one FDA approved aptamer drug 
available (pegaptanib/Macugen® in the therapy of exudative macular degeneration, [84, 85]). 
However, several further aptamer drugs are presently undergoing clinical trials, some having 
reached late-stage phases [86, 87]. Especially cancer treatment emerges as a new field of 
application, with aptamers being considered not only as cancer therapeutics, but also as cancer 
biomarkers, in vitro diagnostics and in vivo imaging systems [88].  
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The generation of novel aptamers and their potential application in synthetic biology are at the 
core of the presented thesis. In the course of this thesis, novel aptamers selectively binding to 
one isoform of a photo-switchable molecule should be developed.  
 
 
2.1.7 SELEX 
SELEX (systematic evolution of ligands by exponential enrichment) is a method for the 
development of aptamers, in which an iterative selection procedure is carried out [72, 73]. The 
starting point of each SELEX is a random combinatorial library (or “pool”) of 1014-1016 
sequences, with the amount of potential sequences typically limited by the synthesis 
capability of the library supplier [89]. Even though larger libraries of up to 10
20
 
oligonucleotides are technically feasible [90], they are very rarely used in practice [91].  
While DNA and peptide libraries exist, this thesis only discusses RNA libraries. RNA 
libraries are prepared by in vitro transcription of a chemically synthesized DNA pool (2.1.8). 
Specific aptamer sequences can be enriched during SELEX and dominate the library 
population, hence the term “evolution” in the method’s name [67]. 
At the start of each SELEX, an RNA library is incubated with its target molecule (typically 
immobilized on a non-reactive carrier material) in a suitable buffer system. RNA aptamers 
with a binding affinity for the target molecule (ligand) are separated from the rest of the 
library in a partitioning or selection step. Commonly, after incubating the RNA with the target 
molecule, several washing steps occur, to remove any unbound aptamers that do not show 
affinity to the target molecule from the library. The ligand-binding aptamers are recovered in 
an elution step, which can be carried out using unspecific means or specific elution. 
Unspecific elution employs thermal or chemical denaturation of the RNA-ligand binding, 
complexation of divalent cations with EDTA [68], or the application of a salt gradient [92]. 
Specific elution (“affinity elution”) is carried out by the incubation of the bound RNA-ligand 
complex with a highly concentrated free target molecule solution. Competition between the 
free and immobilized target molecule leads to the elution of aptamers, however binding 
aptamer sequences can be lost in this step if they remain bound to the immobilized target 
molecule. Amplification of the aptamers is performed through reverse transcription into 
cDNA (complementary DNA) and subsequent amplification by polymerase chain reaction 
(PCR). During the PCR, oligonucleotides introducing a T7 polymerase promoter are used, 
 Introduction 22 
leading to a pool of aptamer PCR products which can be immediately used as a template for 
in vitro RNA transcription. The resulting RNA constitutes the potentially enriched aptamer 
pool for the next round of SELEX. 
 
 
Figure 4: Schematic representation of the SELEX process. Shown are the five main SELEX steps of every 
round, binding, washing, elution, amplification and transcription of the RNA aptamers. Prior to the first SELEX 
round, an initial randomized RNA aptamer pool is applied to a ligand-derived column and binding of the 
aptamers occurs. If the progress of a SELEX is monitored, samples of amplified aptamers can be taken for 
analysis following the RT-PCR amplification step.  
 
Particularly in the first rounds of a SELEX, a negative SELEX step is carried out additionally. 
In this step, the RNA library is incubated with the non-derivatized carrier material prior to the 
selection step, to avoid enriching RNA aptamers that show primarily an affinity to the carrier. 
Another common technique in SELEX is counter selection. To enable the generated aptamers 
to differentiate between closely related molecules, the RNA library is incubated with the 
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undesired target molecule prior to incubation with the target molecule, as demonstrated for 
the theophylline aptamer [65]. 
Typically, the progression of a SELEX is monitored as it advances. This can be done via 
radioactive labelling of nucleotides incorporated into the RNA during transcription. This way, 
all incubation fractions the RNA undergoes (with the carrier material, with the target material, 
washing steps as well as elution) can be quantified using “radioactive counts” (measured in 
counts per minute, cpm). Over the course of the different SELEX rounds, an increase in cpm 
in the elution fractions can indicate an enrichment of RNA aptamers which have been eluted 
from the immobilized target. Most SELEX experiments require eight to fifteen rounds to 
show enrichment of one or more aptamer families [93]. Aptamers from rounds that show 
enrichment by measurement of cpm can be integrated into backbone-vectors and amplified in 
single-clone bacterial cultures (typically Escherichia coli) to obtain enough genetic material 
for sequencing. That way, aptamer sequences can be identified and compared to each other. 
Families (groups of aptamers with minor sequences differences) and conserved motifs 
(sequence stretched within a larger sequence) can be identified and secondary and tertiary 
structure predictions can be carried out using bioinformatic tools, such as mfold (Table 12), 
LocARNA (Table 12, [94, 95]) or SICOR [96]. 
Once the sequence of aptamers is known, further experiments like affinity assays (3.2.15), 
structural probing (2.1.14, 3.2.14) and tests regarding their ability to act a riboswitch can take 
place (2.1.11, 3.3.8). 
Often, the most abundant aptamers from a SELEX round show good binding abilities. But in 
some cases, rarely occurring aptamer sequences (“orphans”), without any structural or 
sequence familiarity to the other aptamers discovered, show the best binding properties [97]. 
One of the reasons for this can lie in the bias introduced into the RNA libraries in every round 
by steps such as reverse transcription, PCR or in vitro transcription [98-100]. Aptamers with 
e.g. a strong secondary structure might be artificially decreased in these steps, because the 
enzymes involved have difficulties processing them, even though they might be some of the 
best aptamers fitting to the target molecule. 
There are many different protocols for SELEX, sometimes based on very different and 
complex techniques, such as surface plasmon resonance spectroscopy (SPR) [101-103] or 
capillary electrophoresis (CE) [104]. When a new aptamer is to be generated by SELEX, the 
choice of the method is often based on the later application of the aptamer (e.g. if the aptamer 
is to be used as a therapeutic biomarker, whole cell SELEX might be an appropriate tool [105, 
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106]). Otherwise, the decision on a SELEX method often depends on the equipment and 
know-how already present in the research group [107, 108]. The most common method for 
SELEX remains the immobilization of the ligand on a matrix, so that column based SELEX 
can be carried out. However, all SELEX protocols, even those using DNA or peptide libraries, 
share the core steps described above: target binding, partitioning of binding aptamers, aptamer 
recovery and re-amplification of aptamers. 
The SELEX protocol used during this thesis is based on ligand immobilization on a non-
reactive resin (see Figure 10). The resin is placed inside a column, allowing solution used for 
RNA binding, washing and elution to flow through it and the collection of these liquid 
fractions for process monitoring. The SELEX method is referred to as “affinity SELEX” in 
the course of this work. 
 
 
2.1.8 Aptamer libraries 
The starting library used for any SELEX determines the basic elements the final aptamers 
show, namely their size and overall structure. An aptamer in an RNA library typically consists 
of three different sequence stretches: 5’ and 3’ binding regions (“constant regions”) for 
oligonucleotides used in re-amplification of the recovered aptamers, as well as the core region 
in which a set number of nucleotides in a randomized composition later mostly makes up the 
reactive center of the aptamer. However, it is possible that the constant regions are involved in 
the structural folding of the aptamer, more rarely also in the binding of the target molecule 
[109]. The number of randomized nucleotides of the core region is usually chosen to be 
between 30 to 70 nucleotides [70], but more complex libraries of 120 nt [110] or 134 nt [111] 
exist and have led to the selection of functional aptamers. The number of molecules usable in 
the first round of SELEX is typically limited to 10
14
 to 10
16
 sequences, due to synthesis 
limitations by the library supplier [89, 90]. Hence, any aptamer library with more than 25 
randomized nucleotides cannot be covered in its entire sequence space. The theoretically 
possible number of sequences in the library is calculated as 4
n
, with 4 representing the four 
possible nucleotides (A, C, G, T/U), and n the amount of randomized nucleotide positions. A 
typical library of 30 nt therefore contains 1.15x 10
18
 sequences, a 70 nt even 1.39x 10
42 
sequences. Therefore, if a SELEX against a target molecule is not successful, it could be 
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possible that the application of a different library, even of the same size, could contain 
binding aptamers not found in the particular library used. 
A strategy that has been used in the generation of SELEX libraries, is pre-structuring parts of 
the aptamers. Incorporating sequence stretches that reliably fold into certain structures (e.g. 
stem-loops) are supposed to increase the overall stability of all aptamers generated. In turn, 
this is supposed to lead to more complex and more ligand-affine aptamers [112, 113]. 
In order to generate aptamers with a high target molecule affinity, one aim of SELEX has 
often been to generate aptamers with a low dissociation constant (kD), a measure indicating 
how strongly a molecule binds to another one (equilibrium dissociation constant between an 
aptamer and its ligand) [114-116]. To achieve this, the stringency of SELEX conditions can 
be increased during different rounds. Ways to increase stringency can be the introduction of 
more washing steps, elution of the RNA with a lower target molecule concentration or 
reducing the incubation time of the RNA with the immobilized target before the first wash 
steps.  
So far, SELEX has been performed against a multitude of different targets. From ions like 
Zn
2+
 [117], small molecules like amino acids [118], up to cells [119] and even entire 
organisms [120], the range of SELEX using a variation of libraries can be enormous. 
Particularly small molecules are of interest for biotechnological and pharmaceutical 
application (2.1.6). They do pose a challenge in SELEX, however, as they do not have as 
many functional groups in which interactions with the aptamer can take place, as for example 
proteins. Small molecule targets with a lower number of rotatable bonds and thus fewer 
degrees of freedom are said to have better interaction with macromolecules like RNA 
aptamers [121].  
During this thesis, different libraries for SELEX were used and are discussed. The process of 
optimizing the production of the initial library DNA template is described, different SELEX 
procedures were tested and compared, and the reasoning for the finalized SELEX protocols 
are discussed. New findings regarding the development of small molecule binding aptamers 
may improve current knowledge in the field. The insights gained from this thesis could 
therefore help to improve further RNA based research and may possibly enhance the 
effectiveness of other SELEX studies.  
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2.1.9 Synthetic eukaryotic riboswitches 
RNA is a molecule of great interest to synthetic biologists, as it unites several useful functions 
in one molecule: it can act as both a sensor and effector, it can take on highly specific three-
dimensional structures and it can sense ambient conditions like temperature, acidity, or a 
specific molecule’s concentration [55, 56, 122-125]. Therefore, the development of synthetic 
aptamers able to fulfil such specific functions as part of a riboswitch is of major interest to the 
field of synthetic biology. Coupling such synthetic aptamers to an expression platform could 
deliver synthetic riboswitches tailored to specific applications. For example, transcriptional 
riboswitches have been constructed in a modular approach combining expression platforms 
from natural riboswitches with aptamer domains both derived from riboswitches and selected 
in vitro [126, 127]. The best-known synthetic riboswitches in bacteria are using the 
theophylline aptamer as their sensing domain [128, 129].  
While there are many natural riboswitches in bacteria, in eukaryotes only one has been 
discovered so far [130]. The need to develop synthetic riboswitches for eukaryotic systems is 
therefore even greater than for bacteria. A few well-working examples of eukaryotic synthetic 
riboswitches exist, regulating gene expression depending on the presence of the ligands 
tetracycline, neomycin, and ciprofloxacin [131-133]. They were generated by inserting 
selectively ligand binding aptamers identified through SELEX (2.1.7) into the 5′ UTR of a 
gene of interest on a plasmid vector. Binding of the aptamer domain to the ligand is expected 
to lead to a restructuring of the riboswitch, generating a “roadblock” which the translational 
machinery cannot pass, thereby inhibiting gene expression. In order to screen aptamers for 
this restructuring capability, the next step towards a riboswitch typically involves an in vivo 
screening approach in the organism of choice to identify functional genetic constructs. These 
constructs could then be further analyzed and optimized for other potential applications. This 
way, synthetic riboswitches have already been used to control pre-mRNA splicing [134-136], 
microRNA processing [137, 138], or internal ribosome entry site-mediated translation 
initiation [139]. Next to in vitro generation of new aptamers and improvement of in vivo 
screening systems to identify functional riboswitches, other steps towards the generation of 
new riboswitches are in silico design and structure prediction methods [140-142]. Particularly 
structure prediction methods are helpful for the design of new experiments, and are frequently 
referenced and used in this thesis. 
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The development of an aptamer able to bind to a novel small molecule would be an important 
result of the presented thesis, whereas novel synthetic riboswitch working in eukaryotic 
organisms would significantly enrich the toolbox of synthetic biologists. 
 
 
2.1.10 Yeast as a model organism for the development of synthetic riboswitches 
Saccharomyces cerevisiae is a prominent model organism in molecular biology, partly 
because humans have thousands of years of experience working with this yeast in the 
production of beer, bread etc., and partly because it is an example of unicellular eukaryotes, 
which can be grown fast and easily [143-145]. In biotechnology yeast cultures are widely 
used as cell factories to produce various proteins [146], as well as a model organism to study 
gene regulation. 
As eukaryotes, S. cerevisiae cells are able to glycosylate proteins, meaning they are able to 
attach sugar chains to proteins, a necessity for the function of many biotechnologically 
relevant proteins [147]. Furthermore, they are able to secrete these (glyco-) proteins into the 
surrounding nutrient medium – a big advantage for biotechnologists. The proteins produced in 
yeasts are identical or very similar to the proteins of animals or of humans, making yeast a 
focus of many research groups and a tool in genetic engineering as well as synthetic biology 
[148].  
Gene regulation in yeast cells is very similar to other eukaryotes. Therefore, riboswitches 
developed in yeast would be expected to work in a comparable manner in other eukaryotic 
cells, e.g. human cell lines. Corresponding examples of synthetic riboswitches have been 
published, e.g. the recently developed ciprofloxacin-riboswitch [133]. This shows that 
riboswitches developed in yeast cells are not necessarily limited to their genetic context, but 
applications in fields like novel therapeutic approaches are conceivable.  
For this reason, research in this thesis carried out in S. cerevisiae could be a valuable addition 
to the analysis of synthetic biology applications in other eukaryotic systems, such as humans.  
 
 
2.1.11 In vivo screening  
The development of novel synthetic riboswitches from aptamers is not trivial and has, 
particularly for application in eukaryotes, been only successful a handful of times [132, 133, 
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149]. While a SELEX can enrich highly specific aptamers, these aptamers do not necessarily 
function as riboswitches in vivo. 
The typical process of generating a synthetic eukaryotic riboswitch consists of the integration 
of an aptamer into the 5’ UTR of a gene of interest (often a reporter gene) [132]. If the 
aptamer can recognize and bind its ligand in the biological context, the scanning process of 
the ribosomes and thus translation in the presence of the target molecule would be inhibited. 
Depletion of the target molecule would lead to the resumption of protein expression [150, 
151].  
For the first verification of a functional riboswitch, a screening method developed by 
Weigand et al. can be applied, as in this stage it is not important, whether the target molecule 
is photo-responsive or not [132]. Weigand et al. could show that for a SELEX-enriched pool 
of neomycin-binding aptamers only a few sequences could be used as switching elements in 
S. cerevisiae. Only aptamers, which were poorly structured in the unbound state but 
underwent a distinct conformational change upon ligand binding, were also able to regulate 
translation in a ligand-dependent fashion. As many aptamers derived from SELEX already 
exhibit a preformed, stable tertiary structure in the absence of the ligand, this seems to limit 
their application as riboswitches, and thus makes in vivo screening of in vitro enriched pools 
almost inevitable [129, 152]. 
The in vivo screening method is based upon the integration of an aptamer library in the 
5’ UTR of the reporter gene GFP (green fluorescence protein) on a plasmid backbone. A large 
range of plasmids containing the different aptamers is generated, and yeast cells are 
transformed with the DNA. After growth on selective solid media, cell colonies (clones) can 
be individually transferred into multi-well plates and grown in liquid culture. The resulting 
cell culture can then be split in two identical, parallel samples. To only one of the samples, a 
defined amount of the ligand molecule is added, and the culture is grown in its presence.  
 
 
2.1.12 Fluorescence analysis 
Fluorescence measurement of cell cultures has become a standard analysis method when 
fluorescent proteins or compounds are used in biological settings [153]. Particularly proteins 
from the GFP family are used in molecular biology to accurately quantify, localize or even 
track cellular processes [154-158]. The measurement of GFPs’ fluorescence involves using a 
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beam of light (with a wavelength of 395 nm) that excites the electrons in GFP and causes 
them to emit light; typically of a wavelength of 509 nm [159]. This emitted light is then 
detected and quantified as “counts” of detected signals on the detector. A biological sample 
producing a lot of GFP would emit many more counts of fluorescence than a sample not or 
barely producing GFP.  
Often, sophisticated machines are used to measure fluorescence levels. Here, the approaches 
can differ vastly as well. Two such methods used to measure a lot of samples in parallel are 
described in the following. 
Similar to measuring absorbance of a cell culture in single cuvettes in a spectrophotometer 
(Table 3), a microplate reader can be used to measure multi-well plates (typically 96 wells). A 
beam of light of a certain wavelength is used to either excite electrons of molecules in the cell 
culture wells and thereby enable fluorescence measurements or used to measure a culture’s 
density using its refractory index to measure absorbance. Microplate readers typically allow 
the beam of light to pass through the sample from above or below, giving a measurement of 
the mean fluorescence or absorbance of all cells in the culture. 
A second method to measure many samples in parallel is flow cytometry. Opposed to a 
microplate reader, fluorescence is not measured as a mean of the culture, but individual cells 
are moved through a “flow cell” (measurement chamber). Inside the flow cell, the cytometer 
measures the fluorescence level of each individual cell with a sensor. The output of the 
measurement is the mean and median fluorescence values of a set number of single cells. The 
cytometer can measure several fluorescence levels per cell as well. This is useful e.g. to 
measure GFP and the fluorescence protein mCherry at the same time in the same cell. Some 
cytometers contain a sorting system next to the fluorescence sensor (fluorescence-activated 
cell sorting, FACS). Using previously defined parameters, the cell sorter is able to divert 
single cells fitting these parameters (e.g. emitting a certain wavelength of light) into separate 
tube for collection. Cell sorting is a powerful tool to divide large diverse cell populations into 
subgroups or even single cells for later use.  
In this thesis fluorescence measurements were used to investigate the influence of 
riboswitches on the production of fluorescent reporter genes. FACS was used to sort cells 
according to their individual fluorescence levels. 
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2.1.13 Next generation sequencing (NGS) 
DNA sequencing has been a standard method for molecular biologists since the 1970s [160-
162]. Sequencing methods have continued to improve since then, leading to a selection of 
commercial sequencing facilities available. The development of automated DNA sequencing 
has enabled the Human Genome Project in the early 2000s to analyze the first human genome 
in its entirety [163-165]. Since then, large-scale sequencing techniques have evolved 
dramatically, making the analysis of large amounts of DNA affordable and therefore useful 
for a broad range of experiments. The application of next-generation sequencing (NGS) or 
deep-sequencing methods for SELEX experiments allows detailed analysis of individual 
selection rounds. Applying NGS to SELEX can make decisions for downstream experiment 
like in vivo screening or in vitro binding studies of aptamers easier and sheds light into the 
“black box” SELEX has been described as [166]. 
 
 
2.1.14 Structural characteristics and analysis of RNA aptamers and riboswitches 
As single-stranded nucleotides RNA aptamers can take on complex structures. Typical 
secondary structure elements are hairpins, internal loops, nucleotide bulges and junctions 
[167]. Tertiary structure elements are possible as well, such as pseudo-knots, kissing-
complexes and tetraloop-tetraloop interactions [61, 168]. Tertiary structures can additionally 
be stabilized by kations [169].  
In the formation of aptamer-ligand complexes, electrostatic interactions, stacking interactions 
as well as hydrogen bonds between the functional groups of the ligands and the RNA bases 
play an important role. 
Aptamers are very flexible molecules and can adopt more than one conformation and several 
complex tertiary structures without ligand [170, 171]. Therefore, their structural analysis is at 
the same time highly important and laborious. The binding process to a target induces a 
conformational change in the aptamer. This is why most aptamer structures to date are only 
solved in combination with their respective target molecule, as only the binding of the ligand 
leads to the adoption of a rigid and relatively inflexible structure [172]. This allows structural 
analysis which comprises time-consuming methods, necessary to capture accurate 
information. There is a number of these complex methods, all allowing for their own 
advantages and weaknesses. Smallangle X-ray scattering (SAXS) analysis can deliver 
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information on different conformations of a riboswitch in solution, but it does not yield high-
resolution insights [173, 174]. As a contrast, X-ray crystallography [175-177] leads to very 
highly resolved results, but can only show the details of one “time-frozen” conformation, 
which is why X-ray crystallography is typically carried out with the aptamer’s ligand present. 
Nuclear magnetic resonance (NMR) spectroscopy [178, 179] is able to deliver atomic-
resolution information on several conformational states in solution, but its limits regarding 
molecule size are dramatic, with aptamers and riboswitches often above the upper threshold 
[180, 181]. Despite of these various limitations, plenty of aptamer and riboswitch structures 
have been solved (in the case of NMR, often their reaction core motifs). A lot has been and is 
being learned by the application of these methods. To get a comprehensive overview over a 
molecule’s structure, however, it can be necessary to combine several of these methods, 
which takes a lot of expertise and often years to complete. A new method emerging to reduce 
a few of these obstacles is single-molecule fluorescence resonance energy transfer (smFRET) 
[172, 182, 183]. It has recently been used to study the dynamics of ligand-free riboswitch 
structures in particular, as the observation of one isolated molecule makes signal-to-noise 
compensation of such flexible structures much easier and even allows the following of kinetic 
events inside the sample. Folding of RNA can be observed in “Live Mode” using this 
technique [184].  
Altogether, RNA structure determination remains a complex issue. As researchers in the 
aptamer and riboswitch field often lack the expertise or equipment to employ these high-tech 
methods, faster, low-tech methods are often employed as a first look into RNA structure [51]. 
One such method is in-line probing [185, 186]. This probing method exploits the inherent 
instability of RNA single-stranded regions. Single-stranded RNA is more flexible and can 
perform nucleophilic attacks on itself, taking on the so-called “in-line position”, leading to a 
self-degradation over time [186, 187]. Double stranded RNA regions, on the contrary, are 
more stable and less prone to self-degrade, a behavior which is mimicked by single-stranded 
nucleotides that are part of ligand molecule interactions. Incubating an RNA of interest over a 
longer time period (up to several days) with the target molecule and the subsequent 
visualization of the degradation bands on a gel leads to a distinct pattern giving information 
on stable und unstable regions in the RNA. Incubation of the RNA together with a ligand 
molecule leads to a modified degradation pattern, highlighting ligand binding nucleotides or 
regions within the RNA (Figure 5) [188]. 
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Figure 5: Schematic depiction of an in-line probing gel. Shown is an exemplary cleavage pattern of RNA 
incubated with and without ligand. Changes occur in the secondary structure configuration of the RNA upon 
binding of the metabolite (RNA structures left and right of the gel). Nucleotides locked into position by ligand 
binding are less flexible and less likely to self-cleave by taking on the in-line conformation, thus cleavage bands 
are reduced. The figure was adapted from Regulski et al. [186]. 
 
Adding variations of ligand concentration to the RNA even allows for the approximation of 
the dissociation constant (kD). As the in-line reaction can be carried out in aqueous solution, 
it yields structural information which can be more likely to reflect the natural state of the 
RNA inside their organisms. Because in-line probing and other structural probing methods 
yield results in a fast and easy manner, without the need for sophisticated and specialized 
material, many researchers in the aptamer and riboswitch field first apply in-line probing to 
obtain information on the secondary structure of putative riboswitches [51]. For the 
mentioned reasons, in-line probing was used in the course of this thesis as well. 
After growth, the two parallel cultures (with and without ligand) are analyzed and compared 
to each other. As an aptamer acting as a riboswitch should reduce gene expression (and 
therefore GFP fluorescence levels) when its ligand is present, the GFP value of the culture 
with ligand should be lower than in the culture grown without ligand. 
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Figure 6: Schematic in vivo screening process A Shown is a solid media plate with yeast colonies displaying 
different levels of GFP fluorescence, low or none (white) and medium and high fluorescence (green, arrows). 
B Inoculated and grown yeast colonies in a multi-well plate showing medium or high fluorescence (green) are 
split into two new multi-well plates. Of the two plates, one contains ligand in the medium, which leads to a 
decrease in GFP expression when a riboswitch can interact with it (white wells in plate). Comparison of the 
fluorescence levels of corresponding wells between the two wells can therefore lead to the identification of a 
ligand responsive riboswitch. The figure was adapted from Weigand et al. [132].  
 
The regulatory activity for an aptamer/riboswitch is calculated as the quotient of the GFP 
values of the two cultures (Equation 1). 
 
Equation 1: General calculation of the regulation factor of a riboswitch using a fluorescence gene 
GFP fluorescence without ligand
GFP fluorescence with ligand
= regulation factor (x − fold) 
 
As controls, plasmids without GFP expression and with constitutive GFP expression (GFP 
ON and GFP OFF) are grown and measured in parallel to any experiment. Aptamers 
developed in the course of this thesis were to be tested in such an in vivo setting, to examine 
any potential riboswitch abilities they might possess. 
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2.2 Motivation and relevant previous results from the Suess and Heckel group  
2.2.1 Development of a light-switchable riboswitch 
Synthetically produced aptamers have the potential to act as a riboswitch (2.1.9). 
Light-switchable aptamers could bring advantages if used as part of a riboswitch in a 
biological application, as light is an ideal trigger for reactions in the cell. It can be controlled 
spatially, temporally and in terms of its intensity without major technical effort. Most cells do 
not respond to light as a stimulus, so other cellular processes are not disrupted [189-191]. 
Light of an adequate wavelength does not damage cells or their content, but as most cells are 
at least partially translucent, it can reach the inner regions and stimulate a response from a 
light-sensing aptamer or riboswitch [192-194]. Thus, light-switchable riboswitches could be 
promising tools for genetic circuits, as they would add another synthetic class of orthogonal 
triggers to the “toolbox” of genetic engineers, particularly when they show a reversible 
turning “on” and “off” of gene expression (Figure 7). In nature, no mechanism is known in 
which nucleic acids act as photoreceptors and regulate gene expression [195].  
 
 
Figure 7: Schematic representation of the function of a synthetic light-regulated riboswitch Shown is a 
riboswitch on the left, able to bind the trans isoform of azoCm, and thereby repressing gene expression. azoCms 
trans state is induced by irradiation with light of λ=365 nm. On the right, the conformation of azoCm has been 
switched to cis, using light of λ=420 nm. The cis isoform cannot be bound by the riboswitch anymore, and gene 
expression is turned on. The system is reversible upon changing of the irradiation wavelength. The figure was 
adapted from Rudolph [196]. 
 
Light-switchable aptamers developed in this thesis should therefore also be tested regarding 
their regulative functions in an in vivo setting within living cells. Because not all aptamers 
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working well in vitro show a functionality of a riboswitch in vivo, as many aptamers as 
possible from an enriched SELEX round were tested regarding their regulation ability (see 
2.1.11). As this photo-responsive riboswitch would have two responsive states, dependent on 
the wavelength of light surrounding the system, in vivo analysis of the regulative ability of the 
riboswitch could be carried out in two stages as well. Firstly, binding and the subsequent 
structural change of the riboswitch to its target would need to be verified. Secondly, the 
reversibility of this binding upon irradiation with a fitting wavelength would need to be 
verified. 
 
 
2.2.2 azoCm - a light-switching molecule 
During the last decade, light controlled tools have come into the focus of the biological and 
biochemical research area as they offer spatial and temporal control of processes [189]. The 
development of new light sources, mainly light-emitting diodes (LEDs) and light 
amplification by stimulated emission of radiation (lasers), have benefited this research area. 
Light from these sources can be controlled to only emit a certain wavelength, without emitting 
additional, potentially harmful, wavelengths. Regulation of biological processes by light has 
already been carried out in transparent organisms such as the nematode Caenorhabditis 
elegans or the zebra fish Danio rerio [193]. In large, non-transparent organisms, light control 
of reactions close to the skin surface has been carried out. Recently, research groups have 
demonstrated that ultraviolet (UV-) light can penetrate the tissue of mice [194]. Even 
experiments with glass fibers inserted into the brain of mice to control behavior have been 
executed [197].  
Previously to this thesis, Dr. Thomas Halbritter from the Heckel Lab in Frankfurt has 
developed a light-switchable small molecule; called azoCm (Figure 8, Table 2 [198, 199]). 
azoCm is a molecule of the azobenzene group. It can undergo a photochromic isomerization 
process, meaning it can reversibly switch from its trans to its cis conformation. Both 
isomerization states have different absorption spectra [198]. The basic structure of 
azobenzenes consists of two phenyl rings, which are connected by nitrogen double bonds 
(N=N). These two nitrogen atoms are called “azo group” and give the family of molecules its 
name. In the thermally preferred state, the molecule takes on a planar conformation, the trans 
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state. Irradiation with ultra violet (UV) light with a wavelength of about 350 nm induces the 
isomerization to the cis state (Figure 9).  
 
 
Figure 8: azoCm and azoCm Amino Shown is the light-switchable compound azoCm, left with a carbon 
terminal group (COOH), right with a NH2 terminal group (Amino). 
 
In the cis state, the phenyl rings are inclined at about 55° to each other, however, due to an 
overlay of the UV/VIS spectra, a photostationary state with a maximum of 80% cis can be 
achieved [189, 200]. The isomerization back to the trans state is induced by irradiation with 
visible light (VIS) of about 450 nm, or thermally by heating (Figure 9). The isomerization to 
trans takes place within picoseconds, the thermal backreaction takes up to several days at 
room temperature.  
The azobenzene can be chemically modified on both phenyl rings, the substituents having a 
decisive influence on the isomerization wavelengths and the stability of the two states. Due to 
high quantum yields during isomerization and low photobleaching, azobenzenes have been 
widely used to date [198, 200-202].  
The developed azobenzene azoCm was designed to be a favorable target molecule to be used 
in biological systems. The substituent groups of the phenyl rings were modified in a way that 
lead to a trans-cis isomerization at 365 nm, a wavelength on the longer spectrum of UV light 
and less likely to cause any damage in biological systems [201, 202]. They were also chosen 
to grant azoCm a long stability in aqueous solution, a necessity when working in biological 
systems and not typical for azobenzenes [199]. Next to a stable azobenzene compound 
compatible with aqueous conditions (azoCm-COOH, usually referred to as azoCm), a 
derivative was designed (azoCm Amino or azoCm-NH2). To allow immobilization of azoCm 
on the surface of Affi-gel 10 (Table 1), the matrix used in SELEX experiments, a primary 
amino group on the molecule was necessary to allow the formation of a stable amide bond. If 
not specifically mentioned otherwise, azoCm Amino was only used to generate the azoCm 
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derived matrix for SELEX. All elution steps during SELEX and all in vivo screening 
experiments were carried out using the original compound azoCm. 
 
 
Figure 9: Trans-cis isomerization of azoCm Amino Shown are the two isoforms azoCm Amino can take on 
upon irradiation with different wavelengths of light. Light with λ=365 nm leads to the cis, light with λ=420 nm 
leads to the trans conformation. The reaction from cis to trans can also occur thermally (not shown), but at a 
much slower rate.  
 
Due to the properties of azoCm, toxicity studies using several biological model systems were 
carried out previously to this thesis. As demonstrated in Lotz et al., azoCm shows toxicity at 
high concentrations of 1 mM in human cells, and no detectable toxicity for Bacillus subtilis, 
E. coli and S. cerevisiae for up to a 5 mM ligand solution [198]. Therefore, the use of lower 
concentrations would make azoCm a feasible molecule to use in biological application. Tests 
carried out during this thesis were typically carried out using 100 µM ligand solutions. 
 
 
2.2.3 SELEX against azoCm  
A main goal of this thesis was the development of an aptamer (using the SELEX method), 
which selectively binds to only one isoform of azoCm. So far, three other research groups 
have carried out SELEX against photochromic molecules [203-205]. Of the three small 
molecules used as targets, only one contained an azobenzene photosensitive group [205]. The 
used azobenzene was flanked by three amino acids, making it a small peptide target molecule. 
Using SPR, Hayashi et al. could detect RNA aptamers binding the trans isoform of their 
peptide target with a high nanomolar to a low micromolar kD. Binding to its cis isoform was 
reported as ten times worse, making it an example of a successful light-selective RNA against 
an azobenzene target [205, 206]. 
In order to be able to use azoCm as a target molecule in SELEX, a modified version of it had 
to be developed to allow covalent binding to a carrier material. As immobilization of the 
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target molecule is crucial during the applied affinity SELEX method, Dr. Thomas Halbritter 
designed an azoCm derivative with a NH2-group attached to a C2-linker to allow coupling of 
azoCm to a carrier matrix (0) while keeping it accessible for aptamers to interact with. 
 
 
 
 
 
Figure 10: AzoCm-NH2 AzoCm-NH2 is shown covalently coupled to activated resin (red sphere). 
 
A SELEX carried out against azoCm previously to this thesis yielded aptamers binding in an 
isoform selective manner (4.1, see [196, 198]). Its development over the nine SELEX rounds 
carried out is shown in chapter 4.2. A gradual enrichment of RNA until round 5 can be 
observed, after which unspecific elution with 20 mM EDTA was switched to specific elution 
using a 5 mM azoCm solution. 
 
 
2.2.4 An existing light-selective aptamer against azoCm 
A truncated aptamer from the SELEX described in 2.2.3 called “aptamer 42” was analyzed 
using isothermal titration calorimetry (ITC, 3.2.13), allowing the determination of its binding 
constant (kD).  The 42 nt long RNA aptamer was able to bind to azoCm in its trans form with 
a kD of 3.55 ± 0.04 µM, while showing no binding to its cis form (two independent 
measurements, example see Figure 11).  
While the aptamers generated by Rudolph did show isoform specific binding to azoCm trans, 
testing the two aptamer versions in an in vivo context showed that they could not work as 
riboswitches [196]. Introducing them into the 5’ UTR in front of the reporter gene GFP 
(compare to 3.3.8) reduced all GFP expression to background levels, comparable to a negative 
control which did not contain a start codon in front of the GFP gene. Therefore, a closer 
analysis of the generated aptamers was planned, to find out more about their structural 
properties. Additionally, it was planned to generate a new aptamer binding isoform selectively 
to azoCm. 
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Figure 11: ITC measurement of aptamer 42 with 200 µM azoCm. A A kD of 3.55 ± 0.04 µM was determined 
upon binding of aptamer 42 with 200 µM azoCm trans. B ITC measurement of  aptamer 42 with 200 µM azoCm 
cis. No binding could be determined. ITC measurements were carried out by Rudolph [196]. 
 
In a 2D structure prediction using mfold (Table 12), aptamer 42 showed the structures shown 
in Figure 12. The verification of the structural prediction of the truncated version by in-line 
probing constituted the first objective of this doctoral thesis (3.2.14).   
 
 
Figure 12: Predicted secondary structure of aptamer 42 For structure prediction of the shown aptamer 42 the 
software mfold was used (Table 12).   
5‘ 3‘ 
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2.3 Objectives    
The aim of the presented work was to generate RNA aptamers specifically binding to one of 
two photo-inducible isoforms of a small azobenzene-derived molecule, called azoCm. From 
such aptamers, a light-selective riboswitch should be engineered.  In order to achieve this, 
four steps were taken in the course of this work (see Figure 13):  
 
 Performing a SELEX against azoCm and generating specifically binding aptamers.   
 Developing a light SELEX protocol to generate isoform specific aptamers. 
 Testing selected aptamers in vitro regarding their binding ability and affinity. 
 Analysis of selected aptamers in vivo whether they show regulatory function and can 
work as riboswitches. 
 
To generate aptamers binding specifically to azoCm, the compound was used as a target 
during SELEX. Throughout the SELEX rounds, the majority of RNA aptamers from a large 
randomized library are eliminated and at the end an enriched aptamer pool with mainly 
ligand-specific aptamers is generated. Aptamers from this SELEX should be tested regarding 
their binding affinity and specificity to azoCm.  
 
 
Figure 13: Planned steps performed to generate a light-sensitive riboswitch As a first step, SELEX against a 
light-selective molecule is performed. A light SELEX protocol is developed and applied to the SELEX pools 
derived from the previous SELEX. Aptamers from the light SELEX are tested in in vitro and in in vivo assays, to 
discover a new light-sensitive riboswitch for S. cerevisiae. 
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As the molecule azoCm undergoes a reversible conformation change induced by white light 
and UV light, respectively, these properties should be used to develop a light SELEX 
protocol. The protocol should be designed to ensure that the generated aptamers bind 
selectively to only one of the two isoforms of azoCm.  
The possibility of using these aptamers in an in vivo context should be investigated. The 
aptamers should be introduced into the 5’ UTR of a reporter gene (GFP) to measure GFP 
expression in dependence of added ligand in Saccharomyces cerevisiae. The successful gene 
regulation in dependence of azoCm would be the first indication of a functional riboswitch. 
To generate a functional light-dependent riboswitch, it needs to be proven that addition of the 
photo-switchable molecule azoCm and irradiation with light of an adequate wavelength is 
able to regulate gene expression in a reversible manner. Using such a light-dependent 
riboswitch, gene expression in cells could be turned on and off in reversibly and with exact 
spatial and temporal control using only light as a trigger. A successful experiment would 
prove the establishment of a novel, light-dependent synthetic riboswitch. 
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3 Material and Methods 
If not otherwise mentioned, water or MQ always refers to purified water from a PURELAB 
flex 2 purification machine (Table 3).  
If not stated otherwise, alcohol or pure alcohol always refers to 99.6% ethanol (ethanol 
absolute), or 99.6% ethanol diluted with MQ, e.g. used for washing nucleic acids. Methylated 
ethanol was used to clean surfaces only. 
 
 
3.1 Listing of the used resources and chemicals 
In the following, the resources used in this thesis are listed. 
 
Table 1: Chemicals 
Chemical Manufacturer 
  
[γ-32P] ATP Hartmann Analytics 
[α-32P] UTP Hartmann Analytics 
2-Propanol (Isopropanol) Sigma-Aldrich 
6x DNA loading dye New England Biolabs 
Acetic acid Carl Roth GmbH 
Acetone Sigma-Aldrich 
azoCm Detailed in Table 2 
azoCm Amino Detailed in Table 2 
Adenine Carl Roth GmbH 
Affi-Gel 10 Gel Bio-Rad Laboratories GmbH 
Agar Carl Roth GmbH 
Agarose peqGold Universal PeqLab 
Ammonium sulphate  Carl Roth GmbH 
Ampicillin Carl Roth GmbH 
Bromophenol blue Carl Roth GmbH 
Butanol Carl Roth GmbH 
Calcium chloride dehydrate (CaCl2) Carl Roth GmbH  
Chloroform Carl Roth GmbH 
Compound 3 Detailed in Table 2 
CytoFLEX Sheath Fluid Beckman Coulter GmbH 
D(+)-Glucose Carl Roth GmbH 
D-Sorbitol Carl Roth GmbH  
Difco Yeast BD 
Disodium phosphate dihydrate (Na2HPO4 ⋅ Carl Roth GmbH 
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2 H2O) 
Dimethyl sulfoxide (DMSO) Carl Roth GmbH 
dNTPs PeqLab 
Dithiothreitol (DTT)  Roche 
Ethanolamine Carl Roth GmbH 
Ethidium bromide Carl Roth GmbH 
Ethanol absolute (99,6%) VWR 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH 
FlowClean Cleaning Agent Beckman Coulter 
Formamide Carl Roth GmbH 
Glycerin/glycerol Carl Roth GmbH 
GlycoBlue™ Coprecipitant  Ambion 
Glycogen Thermo Fisher Scientific 
Kohrsolin Bode Chemie GmbH 
Lithium acetate (LiAc) Carl Roth GmbH 
MEM amino acid mix Sigma-Aldrich 
Methanol Carl Roth GmbH 
Methylated ethanol Richter Chemie GmbH 
Molox RNase inhibitor moloX GmbH 
MQ Produced with PURELAB flex 2, see Table 
2 
Neomycin trisulphate Carl Roth GmbH 
NTPs Peqlab 
PEG 4000  Carl Roth GmbH  
Peptone  Carl Roth GmbH 
Potassium chloride (KCl) Carl Roth GmbH 
Potassium dihydrogen phosphate (KH2PO4) Carl Roth GmbH 
RNase ZAP Sigma-Aldrich 
Roti Szint Eco Plus (Scintillation Cocktail) Carl Roth GmbH 
Sodium acetate  Carl Roth GmbH  
Sodium azide Carl Roth GmbH 
Sodium carbonate (Na2CO3) Carl Roth GmbH 
Sodium citrate Carl Roth GmbH 
Sodium chloride (NaCl) Carl Roth GmbH 
Sodium phosphate, monobasic, anhydrous  
(NaH2PO4)  
Carl Roth GmbH 
Sorbitol Carl Roth GmbH 
Spermidine Sigma-Aldrich 
Sulfuric Acid (H2SO4), 96% Carl Roth GmbH 
Tetracycline hydrochloride Sigma-Aldrich 
Tris-HCl Carl Roth GmbH 
Triton X-100 Carl Roth GmbH 
Tryptone  Carl Roth GmbH  
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Yeast extract Oxoid 
Yeast nitrogen base Becton, Dickinson and Company 
Yeast tRNA  Life Technologies 
 
 
Table 2: Small molecule compounds used in this thesis 
Compounds  Published in Structural formula 
   
azoCm Lotz et al. [198] 
 
azoCm-NH2 or 
azoCm Amino 
Lotz et al. [198] 
 
Compound 3 Halbritter & Kaiser et al. [207] 
 
 
 
Table 3: Appliances and disposables 
Equipment Manufacturer 
  
-20°C Freezer  Liebherr  
24 Well plate (u-bottom) Greiner bio-one Inc 
-80°C Freezer  New Brunswick  
96 Deep well plate (u-bottom) Greiner bio-one Inc 
96 Well plate (flat bottom) Greiner bio-one Inc 
ATL224I Analytical Balance Acculab Sartorius group 
ATL8201-I digital gram scale Acculab Sartorius group 
Autoclave Tuttnauer 3870 ELV-3  Tuttnauer Biomedis  
Benchtop Centrifuge Micro Star 17 VWR international GmbH 
Bio-Spin® Chromatographic columns  Bio-Rad  
BREATHseal™ Greiner Bio-One 
Bunsen burner Carl Roth GmbH 
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Chicane flask (50 mL, 250 mL, 500 mL, 
1000 mL) 
Schott Duran 
Consort EV243 power supply Wolflabs 
CytoFLEX S Flow Cytometer Beckman Coulter GmbH 
Electrophoresis Power Supply Consort  PeqLab  
Electroporation cuvette (0,1 and 0,2 cm)  Bio-Rad 
Eppendorf multichannel pipette Eppendorf 
Eppendorf™ ThermoStat Plus Fisher scientific 
Falcon™ Cell Strainers, 40μm Thermo Fisher Scientific 
FastPrep®-24  MP Biomedicals   
Fluorescent Image Analyzer FLA-500  Fujifilm   
Fluorolog FL3-22 Spektrofluorometer  Horiba   
Flüssigkeitsszintillationszähler 1409 
(scintillation counter) 
Wallac Monza 
Gel electrophoresis chamber Carl Roth GmbH 
Gel documentation chamber  INTAS   
Glassbeads (0.25–0.5 mm)  Carl Roth GmbH   
Glassbeads (425-600 μm) Sigma-Aldrich 
Glasfrit Duran  
Heating block VWR   
Heraeus Pico 17 centrifuge  Thermo Fisher Scientific  
Ika vortex genius 3 Sigma-Aldrich 
Image Eraser SF  Molecular Dynamics   
Incubation Shaker Multitron Infors AG  
Incubator Thermo Fisher Scientific 
Incubator Titramax 1000 Heidolph Instruments 
LED LENSER® - T7  LED LENSER   
Leica M50 with GFP plus filter 10446143 Leica Microsystems GmbH 
Magnetic stirrer Ikamag Reo IKA 
Magnetic stirrer IKA RET basic  IKA   
Membrane filter SUPOR 450, 0,2 μM  Pall Corporation   
Membrane filter SUPOR 450, 0,45 μM  Pall Corporation   
MicroCal PEAQ iTC200  Malvern Instruments  
Microcentrifuge tube 1.5 mL, 2 mL Greiner bio-one Inc 
Micropipette 
(2 µL, 20 µL, 200 µL, 1000 µL) 
Gilson Inc 
MicroPulser Electroporator Bio-Rad 
Microplate Reader Infinite 200 PRO Tecan   
Multifuge 1L-R  Heraeus Christ   
NanoDrop ND 1000 Spectrophotometer PeqLab 
Nitrile gloves Starlab International GmbH 
PeqSTAR 96 Universal Gradient PeqLab 
Peqstar XS PCR Cycler  PeqLab  
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Petri dish, plastic Sarstedt 
pH-meter 766 calimatic Knick 
Storage Phosphor Screen, 20 x 23 cm  Fujifilm 
Pipette controllers Pipetboy VWR International GmbH 
Pipette tip Gilson® - Style (10, 20, 200, 
1000 µL) 
Greiner bio-one Inc 
Power station 300  Labnet  
Purelab® flex  Elga 
Refrigerator Liebherr  
Refrigerator Comfort Refrigeration Inc 
Rotating mixer CAT-RM5  CAT M. Zipperer GmbH   
Sigma 4 – 16KS Sigma Laborzentrifugen GmbH 
Single use pipette (5 mL, 10 mL, 25 mL) Greiner bio-one Inc 
Spektrophotometer Ultrospec 2100 pro  Biochrom Ltd   
Sterile Bench  BioFlow Technik  
Sterilfilter Filtropur S 0,2 μm  Sarstedt   
Terasaki plate Greiner Bio-one Inc 
Test tube Schott Duran 
Thermocycler peqSTAR 96 Universal  PeqLab   
Thermometer “Platinum Ultra-Accurate 
Digital Traceable Thermometer” 
Traceable® Products 
Thermomixer Comfort  Eppendorf AG   
ThermoStat plus  Eppendorf AG   
TipOne® Filter Tips (10/20, 20, 200, 
1000 µL) 
StarLab 
Tissue-Box Carl Roth GmbH 
Towels Hegro Eichler GmbH 
Tube Cellstar®, 15 mL, 50 mL Greiner bio-one Inc 
UV/VIS spectrophotometer Amersham Biosciences 
UV handlamp Nu-6 KL  Benda   
UVLED 365  Fabrikat Bonn  
Waterbath WNB14  Memmert   
 
 
Table 4: Kits and systems 
Name Manufacturer 
  
TOPO-XL PCR Cloning Kit Invitrogen (Thermo Fisher Scientific) 
Wizard® SV Gel and PCR Clean-Up 
System 
Promega, USA 
Zymoclean™ Gel DNA Recovery Kit Zymo Research 
Frozen EZ Yeast Transformation II Kit™ Zymo Research 
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QIAprep® Spin Miniprep Kit QIAGene 
QIAprep® Spin Midiprep Kit QIAGene 
QIAquick® PCR purification Kit QIAGene 
 
 
Table 5: Enzyme systems and DNA standards 
Enzymes & buffers Manufacturer 
  
40 U Ribonuclease Inhibitor (Molox) moloX GmbH 
AgeI HF® New England Biolabs 
Antarctic Phosphatase  New England Biolabs 
Antarctic Phosphatase Buffer (AP Buffer) New England Biolabs 
First Strand Buffer Invitrogen (Thermo Fisher Scientific) 
NheI HF® New England Biolabs 
peqGold 1kb DNA Ladder PeqLab 
peqGold Ultra Low Range DNA Ladder PeqLab 
Q5® High GC Enhancer  New England Biolabs  
Q5® Reaction Buffer  (5x) New England Biolabs  
Q5 polymerase  
RNA-free DNase Ambion Life Technologies 
RNase T1 Thermo Fisher Scientific 
SuperScript IV Reverse Transcriptase Invitrogen (Thermo Fisher Scientific) 
T4 Ligase buffer New England Biolabs 
T4 Polynucleotide Kinase New England Biolabs 
T4 Polynucleotide Kinase Reaction Buffer 
(PNK Buffer) 
New England Biolabs 
T7 RNA Polymerase New England Biolabs 
Taq DNA Polymerase  New England Biolabs 
Thermopol Buffer  New England Biolabs  
 
 
Table 6: Oligonucleotides used in this work, in 5’ to 3’ direction 
Name Specifications Sequence 
   
Library 
1A 
For partially 
structured 
SELEX pool 
GGGAGACGCAACTGAATGAANNNNNNNNNNNNNNN
NNNNNNNNNNNCTGCTTCGGCAGNNNNNNNNNNNN
NNNNNNNNNNNNNNTCCGTAACTAGTCGCGTCAC 
Library 
1B 
For N64 
randomized 
SELEX pool 
GGGAGACGCAACTGAATGAANNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNTCCGTAACTAGTCGCGTCAC 
Library 1  GTATAATACGACTCACTATAGGGAGACGCAACTGAA
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fwd TGAA 
Library 1 
rev 
 GTGACGCGACTAGTTACGGA 
Library 2 For N74 
randomized 
SELEX pool 
GTGGATCCGACCGTGGTGCCNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNGCAGTGAAGG
CTGAGCTCC 
Library 2 
fwd 
 TCTAATACGACTCACTATAGGAGCTCAGCCTTCACTG
C 
Library 2 
rev 
 GTGGATCCGACCGTGGTGCC 
Library 
doped 
For Doped 
SELEX pool 
CCAAGTAATACGACTCACTATAGGGCCAAGCTAGAT
CTACCGGTNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNN[GG](CCTACGGGAAAGG)NNNNNAAAATGGCTA
GCAAAGGAGAAGAACTTTTCACT 
[ ] 50% randomized, ( ) 6% randomized 
Library 
doped 
fwd 
 CCAAGTAATACGACTCACTATAGGGCCAAGCTAGAT
CTACCGGT 
Library 
doped 
rev 
 AGTGAAAAGTTCTTCTCCTTTGCTAGCCATTTT 
GFP rev Sequencing of 
aptamers in 
pWHE601 
CCACTGACAGAAAATTTGTGC 
 
Library 
B2-10 
B2-derived 
pool for in 
vivo screening 
ATCTACCGGT(GCTCCCTTTAGATGTTAGTCGAAGAC
ATCTAACCTACGGGAAAGGAGACC)AAAATGGCTAG
CAAAGGAGAAGAACTTTTCACTGGAG 
( ) 10% randomized 
Library 
B2-6N6 
B2-derived 
pool for in 
vivo screening, 
truncated 
ATCTACCGGT(GCTCCCTTTAGA)NNNNNN(TCTAACC
TACGGGAAAGGAGACC)AAAATGGCTAGCAAAGGAG
AAGAACTTTTCACTGGAG  
( ) 6% randomized 
Library 
B2-N6 
B2-derived 
pool for in 
vivo screening, 
truncated 
ATCTACCGGTGCTCCCTTTAGANNNNNNTCTAACCTA
CGGGAAAGGAGACCAAAATGGCTAGCAAAGGAGAA
GAACTTTTCACTGGAG 
Libraries 
B2 rev 
 GTCCAGTGAAAAGTTCTTCTCCTTTGC 
Library 
B2-5 
B2-derived 
pool for in 
vivo screening 
GCATACAATCAACTCCAAGCTAGATCTACCGGT(GCT
CCCTTTAGATGTTAGTCGAAGACATCTAACCTACGGG
AAAGGAGACC)AAAATGGCTAGCAAAGGAGAAGAAC
TTTTCACT 
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( ) 5% randomized 
Library 
B2-1 7 
Riboswitch 
B2-1 derived 
pool for in 
vivo screening 
GTTTCTTTTTCTGCACAATATTTCAAGCTATACCAA(G
CATACAATCAACTCCAAGCTAGATCTACCGGT)GCTC
CCTTTAGAGGTTTGTCGAAGACCTCTAACCTACGGGA
AAGGAGACCAAAATGGCTAGCAAAGGAGAAGAACT
TTTCACT 
 ( ) 2.5% randomized 
Library 
B2-1 8 
Riboswitch 
B2-1 derived 
pool for in 
vivo screening 
GTTTCTTTTTCTGCACAATATTTCAAGCTATACCAA(G
CATACAATCAACTCCAAGCTAGATCTACCGGTGCTCC
CTTTAGAGGTTTGTCGAAGACCTCTAACCTACGGGAA
AGGAGACC)AAAATGGCTAGCAAAGGAGAAGAACTT
TTCACT 
( ) 6% randomized 
Library 
7/8 fwd 
 GTTCTCGTTCCCTTTCTTCCTTGTTTCTTTTTCTGCACA
ATATTTCAAGCTATACCAA 
Library 
7/8 rev 
 AGAATTGGGACAACTCCAGTGAAAAGTTCTTCTCCTT
TGCTAGCCATTTT 
HR_fwd HR in 
pWHE601 
fwd 
CAAGCTATACCAAGCATACAATCAACTCCAAGCTAG
ATCTACCGGTGGAGCTCAGCCTTCACTGC 
HR_rev1 HR in 
pWHE601 rev 
CAAGAATTGGGACAACTCCAGTGAAAAGTTCTTCTC
CTTTGCTAGCCATTTT GTGGATCCGACCGTGGTGCC 
HR_rev2 HR in 
pWHE601 rev 
plus G 
(frameshift) 
CAAGAATTGGGACAACTCCAGTGAAAAGTTCTTCTC
CTTTGCTAGCCATTTTG GTGGATCCGACCGTGGTGCC 
HR_rev3 HR in 
pWHE601 rev 
plus TG 
(frameshift) 
CAAGAATTGGGACAACTCCAGTGAAAAGTTCTTCTC
CTTTGCTAGCCATTTTTGTGGATCCGACCGTGGTGCC 
B2-1 fwd  CCAAGCTAGATCTACCGGTGCTCCCTTTAGAGGTTTG
TCGAAGACCTCTAACCTACG 
B2-1 rev  AGTGAAAAGTTCTTCTCCTTTGCTAGCCATTTTGGTCT
CCTTTCCCGTAGGTTAGAGGTCTTCGACAAACCTC 
B2-1 
short fwd 
 CCAAGTAATACGACTCACTATAGGTCTACCGGTGCTC
CCTTTAGAGGTTTGTCGAAGACC 
B2-1 
short rev 
 GGTCTCCTTTCCCGTAGGTTAGAGGTCTTCGACAAAC
CTCTAAAGGGAGCACCGG 
42 fwd  CCAAGTAATACGACTCACTATAGGTTGACCCTACTGC
TTCGGCAGGCCTACG 
42 rev  TGTTACCTTTCCCGTAGGCCTGCCGAAGCAGTAGGGT
CAACCTATAGTGAG 
pWHE60  CCACTGACAGAAAATTTGTGCCC 
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1-seq 
pSP64 
fwd 
 ATGAGCCCGAAGTGGCGAGCC 
 
 
Table 7: Aptamer sequences 
Name Sequence 
  
42 GGUUGACCCUACUGCUUCGGCAGGCCUACGGGAAAGGUAACA 
1 GUGUUCCGACACGUGAACUCCAGCCCCCUUAAUAACGCUGUCGACCC
UUGCGCUGUUACCUACGGGAAAGGGGU 
3 UAGGGACCCUAAAGCAGGGCUUCAACGGAUACGGCCAUGAGGCGUUC
UAGGAACCAAAGAGCGUAAUAAGCAAUC  
5 AGUUAAUGCACGACGCAGUGAUCGACGUAGGUAGAAAAGCGAUAAG
UAUGGGCCUAAUCCGAUACCGCGAUCAC  
10 GAAUGCUAACAUCCGAUUGUCCAGUACUGCCUUGGUAUAAGUCUGA
AUACGUGGAUCCGACCGUGGUGCC 
11 UUCCAUCCAUUCUCACCCGUGGAUGAAAAGGGACCCGUAUAAGCACA
GAGGCCGCCGAGGAGCCAAGGAACCAAU 
12 CCCCUCCCUACUGUGACUGAACGAACCCACAGUAGGGCCUACGGGAA
AGGGGAGUGACCUGGCCCAAAGCCACC   
13 AGUUAAUACACGACGCAGUGAUCGACGUAGGUAGAAAAGCGAUAAG
UAUGGGCCUAAUCCGAUACCGCGAUCGC  
14 AAAACCGAUUUAAAGGCUACCCAGUGAUCCAUGGAGUAGGAAAAGC
UGCUAACGAGCCGCUCCAUCCAGCCGA   
15 CCCGCAACCGCGACCCCUUGCCGCCUGAGGCUAAAUGCCCCUCUACG
GAAAAGCGGAAGACUCGUGAGUGGGA  
16 AGUUAAUACACGACGCAGUGAUCGACGUAGGUAGAAAAGCGAUAAG
UAUGGGCCUAAUCC 
A AGUUAAUACACGACGCAGUGAUCGACGUAGGUAGAAAAGCGAUAAG
UAUGGGCCUAAUCCGAUACCGCGAUCAC  
E GACGGGCUCCCGCACCUGAGGUGUCUGCCAGAAACGACAAACGUCGC
CUCGGCCACCACUCUGGUUACAAGAGG  
B2-1 CCAAGCUAGAUCUACCGGUGCUCCCUUUAGAGGUUUGUCGAAGACCU
CUAACCUACGGGAAAGGAGACCAAAAUGGCUAGCAAAGGAGAAGAA
CUUUUCACU  
B2-1 
short 
UCUACCGGUGCUCCCUUUAGAGGUUUGUCGAAGACCUCUAACCUACG
GGAAAGGAGACC 
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Table 8: Plasmids 
Plasmid Characteristics Reference/Provided by 
   
pWHE601 Gfp Adapted from Dr. Julia 
Weigand,   
pWHE601* ΔATG-gfp Adapted from Dr. Julia 
Weigand 
pWHE601_neo Neo_gfp Adapted from Dr. Julia 
Weigand 
pCBB05 gfp 
mCherry 
Adapted from Dr. Cristina 
Bofill-Bosch 
pCBB06 ΔATG-gfp 
mCherry 
Adapted from Dr. Cristina 
Bofill-Bosch 
pCBB07 Neo_gfp 
mCherry 
Adapted from Dr. Cristina 
Bofill-Bosch 
pSP64 T7 promoter with aptamer 
insertion site 
Promega 
 
 
Table 9: Organisms 
Organism Genotype 
  
Escherichia coli 10-beta (New England 
Biolabs) 
Δ(ara-ley) 7697 araD139 fhuA ΔlacX74 
galK16 galE15 e14- ϕ80dlacZΔM15 rec1A 
rel1A end1A nupG rpsL (Str
R
) rph 
spoT1Δ(mrr-hsdRMS-mcrBC)   
Saccharomyces cerevisiae RS453α MATα ade2 trp1-1 can1-100 leu2-3 leu2-
112 his3-1 ura3-52 
Escherichia coli (E. coli) F
-
 mcrA Δ(mrr-hsdRMS- 
mcrBC) φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara-leu)7697 galU galK rpsL 
(Str
R
) endA1 nupG 
 
 
Table 10: Solutions and buffers 
General solutions Composition (in distilled water) 
  
1x PCR buffer 10 mM Tris-Cl (pH 9.0), 50 mM KCl, 0.1% 
Triton X-100 
1x SELEX buffer [208] 10 mM Tris-HCl (pH 7.6), 250 mM NaCl, 5 
mM MgCl2  
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2x RT-PCR mix 1x PCR buffer (see above), 1x first strand 
buffer, 2 mM DTT, 1 µM Library_fwd 
oligo, 1 µM Library_rev oligo, 1.5 mM 
MgCl2 and 0.3 mM dNTPs (each) 
Agarose solution for gels 1% (w/v) or 3% (w/v) of agarose in 1x TAE 
buffer, autoclaved 
Ampicillin stock solution (1000x)  100 mg/mL ampicillin, sterile-filtered  
dNTP solution  12.5 mM of dATP, dCTP, dGTP and 
dTTP, each  
Electroporation buffer 1 M Sorbitol, 1 mM CaCl2 
Ethidium bromide stock solution (10x)  10 mg/mL ethidium bromide  
In-line reaction buffer 10 mM Tris-Cl (pH 8.3), 10 mM MgCl2, 
100 mM KCl) 
Phosphate buffered saline  140 mM NaCl; 10 mM KCl; 6.4 mM 
Na2HPO4, 2 mM K2PO4   
Sodium azide solution 0.002% solution of NaN3  
SSC (20x, for 1 L) 3 mM NaCl, 340 mM Sorbitol 
ssDNA DNA from salmon testes (salmon sperm 
DNA), autoclaved, 10 mg/mL 
TAE buffer (50x)  2 M Tris-HCl; 1 M acetic acid (conc.); 50 
mM EDTA (pH 8.0)  
TE (10x) 1 mM EDTA, 2 M Tris-HCl 
TE/LiOAc-buffer (1x) 100 mM 1x TE buffer, 100 mM LiOAc 
TK mix (SELEX) 40 mM Tris-Cl (pH 8.0), 5 mM DTT, 2.5 
mM NTPs (each), 15 mM MgCl2, 100 U T7 
RNA Polymerase, 40 U ribonuclease 
inhibitor 
Urea solution 5 M urea 
Yeast tRNA stock solution 25 mg/mL yeast tRNA in MQ, heated to 
95°C for 5 min and cooled rapidly, then 
frozen 
 
 
 
 
Table 11: Culture media 
Medium Composition Concentration 
   
dYT medium Yeast extract  1.0% (w/v) 
 Tryptone  1.6% (w/v) 
 Sodium chloride  0.5% (w/v) 
 Fill to 1 L with distilled water   
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LB medium Tryptone 1% (w/v) 
 Yeast extract 0.5% (w/v) 
 NaCl 1% (w/v) 
 Agar 
Fill to 1 L with distilled water 
1.5% (w/v) 
SCD-URA medium Glucose 2% (w/v) 
 Ammonium sulphate 0.55% (w/v) 
 Yeast nitrogen base 0.2% (w/v) 
 Adenine 0.0012% (w/v) 
 MEM amino acid mix 2% (v/v) 
 Agar 
Fill to 1 L with distilled water 
1% (w/v) 
YPD medium Yeast extract 1% (w/v) 
 Peptone 2% (w/v) 
 Glucose 4% (w/v) 
 Agar 
Fill to 1 L with distilled water 
2% (w/v) 
 
For liquid media, no agar was used in the preparation process. 
 
 
Table 12: List of software and databases 
Software Use Copyright 
   
Clustal omega [209-211] Multiple sequence 
alignment 
EMBL-EBI 
CorelDrawX4 Design of graphics Corel Corporation 
Cytometer software 
CytExpert 
Fluorescence measurements 
of single cells from 96 well 
plates 
Beckman Coulter GmbH 
Endnote X7 and X8 Literature management Clarivate Analytics 
FluorEssence™ Fluorescence spectroscopy Horiba 
i-control for Microplate 
Reader Infinite 200 PRO 
Reading of 96 well plates Tecan 
ImageJ 1.49b [212, 213] Image processing Wayne Rasband, National 
Institute of Health (NIH), 
USA 
Mfold [214-216] Secondary structure 
prediction of RNA 
Rensselaer Polytechnic 
Institute 
MicroCal PEAQ-ITC 
Analysis Software 1.1.0.1262 
Analysis and image 
generation of ITC 
experiments 
Malvern Instruments 
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Microsoft Office 2010 Excel, Word and 
Powerpoint used for text 
processing, calculations and 
image design 
Microsoft corporation, USA 
Nanodrop software ND-1000 
V 3.8.1 
Analysis of nucleic acid 
quantities 
Thermo Fisher Scientific 
New England Biolabs web 
server 
(https://www.neb.com/) 
Specifications for enzymes  New England Biolabs 
   
Vector NTI 11.0 Sequence analysis, plasmid 
design  
Life Technologies 
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3.2 Molecular biology methods 
If not stated differently, the following biological standard methods were carried out according 
to Sambrook et al. [217]:  
 DNA ligation 
 DNA restriction 
 Nucleic acid detection on agarose gels using UV light and ethidium bromide 
 PAA gel electrophoresis 
 Purification of radioactive nucleic acids using PAA gels 
 
If not stated differently, PCR was carried out according to Landt et al. [218]. 
If not stated differently, E. coli cells were transformed with plasmid DNA according to the 
protocol from Hanahan et al [219].  
Libraries for SELEX or in vivo screenings were ordered at Microsynth Seqlab, Germany. 
 
 
3.2.1 Autoclaving and sterilizing 
Chicane flasks and bottles, as well as growth media were autoclaved at 121°C for 20 min at 
2 bar pressure. Glass pipettes were stored in Kohrsolin solution (Table 1) before washing and 
dry heat sterilizing at 200°C for at least 30 min. Heat sensitive substances were sterile-filtered 
using a filter pore size of 0.22 µM. 
 
 
3.2.2 Plasmid DNA extraction 
To amplify plasmids, one singe colony of E. coli cells containing the plasmid of choice was 
grown in liquid culture medium with the appropriate antibiotic for selection. To extract 
plasmids, a Miniprep or Midiprep Kit by QIAgen (Table 4) was used on 4 or 100 mL of 
bacteria culture, respectively.  
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3.2.3 Nucleotide quantification and analysis 
An analysis of aqueous nucleic acid solutions regarding their purity and concentration was 
carried out using a NanoDrop ND 1000 Spectrophotometer (Table 3). An absorption spectrum 
of wave lengths between 220 nm and 350 nm was generated and values were converted by the 
appropriate software to receive nucleotide concentrations (Table 12, using Lambert-Beer’s 
Law [220-222]). 
 
 
3.2.4 Restriction of DNA  
To digest DNA, an appropriate amount of the chosen restriction enzymes (type II restriction 
enzymes) was added to the DNA, using the respective buffer (all specifications regarding the 
enzymes were taken from the NEB biolabs database (Table 12); enzymes see Table 5). The 
total volume of the reaction was adjusted to 50 µL with MQ. The digestion reaction was 
incubated at 37°C for 1 h in a 1.5 mL reaction tube, and subsequently purified or analyzed on 
an agarose gel (see 3.2.11). 
 
 
3.2.5 Ligation of DNA  
Ligation of DNA fragments was performed using T4 DNA ligase either at room temperature for 
1 h or at 16°C for 16 h. The reaction was carried out in ligase buffer (enzyme and buffer see 
Table 5). The molar ratio of insert to vector was typically 5:1, if not mentioned otherwise. After 
ligation, the generated DNA was either purified for further use, or directly used for transformation 
of organisms.  
 
 
3.2.6 Polymerase chain reaction 
The polymerase chain reaction (PCR) was used for in vitro amplification of DNA. In the 
course of this work it was employed for construction purposes (to generate large DNA 
libraries from a small amount of template), analytical purposes (RT-PCR analysis), cloning 
projects, and in the course of the SELEX procedure. If not stated differently, PCR was carried 
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out according to Landt et al. [218]. PCR variations are described and listed in the 
corresponding context (e.g. RT-PCR see 3.2.7).  
 
 
3.2.7 RT-PCR (reverse transcription polymerase chain reaction) 
Reverse Transcription-PCR (RT-PCR) was used to reversely transcribe RNA into DNA and 
then exponentially enrich this DNA using a one-pot reaction. 
The library of different RNAs generated during one SELEX round (3.4.3) was used as starting 
material of the RT-PCR. 50 µL of eluted RNA in water were added to 48 µL of 2x RT-PCR 
mix (Table 10) and 1 µL each of the enzymes Taq polymerase and SuperScript II reverse 
transcriptase (Table 5). 
The reverse transcription was carried out at in a thermocycler, following the program below 
(Table 13). PCR-products were analyzed on a 3% agarose gel (3.2.11) and could be directly 
used as a template for new RNA transcriptions (3.2.8).  
 
Table 13: PCR program for reverse transcription 
Temperature time  PCR steps 
54°C 10 min  Initial melting 
96°C 1 min  Melting 
58°C 1 min 6 – 14 cycles Primer annealing 
72°C 1 min  Elongation 
 
RT-PCR was also used to transcribe RNA aptamer libraries into cDNA templates to amplify 
DNA for homologous recombination into yeast cells. For this, RT-PCR products were 
generated according to Table 13, and then amplified with oligonucleotides containing a 
30 - 50 nt overhang for recombination into the chosen plasmid. 
 
 
3.2.8 In vitro transcription of RNA 
In vitro transcription is a method to generate RNA from a DNA template outside of an 
organism, using purified RNA polymerase in an adequate buffer [223]. In vitro transcription 
was used in smaller and larger scales during this thesis.  
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As part of the SELEX process, 10 µL of RT-PCR product (3.2.7, 3.4.3) were added to 87 μL 
TK mix (Table 10); subsequently 2 µL of T7 polymerase, as well as 1 µL of Molox RNAse 
inhibitor (Table 1) were added. If the RNA is to be used for radionuclide detection, 1 µL of 
[α-32P] UTP were added to the reaction during the transcription process. The transcription 
mixture was incubated for 2 h at 37°C. 
In order to produce RNA in large quantities, a run-off transcription was carried out, using 
either linearized plasmid or a PCR product as template. 1-2 mg of template were mixed with 
200 mM Tris-HCl (pH 8.0), 20 mM magnesium acetate, 50 mM DTT, 2 mM spermidine, 
15 µL T7 polymerase and 4 mM of ATP, CTP, GTP and UTP each. The reaction was 
incubated for 12 - 16 h at 37°C.  
To purify the produced RNA, it was ethanol-precipitated, dissolved in formamide containing 
25 mM EDTA and loaded on a 6% denaturing polyacrylamide gel (containing 8 M urea, 
[217]). 
The product band visualized by UV shadowing was excised, eluted overnight in 300 mM 
sodium acetate (pH 6.5) and then ethanol-precipitated. The resulting purified RNA pellet was 
dissolved in a suitable amount of water and molarity was determined. 
 
 
3.2.9 Phosphorylation and dephosphorylation of the RNA 5’ end 
In order to generate radioactively labelled RNA, 5’ 32[P] end-labelling of previously generated 
RNA can be performed. For that purpose, RNA has to be dephosphorylated firstly. 
Dephosphorylation was carried out using Antarctic Phosphatase (Table 5) according to the 
manufacturer’s instructions. Typically, 10 pmol of RNA were incubated in AP buffer at 37°C 
for 1 h (Table 5).  
Phosphorylation of the previously dephosphorylated RNA was performed in a radioisotope 
laboratory. In a total volume of 50 µL, 3 mM dephosphorylated RNA in water were mixed 
with 2 µL (10 U) of T4 Polynucleotide kinase (Table 5), the appropriate amount of PNK 
buffer and 3 µL (10 mM) of [γ-32P] ATP. The reaction was incubated for 1-3 h at 37°C. 
Purification of 5’ radiolabelled RNA was carried out according to Sambrook et al. [217]. 
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3.2.10 Sequencing 
For Sanger sequencing [160, 224], 0.7-1 µg of DNA were diluted in 12 µL of MQ, 3 µL of 
the appropriate sequencing oligonucleotide were added, and the sample was submitted to 
Microsynth Seqlab, Germany.  
 
 
3.2.11 Gel electrophoresis 
Agarose gel electrophoresis was used to separate differently sized DNA fragments. 
Depending on the size of the nucleotide fragments, agarose concentrations of 1% (w/v) for 
fragments >1000 bp, and 3% (w/v) for fragments of 1000 to 50 bp were used to cast gels 
(Table 1).  
To apply the nucleic acid mixture to the gel, app. 250 - 500 ng of DNA were mixed with 6x 
DNA loading dye and transferred into the gel pockets. As a standard of size, different ladders 
are used, depending on the nucleotide size to be analyzed (Table 5). 
Electrophoresis was carried out using 150 V of electric tension in a gel chamber filled with 
1x TAE buffer. Afterwards, the gel was incubated for 5-10 min in a staining bath containing 
ethidium bromide to enable analysis by UV light.  
 
PAA Gel electrophoresis of RNA (denaturing or native) was carried out according to 
Sambrook et al. [217]. 
 
 
3.2.12 DNA and RNA purification methods 
In order to purify DNA or RNA from a mixture, there are several methods. The applied 
method was chosen according to the downstream application of the DNA or RNA. 
 
Ammonium acetate purification 
Precipitation by ammonium acetate was performed by adding half the solution’s volume of 
7.5 M ammonium acetate and 2.5 time the solution’s volume of ethanol absolute (Table 1) to 
the nucleic acid solution, and then mixing all ingredients using a vortexer. The mix was 
incubated on ice for 10 minutes and then centrifuged at 17000 x G at RT in a tabletop 
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centrifuge. The supernatant is removed, and 4 times the original solution’s volume of 70% 
ethanol is added. After centrifuging at 17000 x G at RT, the supernatant was removed. This 
washing step is repeated once. The remaining nucleic acid pellet was air dried at RT for 
5 - 10 min. The pellet was taken up in an appropriate amount of water to proceed with further 
experiments, or stored in water at -20°C. 
 
Sodium acetate precipitation 
Sodium acetate based precipitation was performed by adding the 0.1x solution volume of 
sodium acetate and the 2.5x volume of ethanol absolute to the nucleic acid solution to be 
precipitated. If only a small amount of nucleic acids is precipitated using this method, 15 µg 
GlycoBlue (Table 1) can be added to increase visibility of the nucleic acids. The mixture was 
incubated for at least 1 h at -20°C and then centrifuged at 17000 x G at 4°C. After removing 
the supernatant, 2x volumes of 70% ethanol were added to the pellet to wash it. After 10 min 
of centrifugation at 17000 x G at 4°C, the supernatant is removed. This step was carried out 2 
times. After removal of the last supernatant, the pelleted nucleic acids were air dried at RT for 
at least 5 min. The dry pellet was resolved in an appropriate amount of water and stored 
at -20°C. 
 
Butanol precipitation 
For butanol precipitation, the nucleic acid solution was mixed with 10 times the volume of 
butanol and vortexed for 1 min. Afterwards, the reaction was centrifuged at RT for 30 min at 
17000 x G. The supernatant was discarded, washed with 70% ethanol and centrifuged at RT 
for 10 min at 17000 x G. After repeating the washing step, the precipitate was air dried at 
37°C, then solved in the appropriate amount of MQ at 45°C. 
 
 
3.2.13 ITC measurements (isothermal titration calorimetry) 
10 µM RNA was folded using an adequate folding program (important for correct secondary 
and tertiary structure) and diluted in 350 µL 1x SELEX buffer (Table 10). Depending on the 
ligand concentration, the same percentage of DMSO was added to the RNA solution to 
achieve the same buffer background for both solutions (e.g. 100 µM final ligand 
concentration contains 0.1% DMSO, so the final DMSO concentration of the RNA solution 
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was adjusted to 0.1% as well). azoCm was dissolved from its stock solution in 100% DMSO 
to a 100 or 200 µM solution in 1x SELEX buffer (Table 10).  
ITC experiments were carried out with a MicroCal PEAQ iTC200 (Table 3) with the sample 
cell (app. 300 µL) containing 10 µM RNA and 100 - 200 µM ligand solution in the injector 
syringe (app. 60 µL). After thermal equilibration at 25°C, an initial 150 s delay and one initial 
0.4 µL injection, 18 serial injections of 2.0 µL at intervals of 150 s and at a stirring speed of 
750 rpm were performed. Raw data was recorded as power (µc s
−1
) over time (min). The 
temperature associated with each titration peak was integrated and plotted against the 
corresponding molar ratio of ligand and RNA. The dissociation constant (kD) was extracted 
from a curve fit of the corrected data calculated using the MicroCal PEAQ-ITC Analysis 
Software 1.1.0.1262 (Table 12). Measurements were repeated at least twice. The protocol was 
adapted from Groher et al. [133]. 
 
 
3.2.14 In-line probing 
For in-line probing, RNA was dephosphorylated and 5’ 32[P] end-labelled as previously 
described (3.2.9). After PAA gel purification (3.2, 3.2.11), 35 kCPM of multiple 
5′ 32[P] -labelled RNA samples were incubated for 2.8 - 3 d at 22°C in in-line reaction buffer, 
with and without different concentrations of ligand. To generate size markers, a separate 
5′ 32[P] -labelled RNA sample was incubated under alkaline conditions for 3 min at 96°C in 
50 mM sodium carbonate (pH 9.0). Incubation for 3 min at 55°C with 20 U RNase T1 at 
denaturing conditions of a second sample generated a marker enabling the identification of 
guanine nucleotides [186]. After the in-line reaction, alkaline hydroxylation or RNase T1 
treatment, RNA samples were ethanol precipitated and the pellet was dissolved in 5 M urea 
solution. All reactions were applied on one gel (e.g. 12% PAA urea) and separated by 
denaturing polyacrylamide gel electrophoresis. Afterwards, gels were dried and analyzed 
using phosphoimaging. The procedure was adapted according from Regulski et al. [186] and 
Groher et al. [133].  
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3.2.15 Single clone binding studies 
For single clone binding studies, 100 kCPM of a 
32
[P]-labelled RNA were pipetted in an 
azoCm derivatized column. The flow-through was collected. Afterwards, the column was 
washed 4 times with 1 mL of 1x SELEX buffer, and then 2 times with 500 µL of 1x SELEX 
buffer. The last two steps were split up to check in the scintillation measurement whether 
background levels of radioactivity were reached. The RNA was eluted using an appropriately 
concentrated azoCm solution, either in cis or in trans form, or using 1x SELEX buffer for 
background radiation data. All fractions were collected and measured in a scintillation counter 
to assess their radioactive nucleic acid content. The ratio of radioactivity measured in the 
elution fractions compared to all fractions was calculated in percent. In order to compare 
binding studies between different RNAs, elution values with azoCm trans were normalized to 
100% (sum CPM of trans ligand elution). azoCm cis and 1x SELEX buffer elution results 
were compared to that normalized value (sum CPM of one elution relative to trans ligand 
elution in percent, see Equation 2).  
 
Equation 2: Calculation of eluted RNA relative to eluted RNA by azoCm in percent 
𝑠𝑢𝑚 𝐶𝑃𝑀𝑜𝑓 𝑎𝑛𝑦 𝑜𝑛𝑒 𝑒𝑙𝑢𝑡𝑖𝑜𝑛
𝑠𝑢𝑚 𝐶𝑃𝑀 𝑜𝑓 𝑡𝑟𝑎𝑛𝑠 𝑙𝑖𝑔𝑎𝑛𝑑 𝑒𝑙𝑢𝑡𝑖𝑜𝑛
× 100
= 𝑠𝑢𝑚 𝐶𝑃𝑀 𝑜𝑓 𝑜𝑛𝑒 𝑒𝑙𝑢𝑡𝑖𝑜𝑛 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑡𝑟𝑎𝑛𝑠 𝑙𝑖𝑔𝑎𝑛𝑑 𝑒𝑙𝑢𝑡𝑖𝑜𝑛 𝑖𝑛 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 (%) 
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3.3 In vivo methods 
The following methods were carried out using the microorganisms E. coli and S. cerevisiae. 
 
 
3.3.1 Stock keeping and cultivation of microorganisms 
Strains of E. coli were kept in glycerol stocks at -80°C. To this end, 1 mL of the chosen 
E. coli strain in LB medium was mixed with 15% (v/v) glycerol and shock-frozen in liquid 
nitrogen, then stored in a freezer at - 80°C. 
To grow E. coli cells in liquid medium, LB medium with or without a fitting antibiotic for 
selection was used, if not otherwise mentioned. They were incubated in chicane flasks or 
glass vials at 37°C during constant shaking (120 - 150 rpm) in a temperature adjustable shaker 
(Table 3), or in 96 deep well plates and grown at 37°C in a plate shaker. On solid medium, 
100 - 150 µL of cell culture medium was streaked out on LB plates (with or without 
antibiotics for selection) and incubated at 37°C. Cultures on medium plates were stored at 4°C 
for up to two weeks. 
 
S. cerevisiae strains were also kept stored as glycerol stocks at -80°C. To this end, 1 mL of 
yeast liquid culture were mixed with 15% (v/v) glycerol and stored at – 80°C. 
To grow S. cerevisiae in liquid medium, YPD or SCD-URA medium was used. They were 
incubated in chicane flasks or glass vials at 30°C during constant shaking (120 - 150 rpm) in a 
temperature adjustable shaker (Table 3), or in 96 deep well plates and grown at 30°C in a 
plate shaker. On solid medium, 50 - 100 µL of cell culture medium was streaked out on 
medium plates and incubated at 30°C for 2 - 3 d. Cultures on medium plates were stored at 
4°C for up to four weeks. 
 
 
3.3.2 Generation and transformation of competent E. coli cells 
If not stated differently, competent E. coli cells were prepared and transformed with plasmid 
DNA according to the protocol from Hanahan et al. [219].  
 
In order to receive high yields for experiments where a maximum of plasmids should be 
transferred to cells, highly competent commercial cells (NEB 10-beta, Table 9) were used. 
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They were transformed with plasmid DNA using electroporation, and treated according to 
manufacturer’s instructions. 
 
 
3.3.3 Generation and transformation of EZII chemically competent yeast cells 
To generate chemical competent S. cerevisiae cells for daily use, the Frozen EZ Yeast 
Transformation II Kit™ was used, according to manufacturer’s instructions. The method is 
based on the lithium acetate method (3.3.4) [225]. 
To transform the yeast cells with DNA, 50 - 100 µL of cells were mixed with 200 - 1000 ng 
of plasmid DNA and suspended in 5 times the volume of EZ3 buffer (part of the Kit in Table 
4). The cells were incubated for 45 - 180 min at 30°C, under frequent mixing. 100 - 150 µL of 
the mix were plated on SCD-URA agar plates and incubated for 2 d at 30°C. 
 
 
3.3.4 Transformation of yeast with the lithium acetate method  
To transform aptamer libraries from different SELEX rounds into S. cerevisiae, a high 
efficiency standard transformation method was used in order to cover as many different 
aptamers as possible (3.3.4, 3.3.5) [226]). The protocol was adapted from Gietz and Schiestl 
[227], the modified transformation mix components are shown in Table 14.  
 
Table 14: Transformation mix for the lithium acetate transformation of yeast 
Transformation mix components Volume (µL) or mass (µg) 
Yeast cells (in TE/LiOAc buffer (1x) buffer, 
Table 10) 
50 µL  
Denatured salmon sperm DNA  50 µg 
Linearized vector DNA  110 ng  
Insert DNA  10x molar excess to linearized plasmid 
40% PEG4000-solution (with TE/Lithium 
acetate, Table 10) 
300 µL  
 
After transformation, cells were plated on SCD-URA plates (Table 11) and grown as 
described in 3.3.1. 
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3.3.5 Electroporation of yeast cells 
To transform aptamer libraries from different SELEX rounds into S. cerevisiae, a second high 
efficiency transformation method was used in order to cover as many different aptamers as 
possible (compare to 3.3.4). The protocol was adapted from Benatuil et al. [228].  
Cells of the yeast strain RS453α were grown in 100 mL YPD medium to an OD600 of 1.2. 
Cells were kept on ice afterwards until the second incubation step. The cells were harvested 
by centrifugation at 4°C for 3 min at 1600 x G. The supernatant was discarded; the pellet was 
washed twice with 25 mL MQ and centrifuged again. The washed pellet was suspended in 
25 mL electroporation buffer (Table 10). The cell suspension was centrifuged again at 4°C for 
3 min at 1600 x G, the supernatant was discarded and the pellet was resuspended in 10 mL 
0.1 M LiAc / 0.01 M DTT solution. The suspension was incubated in a 50 mL Erlenmeyer 
flask at 30°C for 30 min at a shaker with 150 rpm to condition the cells.  
Cells were transferred into a 50 mL reaction tube and centrifuged at 4°C for 3 min at 
1600 x G. The supernatant was discarded and the pellet resuspended in 50 mL ice-cold 
electroporation buffer (1 M Sorbitol / 1 mM CaCl2). Again, the cells were centrifuged at 4°C 
for 3 min at 1600 x G and the supernatant was discarded. Finally, the cell pellet was 
resuspended in a small amount of electroporation buffer, creating a final cell suspension 
volume of 1 mL.  
For transformation, 400 µL cell suspension were mixed with 1 – 1.3 µg of vector DNA and 
twice the amount of insert DNA. For positive and negative controls, 100 µL cell suspension 
and 0.25 – 0.325 µg of plasmid DNA were used (linearized plasmid for re-ligation control, 
circular plasmid for transformation efficiency control). After incubation for 5 min on ice, the 
cells were electroporated at 2.5 kV and 25 µΩ. After electroporation, the cells were 
transferred into a 50 mL Erlenmeyer flask containing 8 mL YPD Sorbitol buffer (0.5 M 
Sorbitol / YPD) and incubated at 30°C for 1 h at 150 rpm shaking. The controls were 
transferred into test tubes containing 2 mL YPD Sorbitol Buffer. 
After incubation, the suspension was transferred into a 50 mL reaction tube and centrifuged at 
RT for 3 min at 1600 x G. The supernatant was discarded and the pellet resuspended in a 
small volume of SCD-URA resulting in a final volume of 1 mL. A serial dilution from 10-3 to 
10
-5
 in SCD-URA was carried out, 150 µL of each dilution step were plated and incubated at 
30°C for 2 d. The remaining cell suspension was split into four 250 mL chicane flasks, each 
containing 62.5 mL SCD-URA. The cell cultures were incubated at 30°C for 2 d at 150 rpm. 
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The controls were transferred into a 2 mL reaction tube, centrifuged at RT for 3min at 
1600 x G and resuspended in 250 µL SCD-URA after discarding the supernatant. 150 µL 
were plated on SCD-URA agar plates and incubated at 30°C for 2 d. Comparison of the 
transformation efficiency and re-ligation controls resulted in information on the efficiency of 
the homologous recombination of vector and insert DNA. 
 
 
3.3.6 Fluorimeter measurements 
Fluorescence measurements were performed on a Fluorolog FL3-22 (Table 3) with an 
excitation wavelength set to 474 nm (slit 2 nm) and an emission wavelength of 509 nm (slit 
2 nm). The integration time was set to 0.5 s and temperature was adjusted to 28°C. 
Afterwards, OD600 for each culture was determined and fluorescence intensity was normalized 
to it. As negative control, pWHE601* (Table 8) was analyzed in parallel as a blank and its 
value was subtracted from all data, as cells containing pWHE601* did not express any GFP. 
Cells expressing GFP constitutively were transformed with pWHE601 (Table 8) and were 
used as a positive control. Both controls were treated equally as the riboswitch-controlled 
constructs. Each experiment was performed in duplicates and reproduced at least three times  
The protocol was adapted from Groher et al. [133]. 
 
 
3.3.7 Flow cytometry 
Flow cytometry was performed on a CytoFLEX S Flow Cytometer (Table 3). A data set was 
comprised over the mean and median values from a set number of single cell fluorescence 
reads. Typically, 5000, 10000 or 25000 cells were measured.  
To measure single cells from a cell population, liquid cultures of bacteria, yeast or human 
cells were grown under appropriate conditions and diluted 1:10 in 1xPBS (Table 10) in 96 
well plates (flat bottom, Table 3).  
The measuring template shown in Table 15 was used for riboswitch in vivo screening (3.3.8). 
For second screening rounds, the number of cells measured was doubled to 10000 cells. 
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Table 15: Cytometer measurement settings for in vivo screening 
Cytometer variable Variable settings 
Gain forward scatter 15 
Gain side scatter 15 
Gain 510 nm 50 
Gain 610 nm 50 
Flow rate 30 µL/min 
Cells measured 5000 or 10000 in 120 s 
 
 
3.3.8 Yeast in vivo screening  
In vivo screening of yeast was carried out to find potential new riboswitches. The cells were 
transformed with a plasmid containing an aptamer, typically from a library of aptamers 
generated through a SELEX round. Cells from liquid culture were spread on several 
SCD-URA plates in a way that assured a moderate colony density to simplify single clone 
picking.  
In vivo screening consisted of several rounds: first, second and third round of screening. 
During the first round of screening, candidates that deviated from the plate regulation average 
(calculated without the controls) more than 0.2 points were considered as hits and were taken 
into the second round of screening. They were streaked out to single colony on SCD-URA 
plates and incubated at 30°C for 3 d. Four single clones per plate were measured using the 
same conditions as in round one. Could the regulation factor from round one be verified in at 
least two of the four clones from round 2, the positive culture was cultivated in 4 mL 
SCD-URA at 30°C for 1 d and the plasmid DNA was extracted. E. coli cells were transformed 
with the plasmid and grown on plate. Four single E. coli colony were picked, their plasmids 
were isolated, and EZII competent yeast cells (Table 9) were transformed with one single 
plasmid per sample. They were grown and measured again using conditions from round 1. If 
the regulation factor could be verified again, a riboswitch was considered discovered, and 
replications of this measurement could begin. The passaging through E. coli cells was 
necessary as S. cerevisiae can take up more than one plasmid in a transformation, which can 
lead to falsely positive results in fluorescence measurements. A yeast culture streaked out to 
single colony, which is then cultured in liquid media typically only contains one plasmid 
sequence [229]. 
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Two different variants of screening were carried out; one using the Tecan Microplate Reader 
Infinite 200 PRO (Table 3). The protocol was based on Weigand et al. [132]. 
A second variation of the screening was based on single cell measurement in a flow cytometer 
(Table 3). The protocol for this screening variant was adopted from Groher et al. [133]. 
Next to the measurement method, the biggest difference between the two screening protocols 
was the growth conditions of the yeast cultures. In the flow cytometry approach, cultures were 
grown in 96 well plates while shaking, where in the Tecan reader approach, cultures were 
grown in 96 well plates without shaking.  
In both methods, regulation factors were assessed. They were calculated by dividing the GFP 
fluorescence value of a colony grown without ligand by the fluorescence value of the same 
colony grown with ligand (Equation 3). 
 
Equation 3: Basic regulation factor calculation 
𝐺𝐹𝑃 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑)
𝐺𝐹𝑃 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ 𝑙𝑖𝑔𝑎𝑛𝑑)
= 𝑠𝑤𝑖𝑡𝑐ℎ𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
 
Corrections to these values were calculated according to the different methods used for 
measurement of fluorescence. In the case of Tecan reader measurement, each fluorescence 
value was divided by the cultures’ corresponding OD600 value prior to calculation of the 
regulation factor, to remove errors due to a different cell number in each culture. In the case 
of flow cytometric measurement, this kind of correction is irrelevant because the flow 
cytometer measures a set number of single cells. As an improvement to the flow cytometry 
based in vivo screening, a plasmid with a constitutively expressed mCherry gene was 
introduced as a plasmid backbone for screening by Dr. Cristina Bofill-Bosch (pCBB, Table 
8). To calculate regulation factors, the GFP fluorescence value of each colony (with and 
without ligand) was first divided by the culture’s mCherry fluorescence value, to avoid errors 
due to a different individual level of gene expression. The two different error correction 
calculations are shown in Equation 4 and Equation 5). 
 
Equation 4: Corrected regulation factor using OD600 
𝐺𝐹𝑃 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑)
𝑂𝐷600 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑)
𝐺𝐹𝑃 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ 𝑙𝑖𝑔𝑎𝑛𝑑)
𝑂𝐷600 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ 𝑙𝑖𝑔𝑎𝑛𝑑)
= 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑠𝑤𝑖𝑡𝑐ℎ𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
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Equation 5: Corrected regulation factor using mCherry 
𝐺𝐹𝑃 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑)
𝑚𝐶ℎ𝑒𝑟𝑟𝑦 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑙𝑖𝑔𝑎𝑛𝑑)
𝐺𝐹𝑃 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ 𝑙𝑖𝑔𝑎𝑛𝑑)
𝑚𝐶ℎ𝑒𝑟𝑟𝑦 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑔𝑟𝑜𝑤𝑛 𝑤𝑖𝑡ℎ 𝑙𝑖𝑔𝑎𝑛𝑑)
= 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑠𝑤𝑖𝑡𝑐ℎ𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
 
During screening, candidates that showed a decrease in relative GFP expression by a factor of 
1.3 were considered positive hits and were taken into the next round of screening. 
 
Both in vivo screening methods have in common that a set of controls is included in each 96 
well plate of clones that is measured. To minimize false positive hits during screening, three 
controls were included in each plate, using different plasmid backbones for the different 
measurement methods. These controls included a control of functional, constitutive gene 
expression (GFP on, pWHE601 or pCBB006), a control showing no gene expression because 
the construct is lacking an ATG start codon upstream of the gfp reporter gene (GFP off, 
pWHE601* or pCBB005) and a riboswitch control, containing the neomycin upstream of the 
gfp reporter gene (GFP regulated by neomycin, pWHE601-neo or pCBB007 (Table 8). 
In vivo screening results from yeast cells containing one type of aptamers (e.g. aptamers from 
the same SELEX round) are displayed as boxplots. The median of regulatory factors is given. 
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3.4 SELEX procedure 
For SELEX, a large diverse nucleic acid library is necessary. Conception and development of 
the libraries used in this thesis are described in chapters 4.3 and 4.13. In general, the library 
for SELEX needs to be as diverse as possible to cover as many potential sequences as 
possible (2.1.8). Libraries for SELEX were ordered at Microsynth Seqlab, Germany. 
 
SELEX consists of several steps, as well as pre-requisites that must be fulfilled before 
starting. The SELEX carried out in this thesis is column-based affinity SELEX. Before 
starting the SELEX itself, the following pre-requisites must be provided: 
 A large diverse RNA library and aliquots of this library labelled radioactively 
 Columns containing resin with immobilized ligand 
 SELEX buffer stock 
 
The subsequent column-based affinity SELEX consisted of 5 main steps:  
 Loading a radioactively labelled RNA library onto the ligand-derivatized columns,  
 Washing the columns with buffer to elute unbound RNA molecules, 
 Elution of the bound RNAs using high salt concentrations or free ligand solution,  
 Reverse transcription and amplification of eluted RNA using RT-PCR  
 Re-transcription of the enriched library by in vitro transcription using a nucleotide mix 
containing radioactive [α-32P] UTP. 
 
In the following, the relevant steps are described. 
 
 
3.4.1 Ligand immobilization 
The commercially available activated resin Affi-Gel 10 (Table 1, 20 mL column material, 
capacity 15 μmol/mL gel) was filtered through a glass frit previously cleaned with H2SO4 and 
MQ and washed with ice-cold isopropanol. 
7.5 mL of resin were filled up to 10 mL with DMSO. To this, 5 mL of a 3 mM ligand solution 
(dissolved in 100% DMSO) were added.  
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To make mock or pre-columns for depletion of RNAs in the SELEX library able to bind the 
affinity matrix, 5 mL of DMSO without ligand can be added to 10 mL of washed, activated 
resin, instead. 
The reaction was incubated for 4 h on a rotating mixer (Table 3) and afterwards filtered 
through a glass frit and washed twice with DMSO. To deactivate remaining NHS esters, 5 mL 
of a 0.1 M ethanolamine solution (pH 8.0) were added to the derivatized column material and 
incubated for 1 h at RT on a rotating mixer. Afterwards, the derivatized and deactivated 
column material was washed several times with DMSO and finally mixed 1: 1 with a 0.002% 
sodium azide solution. For each individual column, 1 mL of the mixture was aliquoted into 
chromatography columns (Table 3, 1.2 mL bed volume) and stored at 4°C. 
 
 
3.4.2 SELEX buffer 
For SELEX, a buffer based on Berens et al. [208] (see Table 10) and supposed to mimic the 
environment within a yeast cell, was prepared. The buffer consisted of 10 mM Tris-HCl, 
250 mM NaCl and 5 mM MgCl2. As yeast growing in a glucose rich-medium is reported to 
have an internal pH value of 7 to 8, the buffer was adjusted to pH 7.6 [230]. 
As it is important for SELEX to provide stable conditions during the SELEX process, 2 L of a 
5x stock solution were prepared to be sufficient for all experiments (buffer composition see 
Table 10).  
 
 
3.4.3 SELEX process 
The SELEX process consists of 5 main steps making up one round of SELEX. The steps were 
repeated sequentially, so that a round continued with the material generated in the previous 
round. Data points were collected for each round to analyze the progress of the SELEX 
process. To explain the process, it is shown here in an overview of the complete procedure, 
while details to the protocols can be found in the respective Material and Methods sections 
(3.2.7, 3.2.8, 3.2.9, 3.2.11, 3.2.12, 3.2.12).  
 
1.2x 10
15
 RNA molecules from the initial library were spiked with approximately 250 kCPM 
(kilo counts per minute) of 5’ 32P-labelled RNA library in MQ (3.2.9) to use in the first 
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round. RNA folding was performed by heating the mixture to 95°C for 5 min, then cooled on 
ice for 5 min. Afterwards, 100 μL of 5x SELEX buffer, 6 μL of yeast tRNA (final 
concentration 0.3 μg/μL) and 144 μL of MQ were added. The mixture was incubated for 
15 min at RT. In the meantime, the column (and pre-column if applicable) was washed with 
10 volumes of 1x SELEX buffer (10x 500 µL). The RNA mixture was then applied to the 
column (or pre-column) and incubated at RT for 30 min (flow-through fraction).  
Afterwards, the column was washed in steps of column volumes (CV=500 µL), using 
1x SELEX buffer (wash fractions). The number of washing-steps ranged from 10 to 20, 
depending on the applied stringency.  
RNA was then eluted by either 4 CV of 20 mM EDTA or 1 or 5 mM azoCm (elution 
fractions). During the process, stringency could also be increased by a decreased binding time 
of the RNA library to the column from 30 to 15 min, or pre-elution steps (pre-elution 
fractions). All fractions of liquids (all of a volume of 1 CV) were collected individually. 
10 µL of each fraction were measured in a scintillation counter to follow the progress of 
SELEX (3.4.4). 
Eluted RNA fractions were pooled and precipitated with sodium acetate (3.2.12) in the 
presence of 15 µg GlycoBlue™ Coprecipitant (Table 1). The air-dried pellets were dissolved 
in a total volume of 50 µL MQ and reverse-transcribed and amplified (RT-PCR, 3.2.7). 
Product formation was monitored on a 3% agarose gel (3.2.11).  
For the following rounds (all except round 1), RNA was transcribed according to 3.2.8. In 
short, 10 µL of RT-PCR product were mixed with TK SELEX mix (Table 10) and 33 nM 
[α-32P] UTP (Table 1) in a total volume of 100 µL. Purification was performed using the 
sodium acetate precipitation protocol, according to 3.2.12. 
In all SELEX rounds but the first, 500 kCPM RNA were folded, diluted in 1x binding buffer 
with yeast tRNA and subsequently loaded onto the column for the next round of SELEX. 
 
 
3.4.4 SELEX process analysis 
To get comparable results enabling the assessment of aptamer enrichment within the SELEX 
process, all flow-through, wash, pre-elution and elution fractions during SELEX were 
collected and measured regarding their radioactivity. For this, 10 µL of each fraction were 
measured in 2 mL scintillation cocktail in a scintillation counter.  
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Higher radioactive counts measured corresponded to a greater number of radioactively 
labelled aptamers in the corresponding fraction. For each round, the ratio of the sum of ligand 
eluted radioactivity in CPM to the sum of CPM of all fractions (flow-through, wash, elution) 
of a sample was calculated in percent. Over the course of SELEX, an increase in percentage 
should be a sign of enrichment of specifically binding aptamers in the elution. The 
percentages over the rounds are displayed as bar diagrams or as curves.  
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4 Results 
4.1 In-line probing of aptamer 42 
A SELEX previously to this work against azoCm yielded aptamer 42 (2.2.3, 2.2.4), able to 
bind the molecule azoCm in an isoform selective manner. In order to understand more about 
this aptamer, a structural analysis by in-line probing was carried out (3.2.14). 
Radioactively labelled RNA of aptamer 42 was incubated for 3 d with different ligand 
concentrations (10, 100 nM, 1, 10 and 100 µM, and without ligand) in in-line buffer.  
 
 
Figure 14: In-line probing of aptamer 42 A In-line probing gel of aptamer 42 on a 15% PAA urea gel. Lanes 
show from left to right: alkaline hydrolysis ladder (one band for every nucleotide in the aptamer sequence) 
RNase T1d-ladder (digest of aptamer sequence after every G in the sequence), aptamer incubated with 0 nM, 100 
nM, 1 µM, 10 µM, 100 µM ligand. Marked in red are the two nucleotides showing a decrease in band intensity 
with increased ligand concentration, marked in green are nucleotides showing digestion products due to structure 
flexibility, marked in blue are nucleotides not showing digestion products due to structure stability. B Refined 
secondary structure after results from in-line probing gel in A were taken into account. The red, green and blue 
marked areas show a structure that would fit with experimental results. C Shown is a close-up on the two 
nucleotides affected by increasing ligand concentration from 100 nM to 100 µM (left to right). D Shown is the 
close-up on the gel from C with an increased contrast to visually emphasize the difference in band intensities 
with increased ligand concentration. E Direct comparison of the nucleotide bands without any ligand present (0 
nM) and with 100 µM ligand present (red dashed rectangle).  
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Separation of the samples on a 15% PAA gel showed a fragmentation pattern (Figure 14A). 
Cleavage controls were carried out in parallel to receive ladders enabling an exact assignment 
of each band to a nucleotide in the sequence. An alkaline hydrolysis ladder (first lane on the 
left, Figure 14A) showed a band for each nucleotide in the sequence, a RNase T1 enzyme 
treated ladder showed a band for every G residue in the sequence, as well as a few unspecific 
breakdown bands (between G5 and G14, lower quarter of the gel, Figure 14A). 
In-line probing analysis of aptamer 42 showed a distinct cleavage pattern, as depicted in 
Figure 14A. There were three regions noticeable, marked in blue (U13-A22), green 
(G24-C29) and red (A33+A34). Nucleotides inside the blue rectangle showed barely any 
bands on the gel, indicating a very stable and most probably base-paired region. The 
nucleotides within the green rectangle show a strong band at each position, indicating a 
flexible, most probably single stranded region in the aptamer. Nucleotides within the red 
rectangle show a ligand concentration dependent decrease in band intensity, a behavior not 
seen in the green and blue region.  
From this cleavage pattern, information about the secondary structure of RNA aptamer 42 
could be derived. Comparison to a previously assumed 2D structure gathered by mfold 
prediction (Table 12, compare Figure 12) revealed regions that did not fit with the cleavage 
pattern presented on the gel. Nucleotides inside the blue rectangle, which are indicating a 
stable base-paired region, correspond with nucleotides U13-A22, which are single-stranded in 
the previously predicted structure (Figure 12). Opposed to that, the nucleotides within the 
green rectangle of the gel (Figure 14A+B), indicate a flexible, single-stranded region of the 
aptamer, however the predicted structure in Figure 12 shows them to be base-paired.  
Using mfold, the stable tetraloop UUCG [231, 232] is formed (U13-A22), which can be found 
in the previously predicted structure shown chapter 2.2.4. However, the experimental data 
gathered from in-line probing could not support this predicted secondary structure of aptamer 
42. While the UUCG tetraloop is still formed in the data-based structure prediction (blue 
region), refolding of the nucleotides in the green region led to the predicted structure shown in 
Figure 14B. For future studies, this secondary structure was  assumed to represent the correct 
folding, because like that the areas marked in red, green and blue show a structure fitting the 
experimental results (Figure 14B). 
Data regarding aptamer-ligand interaction could be gathered by in-line probing as well. As 
described before, the nucleotides within the red rectangle show a ligand concentration 
dependent decrease in band intensity, a behavior not observable in the green and blue region. 
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This indicated that at these two Adenine positions (A33+A34), ligand interaction may take 
place. A close-up on the gel in this region makes the effect clearer (Figure 14C), particularly 
when the contrast of the close-up image is enhanced using ImageJ (Table 12, Figure 14D) 
[212, 213]. Comparing the aptamer column without any ligand to the one where 100 µM 
ligand were present (Figure 14E, red dashed rectangle) shows that the stability of this aptamer 
position (particularly A34) is strongly increased upon ligand addition, as less spontaneous 
cleavage occurs. 
In-line probing of aptamer 42 did not only lead to a new 2D structure proposal, it also yielded 
first indications of aptamer positions which could be involved in interactions with its ligand 
azoCm. 
 
 
4.2 In vivo screening of affinity SELEX Rudolph   
Rudolph could show that aptamer 42 could not function as a riboswitch in yeast cells [196]. 
As it is known that many well-characterized aptamers cannot be used as riboswitches in vivo, 
a method developed by Weigand et al. was used, allowing the isolation of in vivo active 
riboswitches from an in vitro enriched SELEX pool (2.1.11) [132]. Other aptamers of the 
SELEX by Rudolph were tested regarding their function as a riboswitch in the course of this 
work. 
DNA from round 6 from the SELEX by Rudolph (marked in red, see Figure 15) was 
amplified using PCR (primer pair “Library 1 fwd” and “rev”, Table 6). The resulting aptamer 
templates were cloned into the 5’ UTR of a GFP gene on the plasmid pWHE601 (Table 8). 
Figure 15 shows the result of yeast in vivo screening of round 6 of SELEX Martin (2.2.3). 
Shown in brackets at the top is the amount of 1907 colonies tested in the first round of 
screening. Clones that seemed to indicate riboswitching (upper whisker of boxplot) were 
tested in a second round of screening in quadruplets, and, from cultures seeming to show 
switching, plasmids were extracted. They were passaged through E. coli cells, and then re-
transformed into yeast cells for a third and last round of screening (2.1.11, 3.3.8).  
From the graph shown in Figure 15B, none of the 1907 colonies analyzed showed any azoCm 
dependent regulation of gene expression after a third round of analysis. From this it was 
concluded that all experimental results from the first round of in vivo screening showing 
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regulatory factors in the upper quartile (upper whisker) or lower quartile (lower whisker) of 
results were outliers due to measurement or method inconsistencies. 
 
Figure 15: In vivo screening of SELEX Rudolph A Shown is the fraction of loaded RNA that could be eluted 
from azoCm-derivatized columns after each round of SELEX performed by Rudolph [196]. RNA was eluted by 
either 20 mM EDTA (round 1–5) or 5 mM azoCm (round 6–9). In the first three rounds, a negative selection step 
was performed (*). In round 8, stringency was increased by raising the number of column washes from 10 to 25 
and an increased timeframe for the elution of the RNA from the column (‡). Pre-elution steps were performed in 
round 8 and 9, adding an additional pre-elution step per round (#)The red star marks the SELEX round used for 
in vivo screening. B This boxplot shows the summarized in vivo screening in S. cerevisiae for round 6 (R6). For 
each investigated clone, the regulatory activity was calculated as ratio of GFP fluorescence with and without 
100 µM azoCm (x-fold). The number written above the boxplot indicates the number of clones analyzed. The 
median of all analyzed clones in R6 was 1.0. 
 
As the aptamer discovered in the first SELEX did not work as a riboswitch, nor did any of the 
aptamers tested in in vivo screening, the SELEX carried out by Rudolph (Figure 15B) was 
considered useful to generate specific aptamers, but unfitting to generate specific 
riboswitches. 
 
 
4.3 Development of a new pool for SELEX against azoCm 
The first SELEX yielded specifically binding aptamers with a low micromolar kD, but no 
aptamers showed any regulation in vivo [196]. Aptamers already seemed to be so tightly 
structured that any GFP expression was completely repressed without adding the ligand to the 
cells. As these aptamers were too pre-structured to be useful in a riboswitch context, and 
engineering had not improved them [196], a new SELEX strategy was planned. 
A                B 
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The RNA pool used in the first SELEX consisted of a 1:1 mix of two different pools 
(“pool 1”, see Figure 16) [112, 233]. One of the pools contained a fully randomized region, 
while the other contained a pre-structured element supposed to increase aptamer stability 
(Figure 16). The randomized pool has a randomized region of 64 nucleotides. The pre-
structured pool has a 4 bp stem topped by a stable UUCG tetraloop, flanked by 26 
randomized nucleotides on each side. Both pools are flanked on the 5’ and 3’ ends of their 
randomized regions by constant regions (necessary for cDNA synthesis and PCR 
amplification during SELEX). The 5' and 3' constant regions of the RNA pools were chosen 
so that they could enter into Watson-Crick base-pairings with each other, thus releasing the 
(partially) randomized core region for interaction with the ligand. 
As most aptamers identified from the first SELEX did contain the stable stem loop structure, 
it was concluded that they were too stable to be used as riboswitches in an in vivo application. 
Therefore, the pool designed for the first SELEX of this thesis was adapted from Famulok et 
al. [112] and consisted of a 74 randomized nucleotide region (N74) flanked by two constant 
regions (“pool2”, Figure 16, Table 6). This design should allow a long flexible randomized 
aptamer region without any pre-set bias towards aptamer stability. 
 
 
Figure 16: Pool Rudolph (Pool 1) and new SELEX pool (pool 2) A The pool used for a previous SELEX 
consisted of a 1:1 mix of two different pools. One pool contained a fully randomized region of 64 nucleotides 
(N64), while the other contained a pre-structured 4 bp stem topped by a stable UUCG tetraloop, flanked by 26 
randomized nucleotides on each side (N26). Both pools are flanked on the 5’ and 3’ ends of their randomized 
regions by constant primer binding regions (P1, P2). B The newly designed pool for SELEX consists of a 74 
randomized nucleotide region (N74) flanked by two constant primer binding regions (P1, P2).  
 
Primers were designed which could bind to the constant regions, with the forward primer 
containing a T7 promoter on the 5’ end to generate cDNA for PCR amplification of the 
aptamers during SELEX. From the PCR products, aptamers could directly be transcribed to 
RNA again (pool and primer sequences in Table 6). 
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To use the newly designed pool in SELEX, a highly diverse starting pool is necessary to 
provide a broad sequence space where as many nucleotide combinations as possible can be 
found to make up a specifically binding aptamer. In order to generate this pool, the initial 
pool-oligonucleotide was ordered from the DNA synthesis company Seqlab (Table 6). This 
oligo is taken and amplified in a large scale using PCR (primer pair “Library 2 fwd” and 
“rev”, Table 6). In order to receive the maximum amount of DNA possible from this PCR, 
different protocols were tested and optimized. 
 
 
4.3.1 Pool PCR optimization 
Since a high variability of the source library is important, the PCR protocol for the 
amplification of the DNA provided by the synthesis company Seqlab had to be optimized. 
This is necessary to generate the maximum amount of aptamers from the starting library 
without getting overamplification of PCR products, which could introduce bias into the 
aptamers’ diversity and distribution. After the optimization of the PCR protocol, the large-
scale production of the DNA library follows, since large amounts of DNA are required to 
produce an RNA library.  
First, a so-called scout PCR is carried out, which shows whether the chosen PCR protocol 
works and which number of amplification cycles might be optimal. To this end, a PCR mix 
made, and PCR was carried out for 16 cycles using the PCR program described in Table 16.  
 
Table 16: PCR test program for pool scout PCRs  
Shown are the temperature (T) applied in each PCR step, as well as the time (t) during which the temperature is 
applied. The final three steps are repeated for a number of cycles. 
 
After rounds 5, 7, 9, 11, 13 and 15, 5 µL of the reaction were taken from each PCR sample 
and mixed with 6x DNA loading dye. Comparison of the results after different numbers of 
cycles allowed determination of the optimal number of cycles for this reaction. A negative 
T t  PCR steps 
98°C 30 s  Initial melting 
98°C 10 s  Melting 
58°C  10 s            repeat in cycles Primer annealing 
72°C 10 s  Elongation 
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control was carried out as well, using the same PCR mix but containing no template DNA. 
Figure 17 shows a distinct band at the expected size of 129 bp on a 3% agarose gel. 
 
 
Figure 17: Agarose gel of pool 2 scout PCR Shown is a 3% agarose gel with lanes representing bands of 
different amounts of cycles tested to amplify pool 2 via the PCR program described in (Table 16). Shown from 
left to right in the lanes are PCR-results with: Marker (M), 5, 7, 9, 11, 13, 15 cycles resp. and the negative 
control sample containing no template (-). Annealing temperature was 58°C. 
 
As Figure 17 shows, starting from 9 cycles of PCR amplification, overamplification bands 
begin to appear in the samples. As the amplified band representing 129 bp was weaker after 
5 cycles than after 7 cycles, 6 to 8 cycles were considered to be the optimal number of PCR 
cycles for the amplification. 
In order to further optimize PCR conditions, different annealing temperatures were tested, 
parallel to a range of amplification cycles determined before. Temperatures tested were 54, 58 
and 62°C, the different amount of cycles tested were 6, 7, 8, as wells as 9 cycles, as a control. 
Samples were taken as described before and applied on a 3% agarose gel (Figure 17).  
 
 
Figure 18: Agarose gel of pool 2 scout PCR, details Shown is a 3% agarose gel of the different amount of 
cycles tested to amplify pool 2 via the PCR program described in (Table 17). Shown from left to right in the 
lanes are: Marker (M), 6 cycles: 6a (54°C), 6b (58°C) 6c (62°C); 7 cycles: 7a (54°C), 7b (58°C) 7c (62°C); 8 
cycles: 8a (54°C), 8b (58°C) 8c (62°C); 9 cycles: 9a (54°C), 9b (58°C) 9c (62°C) ; negative control sample 
containing no template (-, 54°C). 
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Figure 18 shows the strongest and cleanest results at 54°C and 7 cycles of amplification. PCR 
efficiency was calculated according to Hall et al. [234]. The final optimized PCR program can 
be found in Table 17. 
 
Table 17: Finalized pool amplification PCR protocol  
Shown are the temperature (T) applied in each PCR step, as well as the time (t) during which the temperature is 
applied. The final three steps are repeated for 7 cycles. 
 
 
4.3.2 SELEX pool generation 
The optimized PCR protocol was applied in a 45 mL PCR reaction carried out in 96 well 
plates, using the entire remaining synthesized pool sample as template. The resulting DNA 
pool was precipitated using sodium acetate precipitation (3.2.12) and resuspended in a total 
volume of 2 mL of water. From this pool DNA solution with a concentration of 4.25 µg/µL 
(or 1.2x 10
-10
 mol/µL), 68.3 µL (or 8.3x10
-9
 mol) were used in a 10 mL transcription sample 
(3.2.8). This amount of DNA should contain the tenfold number of molecules than in the 
initial sample of the pool oligo received from the synthesis company. As matrices are 
transcribed multiple times during in vitro transcription reactions, this should result in several 
RNA copies of all possible sequences contained in the synthesized pool sample. The RNA 
pool was transcribed as described in chapter 3.2.8. The transcribed pool was precipitated 
using sodium acetate precipitation and purified using PAA gels (chapters 3.2.11, 3.2.12). 
Resuspended in 2 mL of RNase free water, the RNA pool had a concentration of 
194 pmol/µL. This pool RNA stock solution was used for SELEX experiments carried out in 
this thesis.   
To calculate the potential sequence space covered by the generated pool, the amount of 
synthesized pool oligo used in the PCR was calculated based on the concentration 
(200 nmol/L) and volume of the oligo (4 mL) according to Equation 6: 
 
T t  PCR steps 
98°C 30 s  Initial melting 
98°C 10 s  Melting 
54°C   10 s    repeat in cycles Primer annealing 
72°C 10 s  Elongation 
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Equation 6: Calculation of DNA amount of substance in mol used for SELEX pool generation 
200 
𝑛𝑚𝑜𝑙
𝐿
∗  0.004 𝐿 = 0.8 𝑛𝑚𝑜𝑙 =  8𝑥 10−10 𝑚𝑜𝑙   
 
Multiplication with the Avogadro constant resulted in the total amount of molecules used in 
the PCR (Equation 7): 
 
Equation 7: Calculation of total DNA molecules used for SELEX pool generation 
8𝑥 10−10 𝑚𝑜𝑙 ∗ 6.022𝑥 1023 𝑚𝑜𝑙−1 = 4.8𝑥 1014 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠  
 
The generated aptamer pool does not cover the sequence space possible in the used N74 
library (4
74
=3.57x 10
44 
potential sequences, see 2.1.8). Having used the complete amount of 
synthesized pool oligo for the large-scale PCR,
 
a bigger sequences space could not be 
achieved. It is possible to find a specifically binding aptamer in the generated sequence space, 
but it should be kept in mind that not all possible nucleotide combinations in the randomized 
region are represented in the generated pool. 
In an RNA pool, equal nucleotide distribution across the sequences is important to not incur 
bias before the start of a SELEX. Therefore, from the original pool DNA, 20 random 
candidates were sequenced as representatives. Sequencing of the 20 candidates showed a 
distribution among the nucleotides as shown in Figure 19 in the randomized region of the 
aptamer (Nmean=74.25 nucleotides). 
 
Figure 19: DNA nucleotide distribution in a random sample of aptamers from pool 2 Shown is the 
distribution of the different nucleotides in the randomized region of the aptamer of 20 randomly selected 
aptamers (mean of nucleotides per aptamer was 74.25 nucleotides). 
24% 
25% 
26% 
25% 
A C G T
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As all nucleotides were represented more than 23% but less than 26%, equal distribution of all 
nucleotides in the randomized region was assumed. 
 
 
4.4 SELEX against azoCm 
The generated N74 RNA library with the variability of 10
14
 was used for SELEX against 
azoCm (Table 2). azoCm Amino derivatized Affi-gel was used as column material (Table 1, 
Table 2).  
In a typical SELEX round, first, radioactively labelled RNA is folded using temperature 
differences to make it take on its natural three-dimensional structure. SELEX buffer and yeast 
tRNA are added and the RNA is applied on an azoCm derived column. The flow-through of 
the liquid passing the column is collected. After an incubation period which allows the RNA 
time to bind to the immobilized ligand, washing steps are carried out, each in fractions of 
“column volumes” (CV, the same volume the column material takes up, in this SELEX, 
500 µL). After washing, the bound RNA is eluted either unspecifically with 20 mM EDTA or 
free ligand solution (in this case, 5 mM azoCm). Typically, 4 elution steps of 1 CV each are 
carried out per SELEX round. All liquid fractions (flow-through, washing, elution) are 
collected individually and aliquots are measured in a scintillation counter, to judge the relative 
amount of radioactive RNA in each fraction. After the SELEX, all elution fractions are pooled 
and used for RT-PCR (3.2.7) for amplification. The DNA resulting from this is used as the 
template for an in vitro transcription of RNA (spiked with radioactive nucleic acids), which in 
turn makes up the RNA starting pool for the next SELEX round. This process is repeated for 
several consecutive rounds to generate an RNA pool enriched with ligand binding aptamers. 
The detailed SELEX protocol can be found in chapter 0. 
In contrast to the first SELEX, where unspecific elution was continued until round 5 (2.2.3,  
Table 18 [196]), in this SELEX already in the second round unspecific elution was switched 
to specific elution. In the first round of SELEX all bound RNAs were eluted with 20 mM 
EDTA, whereas starting from round 2, a 5 mM ligand solution was used. To remove RNAs 
with an affinity towards the column matrix itself, in rounds 1-4, non-derivatized pre-columns 
were used. All RNAs which were able to pass these columns were transferred to the azoCm 
Amino derivatized columns for specific binding.  Table 18 gives an overview over the 
conditions applied. 
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The first enrichment was visible in round 5 (0.9%), round 6 verified this enrichment with 
4.8% RNA elution (Figure 20 and Figure 21). Different variations in the SELEX strategy 
were applied starting from round 7, where the stringency of elution was increased to generate 
binders with a high binding affinity [235]. The amounts of eluted RNA using the different 
strategies are shown in Figure 20.  
One way to increase stringency in this SELEX was the increase of washing steps, which 
would remove aptamers binding not as strongly to the immobilized ligand as others. Another 
method used were so-called pre-elution steps, carried out with ligand solution after the last 
washing step but before the elution samples were collected for re-amplification of the 
aptamers. These pre-elution steps are supposed to remove aptamers from the SELEX, which 
quickly lose their binding to the immobilized ligand as soon as free ligand solution is present 
(fast koff rate [236]). As aptamers eluted by pre-elution steps were discarded, they were 
removed from the RNA pools used for the next SELEX round. The last stringency increasing 
method in course of this SELEX was the reduction of binding time for the RNA aptamers of a 
round. After application of the aptamers on the column, the waiting time before the first 
washing step, in which the aptamers have time to initiate binding to the immobilized ligand, 
was reduced, to wash away aptamers showing a slow ligand binding (slow kon rate [236]). As 
aptamers from washing steps were discarded, those aptamers with a slow binding were 
removed from the SELEX as well. Table 18 lists in which round which stringency method 
was used.  
In the first SELEX variation (S1), stringency was increased by raising the amount of washes 
in round 7 from 10 to 15 washes, as well as pre-eluting the RNA with 1x CV of 1 mM azoCm 
(Figure 20). In round 8, 20 washing steps were used. The incubation time of RNA on the 
column was shortened from 30 min to 15 min, two 1 mM pre-elution steps were carried out 
(Table 18). As can be seen in Figure 20, elution percentages of round 7 and 8 were 4.8 and 
11%, respectively (S1). As this meant no reduction of percentage in eluted RNA compared to 
round 6, it was concluded that the degree of stringency was too low. 
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Table 18: SELEX conditions tested  
 
Shown is a comparison of the different ways SELEX rounds against azoCm were carried out. Conditions per 
round are listed. It is shown whether a pre-column (PC) was used and if unspecific elution (U) or specific elution 
with a certain azoCm concentration was applied (Elu mM). No markings indicated washing of the column with 
10 CV of 1x SELEX buffer, all differing volumes of washes are indicated (W). Pre-elution steps are marked by 
(#), shortened incubation times from 30 min of the RNA on the column before the first are marked by (Incu). If, 
instead of proceeding directly to the next elution step a waiting period was applied, (min wait) is shown. For 
comparison, the previous SELEX against azoCm by Rudolph was included. 
 
In a second SELEX variation (S2), washings steps in round 7 were increased directly to 20 
and two pre-elution steps with 1 mM azoCm were carried out (Figure 20). In round 8, the 
same conditions as in the first variation were used. As can be seen in Figure 20, in this second 
approach the amount of eluted RNA was much higher (16 und 11%, S2) than in the first 
variation S1. This indicated that the increased stringency was not successful immediately in 
round 7, therefore another variation was started. 
 
 
 
Round
1 2 3 4 5 6 7 8 9
Third
Second
W25,       
3x #
Incu15, 
W20,       
2x # 1 mM, 
Elu 5 mM
Elu 5 
mM
W15,       
1x # 1 mM, 
Elu 5 mM
W20,       
2x # 1 mM,        
Elu 5 mM
Incu15, 
W20,       
2x # 5 mM, 
Elu 5 mM
W20,       
2x # 5 mM, 
Elu 5 mM
Incu15, 
W20,       
2x # 5 mM, 
25 min wait, 
Elu 5 mM
W20,       
2x # 5 mM, 
Elu 5 mM
Rudolph/old PC, U
W25,       
2x #
PC, U PC, U PC, U PC, U
First
PC, Elu 
5 mM
PC, Elu 
5 mM
PC, Elu 
5 mM
Elu 5 
mM
PC, U
Variation
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Figure 20: Summary of all SELEX variations against azoCm using pool 2. Shown is the summary of eluted 
RNA per RNA input in percent for every SELEX round of pool 2. Starting after the first distinct enrichment can 
be observed in round 6, variations in the SELEX procedure eluted differing amounts of RNA (see Table 18).  
 
In the third variation of SELEX (S3), stringency was increased in round 7 by doubling the 
number of column washes from 10 to 20 for all consecutive rounds (Figure 20). Additionally, 
two pre-elution steps using 5 mM azoCm were performed starting from round 7. In round 9, 
binding time of the RNA to the column was reduced from 30 min to 15 min. Also, after every 
elution step, the RNA was left to incubate on the column for 25 min. These stringency steps 
lead to Elution percentages were gradually increasing from 0.9%, to 2.3% until 6.3% were 
reached in round 9. As the elution percentages in round 7 (0.9%) were lower than in round 6 
(4.8%) for the first time, but still showed a gradual increase (enrichment) over the rounds, 
these SELEX stringency steps and the resulting SELEX rounds were taken for the final 
SELEX summary and used in future experiments. The final SELEX process with the amounts 
of eluted RNA per round is shown in Figure 21. 
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Figure 21: Summary SELEX against azoCm Shown is the fraction of loaded RNA that could be eluted from 
azoCm-derivatized columns after each selection round. RNA was eluted by either 20 mM EDTA (round 1) or 5 
mM azoCm (round 2-9). In the first four rounds, a negative selection was performed (*). In round 7 and 9 
stringency was increased by doubling the number of column washes or a decreased binding time of the RNA 
pool to the column, respectively (‡). Two pre-elution steps with 5 mM azoCm were performed starting from 
round 7 (#). 
 
 
4.5 Binding studies of affinity SELEX aptamers 
To find out whether the SELEX did actually enrich azoCm binding aptamers, binding studies 
of individual aptamers were carried out. 20 individual candidates of the PCR pools resulting 
from round 6 and round 9 of SELEX were cloned by TOPO TA cloning (Table 4) and 
sequenced. Interestingly, only 6 different sequences could be found, with A (Table 19) being 
the most abundant (12 copies in 20 tested aptamers). Aptamer RNA was prepared from 
candidates A, D, E and F (Table 19) by in vitro transcription (3.2.8), as those were the two 
most abundant aptamers from round 6 and 9, each. 
The elution capacity of the RNA aptamers was tested using column binding assays. This 
experiment was carried out by B. Sc. Georg Pietruschka, as part of his internship in our 
laboratory. The aptamers were radioactively body-labeled and after folding (3.4.3), 100000 
counts of radioactive RNA were filled to a volume of 500 μL using a mixture of 1x SELEX 
buffer with 2.3 μg/μL yeast tRNA. 
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Table 19: Aptamer sequences from affinity SELEX rounds 6 and 9  
Sequence 
name 
Number 
of copies 
SELEX 
round 
Sequence 
A 12 6 
AGTTAATACACGACGCAGTGATCGACGTAGGTA
GAAAAGCGATAAGTATGGGCCTAATCCGATACC
GCGATCAC 
B 1 6 
AAGGACCCTAGGCAGGGGGCTTCGTTACGAGAG
CAAGACCAGGAACCACGGGCTTGCTCTTCTGCA
CAAAACGA 
C 1 6 
GGTCGGTCGAGGACCTTAGACCGTCAGCTTCTTC
TCCGGTGTAAAGGCTGTGAGACCAGGAGGCCAA
GAACCAA 
D 2 6 
GCGACTAGAACCCATGTTGCGAAGTCGACCTGT
GACCCGAGTGAAGCGGGAAAGCAAGGACGAGC
CTTCAATCC 
E 3 9 
GACGGGCTCCCGCACCTGAGGTGTCTGCCAGAA
ACGACAAACGTCGCCTCGGCCACCACTCTGGTT
ACAAGAGG 
F 1 9 
TTTCTGTCTTACGACAACGATAATAAAATGTGGC
GAGGCTAACCGGTACGGATACAGTACGGGCGAC
AATGGTCC 
 
Listed are the sequence names, abundance and the sequences within a group of 20 randomly selected aptamers 
from round 6 and 9 of the SELEX against azoCm. While some sequences occur only once in 20 sequences (B, 
C,F) others occur multiple times  (D, E), with one occurring 12 times out of 20 aptamers (A). 
 
The attempt to elute binding RNA molecules was carried out with different solutions (5 mM 
trans azoCm, 5 mM cis azoCm or buffer). In Figure 22, the results of two measurements are 
shown in percent of RNA recovered from input RNA (Equation 2). 
All aptamers tested showed a specific elution of RNA from the columns with both azoCm 
trans and cis as compared to background elution (buffer elution, light grey bars). While A and 
D show higher RNA elution values with azoCm trans than with azoCm cis, F shows higher 
values with azoCm cis than with azoCm trans. Aptamer E does not show a clear difference 
between the eluted amounts of RNA. Evaluation of this first SELEX results led to the 
conclusion, that the pool seems to be already sufficiently enriched regarding single aptamers 
as Sequence A (Table 19) alone was found 12 times out of 20 sequenced aptamers. 
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Figure 22: Isoform specificity elution analysis Radioactively labelled aptamers (100000 counts of RNA, A, D, 
E, F:  see Table 19) were folded and immobilized on azoCm-NH2-columns (folding program described in 3.4.3). 
The resin volume in the column (CV) was 500 µL, as was the volume of all other washing and elution steps. 
Four elution steps with 5 mM azoCm trans, 5 mM azoCm cis or buffer were carried out. The percentage of 
eluted RNA versus total RNA was calculated and each aptamer’s azoCm trans value was normalized to 100%.  
 
Also, all four tested aptamers (A, D, E, F) could be eluted from azoCm columns using free 
azoCm trans or azoCm cis, while showing almost no elution with buffer alone. These first 
results encouraged us to go ahead with in vivo screening of the aptamers aiming at the 
discovery of potential riboswitches. 
 
 
4.6 Optimization of PCR protocol for aptamer amplification 
As the goal of SELEX against azoCm was not only to generate specific aptamers, but also to 
test their ability to function as light-dependent riboswitches in yeast cells, aptamers were to be 
tested in an in vivo screening system. For this, aptamer pool sequences were introduced into 
the 5’ UTR of the reporter gene GFP using homologous recombination (2.1.2). 
In order to generate a plasmid pool containing as many aptamer sequences as possible, first 
amplification of the aptamers with primers suitable for homologous recombination needed to 
be optimized. A particular feature of PCR design for aptamers resulting from SELEX is that 
only one forward primer, but three different reverse primers are required. The aptamer pool is 
amplified in three samples: each using the forward, and one of the three reverse primers, 
which contain (a) no additional nucleotide (b) an additional G and (c) an additional TG (Table 
20). This diversity is introduced to cover all potential reading frames of the aptamers in an in 
vivo context, as during SELEX random start codons (ATG) could be formed. These additional 
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ATGs should be in frame with the correct start codon to not provide an additional mRNA 
product with a different length. A mix of the three reverse primers should provide functional 
variations of every aptamer. 
 
Table 20: Sequence pool 2 and primers used to amplify aptamers from pool 2 for Homologous 
recombination (HR)  
Pool/ 
Primer 
Sequence 
Pool 5’ GGAGCTCAGCCTTCACTGC-[N74]-GGCACCACGGTCGGATCCAC 3’ 
Fwd 
5’ CAAGCTATACCAAGCATACAATCAACTCCAAGCTAGATCTACCGGT
GGAGCTCAGCCTTCACTGC 3’ 
Rev1 
5’ GGCACCACGGTCGGATCCACAAAATGGCTAGCAAAGGAGAAGAAC
TTTTCACTGGAGTTGTCCCAATTCTTG 3’ 
Rev2 
5’ GGCACCACGGTCGGATCCACCAAAATGGCTAGCAAAGGAGAAGAA
CTTTTCACTGGAGTTGTCCCAATTCTTG 3’ 
Rev3 
5’ GGCACCACGGTCGGATCCACCAAAAATGGCTAGCAAAGGAGAAGA
ACTTTTCACTGGAGTTGTCCCAATTCTTG 3’ 
  
Shown are the sequences of the aptamer pool 2, the forward primer and the three different reverse primers used 
in PCR when aptamers from a SELEX round should be amplified for subsequent homologous recombination in 
yeast cells with the plasmid pWHE601 (Table 8). Marked in blue and green are the binding sequences of the 
forward and reverse primers on the pool DNA. The Kozak sequence (AAA) and the start codon (ATG) are 
underlined. Unmarked regions in the primers are homologous recombination regions, corresponding to the 
plasmid pWHE601. As for easier comparison of the pool DNA to the reverse primers, they are noted in 3’ to 5’ 
direction, the additional G or TG in the sequences of reverse primers 2 and 3 (marked in pink) are shown here as 
the corresponding C and CA. 
 
Before combining the plasmid backbone and the aptamers with the cells to carry out 
homologous recombination, all three PCR amplified aptamer variants are mixed. Only 
aptamers not containing a frameshift regarding the ATG and the reporter gene GFP on the 
plasmid should show a green fluorescence in the cells, so a selection of the appropriate 
aptamer length should automatically occur during in vivo screening. 
Optimization of the PCR conditions was necessary to generate the maximum amount of 
aptamers from a SELEX without getting overamplification of PCR products which could 
introduce bias into the enriched aptamer pool. The optimization protocol was carried out 
using aptamers from SELEX round 9 as a test round. All further PCR amplification of this 
pool were carried out using the resulting protocol. 
To this end, a PCR mix of each primer variant (Table 20) was made, and PCR was carried out 
for 16 cycles using the PCR program described in Table 17.  
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After 6, 8, 10, 12, 14 and 16 rounds, 5 µL of the reaction was taken from each PCR sample 
and analyzed on an agarose gel. As shown in Figure 23, 8 cycles produced the maximum 
amount of PCR product without showing bands of overamplification. This optimized PCR 
protocol (conditions Figure 14, 8 cycles of amplification) was performed for all other SELEX 
round amplifications used for in vivo screenings. 
 
 
Figure 23: Agarose gel of aptamer scout PCR Shown is a 3% agarose gel with PCR-reactions performed with 
different amounts of cycles to test the amplification of aptamers from SELEX round 9 via the PCR program 
described in Figure 14. Shown from left to right are the PCR samples using each the forward primer and either 
the reverse primer 1 (rev1), 2 (rev2) or 3 (rev 3). Shown in the lanes are Marker (M), 6, 8, 10, 12, 14 and 16 
cycles and the negative control sample containing no template (-).  
 
Table 21: PCR program for aptamer amplification for in vivo screening  
T T  PCR steps 
98°C 30 s  Initial melting 
98°C 10 s  Melting 
58°C   10 s repeat in cycles Primer annealing 
72°C 10 s  Elongation 
Shown are the temperature (T) applied in each PCR step, as well as the time (t) during which the temperature is 
applied. The final three steps are repeated for 8 cycles. 
 
 
4.7 In vivo screening of affinity SELEX aptamers 
To see whether the aptamers of SELEX round 6 or 9 contained riboswitches, in vivo screening 
in yeast was carried out. To this end, the aptamers from round 6 and 9 were amplified as 
described in Table 21 and purified using sodium acetate precipitation (3.2.12). S. cerevisiae 
cells were made competent using the lithium acetate protocol (3.3.4). The cells were then 
transformed with the linearized plasmid pWHE601 (Table 8) and the amplified aptamers from 
SELEX. As the aptamers were amplified with primers fitting for homologous recombination 
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(Table 6), the yeast cells could incorporate them into the linearized plasmids carrying the 
same homologous regions as the aptamers, thus creating at least one functional plasmid per 
cell, containing an aptamer and conveying also an auxotrophy marker to the transformed yeast 
cells which enabled them to grow on drop-out medium.  
After plating and incubating the cells, colonies could be observed on the agar. Analyzing 
them by eye using the binocular (Table 3), all semi-fluorescent and fully fluorescent cells 
were marked and then transferred into individual wells on a 96 well U-bottom plate (3.3.8). 
Only semi- and fully fluorescent cells were analyzed, as it was assumed that a reduction of 
gene expression by a riboswitch would only be measurable if the initial fluorescence level of 
the cell was sufficient. 
 
 
Figure 24: In vivo screening of SELEX rounds R6 and R9 These boxplots show the summarized in vivo 
screening in S. cerevisiae for round 6 (R6) and round 9 (R9). For each investigated clone, the regulatory activity 
was calculated as the ratio of GFP fluorescence with and without 100 µM azoCm (x-fold). The numbers written 
above the boxplot indicate the number of clones analyzed. The median of all analyzed clones in R6 was 1.13 and 
at 1.07 in R9. 
 
While in vivo screening of round 6 (R6) showed some regulatory activity above 1.0 and the 
median was 1.13, all outliers making up the upper antenna of the boxplot could not be 
validated in a second or third round of screening (3.3.8). Round 9 (R9) had a median of 1.07 
and an altogether lower amount of outliers indicating a regulatory activity lower than in R6. It 
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shows that no riboswitches could be identified in these rounds. Therefore, this experiment 
was stopped at this point and a new approach to SELEX was considered and planned. 
 
 
4.8 Development of a light SELEX protocol  
The main goal of the SELEX against azoCm was to find aptamers that specifically bind only 
to its trans isoform. This requires a method that would enable isoform-specific selection of 
aptamers, which subsequently is called “light SELEX”. The advantage would be, that during 
the SELEX only aptamers which bind to trans azoCm and discriminate against cis azoCm 
would be amplified, whereas those aptamers binding to the cis isoform of azoCm would be 
removed. To establish a light SELEX protocol, some control experiments had to be carried 
out first. The set-up of the light elution experiment is shown in Figure 25. The UV lamp was 
placed 10 cm from the column middle and the column was irradiated with light (λ=365 nm) 
under exclusion of other light sources. In a light SELEX experiment, RNA would be eluted 
from the column upon switching of the immobilized ligand from trans to cis.  
 
 
Figure 25: Set-up of light elution method A column with immobilized ligand was irradiated with light (λ=365 
nm) while all other light sources were excluded. During irradiation, the column was washed with SELEX buffer. 
The UV lamp was placed 10 cm from the column middle. Aptamers losing binding ability to the ligand when it 
is switched from trans to cis would be washed out of the column and could be collected. 
 
As a first step we tested whether UV light was able to penetrate the plastic columns used 
during the SELEX. No penetration would require a different set-up for the light SELEX.  
To enable judgement about UV column penetration and the intensity and duration of UV 
irradiation required to switch azoCm from trans to cis, a marker molecule was used. This 
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molecule (“compound 3“, Table 2) was also light-switchable, and underwent a visible colour 
shift from white to red upon irradiation with the same wavelength of UV light needed to 
switch azoCm to its cis isoform (λ=365 nm) [207].  
A small amount of marker was mixed with non-derivatized column material and a test column 
was filled. As the marker was not linked to the resin, quality analysis, for example whether 
the resin hinders any UV light penetration, could be made (example see Figure 26).  
 
 
 
Figure 26: Irradiated Affi-gel 10 resin with mixed in marker molecule “compound 3” The column was 
irradiated for 60 s with UV light (λ=365 nm, 0.6 A, 15 V; condition 1, Table 22) from the right side, leading to a 
colour gradient within the column. The “compound 3” molecules on the right side of the column have been 
switched in a higher percentage than the ones on the left side of the column. 
 
Irradiation time needed to switch the marker towards strong colour saturation was measured, 
in the assumption of a similar behavior of azoCm. Using an insertion thermometer (Table 3), 
temperature changes inside the column material were measured as well, to see whether a 
temperature increase occurred that could lead to heat-induced RNA elution, independent from 
light elution effects. 
Parameters changed during the irradiation experiments were the amounts of amperage and 
voltage used to generate UV light, the volumes of 1x SELEX buffer pipetted on the column 
during the irradiation, and the exposure time to UV light. Additional experimental set-ups, 
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like shielding the column from heat inducing IR irradiation using an IR filter, or wrapping the 
column in aluminum foil during irradiation were tested as well.  
The efficiency of the irradiation was judged by eye by gauging the saturation of red inside the 
column, as the marker turned red upon switching to its cis isoform. Preferred results would 
show an even distribution of red resin throughout the column while showing little to no 
temperature increase measured in the resin. The results of the experiment are shown in Table 
22. 
 
Table 22: Light SELEX test conditions  
Test Irradiation conditions time [s] ∆T [°C] Results of colour 
saturation 
1 0.6 A, 15 V 60 2 strong red colour, gradient 
through the column (see 
Figure 26) 
2 0.6 A, 15 V, 20 µL 1x SELEX 
buffer inside the column 
60 1.5 strong red colour, gradient 
through the column 
3 0.6 A, 15 V, 300 µL 1x SELEX 
buffer inside the column 
60 1.1 strong red colour, gradient 
through the column 
4 0.6 A, 15 V, 300 µL 1x SELEX 
buffer inside the column, IR filter 
60 1.1 strong red colour, gradient 
through the column 
5 wrapped column in aluminium 
foil, 0.6 A, 15 V, 300 µL 1x 
SELEX buffer inside the column 
60 0.2 no colour 
6 0.2 A, 13 V 60 0.8 lesser colour saturation 
than in test 4 
7 0.02 A, 12.9 V 60 0 low saturation of red 
8 0.1 A, 13.3 V 60 0.15 higher degree of red than 
in test 7 
9 0.15 A, 13.5 V 60 0.2 higher degree of red than 
in test 8 
10 0.15 A, 13.5 V, turn column 
180°C after 60 s 
120 0.2 even degree of red 
throughout the column, 
comparable to test 6 
11 wrapped column in aluminium 
foil, 0.15 A, 13.5 V, turn column 
180°C after 60 s 
120 0.05 no colour 
     
Shown are the different UV light irradiation conditions used to test which are optimal to switch the marker 
molecule towards strong colour saturation within the Affi-gel (Table 1) in the column. Tested were different 
amperages and voltages, as well as irradiation times and directions from which the column was irradiated. 
Temperature changes within the column before and after irradiation were measured and the saturation of red 
colour within the column as a result of UV irradiation was analyzed and compared visually. 
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Table 22 shows, that irradiation conditions as in test 10 seem to be the most favorable ones 
for further experiments. An evenly distributed amount of marker molecule switched to red 
could be achieved with only a minimal temperature increase (∆T=0.2°C). An even 
distribution of red colour could be observed within the column, achieved by irradiating the 
column from both sides for 60 s with UV light (λ=365 nm) generated by 0.15 A and 13.5 V 
(2 W). Compared to condition 1, where 2°C temperature increase were measured by 
continuous irradiation from one side using 0.6 A and 15 V, but no even distribution of red 
could be detected throughout the column indicated the benefits of irradiating the column from 
both sides (condition 1, Table 22, Figure 26).  
As a control experiment, using the same conditions as in condition 10, but wrapping the 
column in aluminium foil prior to irradiation led to an 0.05°C increase in temperature, making 
the pure heat input from irradiation negligible. However, irradiation itself accounts for a 
0.15°C temperature increase within the resin, so heat induced elution of RNA is not entirely 
impossible.  
For this reason, the developed light SELEX condition 10 was tested on RNA, to find out 
whether condition 10 lead to unspecific RNA elution. Four different variations of condition 
10 were drafted, named α-δ. As shown in Table 23, all share the same voltage and amperage 
as in condition 10 from Table 22, but differ in irradiation time and methods (full-time 
irradiation or flashes of light). In this experiment, RNA from an enriched SELEX round 
selected against Kanamycin, provided by M.Sc. Adrien Boussebayle was used. The RNA 
aptamers were loaded onto an azoCm derived column, on which they should not be able to 
bind. 
 
Table 23: Light elution test conditions  
Test Irradiation conditions Elution 1 Elution 2 Elution 3 Elution 4 
10α 0.15 A, 13.5 V, 60 s per side buffer buffer buffer 
10β 0.15 A, 13.5 V, 1 s 
flashes, 32 flashes total  
10 flashes/side 
within 60 s 
6 flashes/side 
within 60 s 
buffer buffer 
10γ 0.15 A, 13.5 V 20 min/side, elute 
with buffer 
buffer buffer buffer 
10δ 0.15 A, 13.5 V, 1 s 
flashes, 16 flashes total 
5 flashes/side 
within 60 s 
3 flashes/side 
within 60 s 
buffer buffer 
      
Shown are the different UV light irradiation conditions tested in each elution experiment (1-4). Unspecific RNA 
was pipetted onto the column and different irradiation times and methods were tested. Amperage was 0.15 A, 
voltage 13.5 V (resulting in a power of 2 W). 
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For the experiment, RNA was pipetted onto the washed column and incubated there for 
15 min. After 20 washing-steps with 1x SELEX buffer, the RNA was eluted using different 
conditions in four elution steps. As can be seen in Table 23, either the column was irradiated 
continuously for a time from both sides (α, 60s/side; γ, 20 min/side), and afterwards eluted 
four times with 1x SELEX buffer. Or the column was irradiated in sets of light flashes of 1 s 
each, before the first and second elution round (β, 10 and 6 flashes per side; δ, 5 and 
3 flashes/side). Afterwards, two rounds of elution with 1x SELEX buffer followed, 
independent from the previous irradiation conditions.  
As the RNA was not supposed to bind to the column, regular amounts of eluted RNA were 
expected to occur. Increased RNA amounts were interpreted as heat effects leading to a higher 
molecule movement, thus leading to increased RNA outflow with the addition of 1x SELEX 
buffer. 
Figure 27 shows the eluted RNA in percentage to the wash fractions for all four conditions. 
As can be seen, conditions 10β and γ show distinct rises in their amounts of eluted RNA with 
the first elution step, compared to the previous wash steps. Condition 10α shows a gradual 
increase of eluted RNA, 10δ shows a smaller gradual increase at a later time. Regarding this 
data, the decision to start a real azoCm light SELEX round using conditions 10α and δ was 
made. 
 
 
Figure 27: Light elution experiments of unspecific RNA Shown are the percentages of eluted RNA from the 
last five wash fractions as well as the elution fractions of the four different elution conditions described in Table 
23. Unspecific RNA had been loaded on the column. Elution conditions 10α and 10δ showed a more or less 
stable amount of RNA eluted over the course of wash fraction 19 (W19) until elution fraction 4 (E4). Conditions 
10β and 10γ show a 5 or 8% increase in RNA elution between W20 and E1, while 10α shows a 2% increase. 
Condition 10δ shows a 1.3% decrease in eluted RNA between W20 and E1. 
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As a starting point for the light SELEX, the last round of the conventional azoCm SELEX 
was chosen. The eluted and PCR amplified DNA obtained after round 9 was transcribed into 
RNA and radioactively marked using [α-32P] UTP (3.2.8, 3.4.3). The folded RNA was 
pipetted onto the washed column and incubated on the column for 30 min. After 20 washes 
with 1x SELEX buffer, the RNA was eluted using conditions 10α or δ. At the same time, a 
control experiment without light elution was carried out, by simply “eluting” the RNA 4 times 
with 1x SELEX buffer. This served as a reference of background RNA, counting the amount 
of RNA that is flushed out of the columns unspecifically. The ratio between light eluted RNA 
and background RNA is shown in Figure 28, comparing values between the SELEX wash and 
elution fractions for conditions 10α and 10δ.  
 
 
Figure 28: Test of RNA elution using two different light elution protocols in a light SELEX round 10 
Depicted are the ratios between elution percentages of light elution protocols under condition 10α (blue 
columns) and 10δ (red columns) resp. and a control elution without irradiation of the column starting with the 
SELEX pool after affinity SELEX round 9 (4.4). The last five wash fractions as well as the elution fractions are 
shown. Elution condition 10α shows a more or less stable amount of RNA eluted over the course of wash 
fraction 19 (W19) until the elution fraction 4 (E4), from an irradiation to background ratio between 0.33 and 
0.51. Condition 10δ shows an RNA elution increase from a ratio of 0.5 in W20 to a ratio of 0.79 and 0.82 in E1 
and E3, and 0.89 in E2. 
 
As can be seen in Figure 28, elution condition 10α (blue bars) shows a more or less stable 
amount of RNA eluted over the course of wash fraction 19 (W19) until the elution fraction 4 
(E4). The irradiation to background ratio fluctuates between 0.33 and 0.51. Condition 10δ 
however (red bars), shows an RNA elution increase from a ratio of 0.5 in W20 to a ratio of 
0.79 in E1 once the column was eluted with irradiation and buffer. Elution fraction E2 even 
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shows an increase of irradiation to background elution ratio of 0.89. Even though in E3 no 
irradiation is used to elute RNA anymore and the column is only treated with 1 CV of buffer 
(Table 23), the eluted RNA ratio drops to 0.82 in the round, indicating plenty of light-eluted 
RNA molecules still in the column from the irradiation rounds E1 and E2. In E4, the eluted 
RNA ratio drops down to 0.39, showing little to no difference to the amount of eluted RNA 
with conditions 10α (E4 10 α=0.42). The increase of eluted RNA to background ratio in 
condition 10δ lead to the use of this protocol for further light SELEX rounds and experiments.  
 
 
4.9 Light SELEX 
As light SELEX was considered too stringent to use from round 1 of a SELEX, it was used as 
a protocol for SELEX rounds following those of the affinity SELEX against azoCm. After 
this SELEX had already enriched an RNA aptamer pool against azoCm trans, light SELEX 
rounds using the RNA from these pools should yield aptamers able to bind azoCm trans, but 
unable to bind azoCm cis. Different rounds from the azoCm affinity SELEX (4.4) were used 
as starting aptamer pools for light SELEX 
As a start, the protocol developed for light SELEX (Table 23) was applied several rounds 
after round 9 of the affinity SELEX (4.4). The RNA was transcribed from the cDNA after 
round 9, pipetted on the column and washed using the same conditions as in affinity SELEX. 
While the RNA-loaded column was irradiated, it was washed with SELEX buffer to flush out 
RNA aptamers that were detached from the ligand due to its conformation change. 
Amplification of the eluted RNAs via cDNA synthesis, PCR and re-transcription into RNA 
lead to a light-selected RNA pool for the next light SELEX round. 
The percentage of eluted RNA is shown in Figure 29. After a steady decrease in eluted RNA, 
there was a visible increase in round 12.  
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Figure 29: Summary SELEX against azoCm with light SELEX after R3 and R9. Shown is the fraction of 
input RNA that could be eluted from azoCm-derivatized columns after each selection round. RNA was eluted by 
either 20 mM EDTA (round 1) or 5 mM azoCm (round 2-9) in the affinity SELEX, shown in black. After Round 
3 or round 9, light-elution of RNA was carried out, shown in purple and red, respectively. While light SELEX 
after round 3 shows a slow increase in input RNA eluted, light SELEX after round 9 shows a sharp decrease 
until light SELEX round 11 (LS-11). Round 12 shows an increase in eluted RNA, this trend could not be 
observed in rounds LS13 to 15, however. 
 
This increase could not be sustained, however, which lead to the discontinuation of the 
SELEX procedure after round 15. It was theorized that light SELEX had been started too late 
in the SELEX process and that potentially light-elutable RNA aptamers constituted a minority 
in the pool, if they were not completely discriminated against by the increase in stringency in 
rounds 7 to 9 in the affinity SELEX. 
For this reason, a second light SELEX was started after round 3 of the affinity SELEX. As a 
strong increase of eluted RNA was observed in the affinity SELEX from round 5 to round 6, 
we expected to see a fast enrichment in the light SELEX approach as well. However, over the 
course of 4 light-elution rounds, there seemed to be a steady increase in eluted RNA, but it 
was considered too gradual in comparison to the affinity SELEX to signal real aptamer 
enrichment (Figure 29). 
 
0
1
2
3
4
5
6
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
%
 In
p
u
t 
e
lu
te
d
 
azoCm R4 δ azoCm R9 δ Affinity SELEX
 Results 101 
 
Figure 30: Summary SELEX against azoCm with light SELEX after R6. Shown is the fraction of input RNA 
that could be eluted from azoCm-derivatized columns after each selection round. RNA was eluted by either 
20 mM EDTA (round 1) or 5 mM azoCm (round 2-9) in the affinity SELEX, shown in black. After Round 6, 
light-elution of RNA was carried out, shown in green. With the first light SELEX round (LS-7) a sharp decrease 
in eluted RNA could be observed. Starting with LS-8, the amount of input RNA eluted increases until LS-10. In 
LS-11 stringency was increased by increasing number of wash steps to 25, a drop in the percentage of eluted 
RNA can be observed. Starting with LS-12, the amount of input RNA eluted increases until LS14. 
 
That is why, as a third experiment, we started a light SELEX approach starting after the 
enriched affinity SELEX round 6 (4.8% of input RNA eluted). As can be seen in Figure 30, 
enrichment of the light-selected pool could be achieved after only four rounds in round 10 to 
6.7%. After round 10, the stringency of the light-elution was increased by raising the number 
of wash steps to 25. After a decreased RNA elution, an increase could again be achieved 
starting in round 13. Altogether, 8 rounds of light SELEX were carried out following six 
affinity SELEX rounds. 
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Figure 31: Comparison of second affinity SELEX and light SELEX Shown is the fraction of loaded RNA that 
could be eluted from azoCm-derivatized columns after each selection round. RNA was eluted by either 20 mM 
EDTA (round 1) or 5 mM azoCm (round 2-9) in the affinity SELEX (black bars). In the first four rounds, a 
negative selection was performed (*). In round 7 and 9 stringency was increased by doubling the number of 
column washes or a decreased binding time of the RNA pool to the column, respectively (‡). Two pre-elution 
steps were performed starting from round 7 (#). Starting with round 7, light-elution was carried out in parallel to 
the affinity SELEX (violet bars). To achieve RNA elution, the column was irradiated with light (λ=365 nm) 
under exclusion of other light sources, while washing the column with SELEX buffer. Conformational changes 
in the immobilized ligands should lead to the elution of isoform specific RNA aptamers, thereby enriching only 
aptamer families that specifically bind the ligands’ trans isoform. 
 
Comparison of the light SELEX rounds with the affinity SELEX rounds starting after the 
affinity SELEX round 6 (LS-6) shows an increase in RNA elution in both protocols. 
Enrichment with light SELEX needs ten rounds to reach RNA elution amounts comparable to 
RNA elution amounts in round 9 of affinity SELEX.  
 
 
4.10 In vivo screening light SELEX 
To assess whether some of the generated aptamers in light SELEX round 7, 8 and 9 or round 
10 would function as riboswitches, in vivo screening in yeast was carried out. To this end, 
aptamers were amplified from light SELEX rounds 7 to 10 and transformation of yeast cells 
with this DNA and linearized plasmid pWHE601 was carried out as described in chapters 
3.3.4 and 4.2 . Aptamers from light SELEX rounds 7, 8 and 9 were amplified and transformed 
 Results 103 
separately, but results were pooled in one boxplot in Figure 32, due to the low amount of 
samples tested. 
 
 
Figure 32: In vivo screening of Light SELEX rounds LS-789 and LS-10 These boxplots show the summarized 
in vivo screening in S. cerevisiae for light SELEX rounds 7 to 9 (LS-789) and round 10 (LS-10). For each 
investigated clone, the regulatory activity was calculated as the ratio of GFP fluorescence with and without 100 
µM azoCm (x-fold). The numbers written above the boxplot indicate the number of clones analyzed. The median 
of all analyzed clones in LS-789 was 1.04 and at 1.13 in LS-10. 
 
While in vivo screening of light SELEX rounds 7, 8 and 9 (LS-789, Figure 32) showed some 
regulatory activity above 1.0 and the median was 1.04, all outliers making up the upper 
antenna of the boxplot could not be validated in a second or third round of screening (3.3.8). 
Round 10 (LS-10, Figure 32) had a median of 1.13 and an altogether lower amount of outliers 
indicating more regulatory activity than in rounds 7, 8 and 9. However, no riboswitches could 
be validated in light SELEX round 10 through a second and third round of screening as well. 
 
 
4.11 Binding studies of light SELEX aptamers 
As in vivo screening did not yield functioning riboswitches, the aptamers generated from 
SELEX were to be tested in vitro regarding their binding abilities of azoCm trans and cis. 
Aptamers from light SELEX round 10 were cloned by TOPO TA cloning (Table 4). Ten 
representative individual aptamers were chosen and tested in an in vitro binding assay, 
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following the protocol described in chapter 3.2.15. For comparison, aptamers A and E 
originating from affinity SELEX rounds 6 and 9 (4.5), respectively, were tested in this 
experiment as well.  
Firstly, aptamers were tested regarding their azoCm trans binding ability. To this end, elution 
of aptamers was carried out using 50 µM azoCm trans solution in 4x 500 µL elution steps, a 
100 times lower concentration than in affinity SELEX rounds and previous binding studies 
(4.4, 4.5). Only samples showing RNA elution of more than 10% of the originally loaded 
RNA (10% input eluted, Figure 33) were considered good binders and taken into the next 
round of testing. As this experiment was considered as first look into the aptamers, and good 
binders were measured again in the next experiment, this experiment was carried out only 
once. Pre-tests for this experiment and its elution conditions were carried out by Leon Kraus, 
as part of his Bachelors thesis in our laboratory [237]. 
 
 
Figure 33: Elution studies of light SELEX aptamers Radioactively labelled aptamers from LS-10 (shown on 
the y-axis) were folded and pipetted on azoCm-NH2-columns using the same conditions as during SELEX 
(100000 counts, folding program described in chapter 3.4.3). Four elution steps with 50 µM azoCm trans were 
carried out and the percentage of eluted RNA versus total RNA was calculated. Only four aptamers (1, 5, 12, A) 
showed more than 10% RNA elution (dotted line). 
 
Figure 33 shows that four out of the twelve tested aptamer samples show more than 10% 
RNA elution compared to the originally loaded RNA. These four aptamers, 1, 5, 12 and A, 
were tested regarding their discrimination between the trans and the cis isoform of azoCm, in 
the next step. Elution with 1x SELEX buffer was carried out as well, as a measure of 
background RNA elution. As control, aptamer E from affinity SELEX round 9 was tested as 
well, as it did not display a selectivity towards azoCm trans in previous binding studies (4.5). 
The binding assays were carried out as described for Figure 33. 
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Figure 34: Isoform specificity elution analysis Radioactively labelled aptamers showing more than 10% elution 
as well as a non-binding aptamer (1,5,12,A,E;  see Figure 33) were folded and immobilized on azoCm-NH2-
colums using the same conditions as during SELEX (100000 counts, folding program see chaptaer 3.4.3). 4 
elution steps with 50 µM azoCm trans, 50 µM azoCm cis or buffer were carried out. The percentage of eluted 
RNA versus total RNA was calculated and each aptamer’s azoCm trans value was normalized to 100%. 
Aptamers 12 and 1 show azoCm cis values below 66% (dotted line, more than 1/3 reduction compared to azoCm 
trans). Shown are the averages and standard deviations from two independent measurements. 
 
As can be seen in Figure 34, aptamers 1 and 12 out of the five tested aptamers show more 
than a 33% RNA elution reduction, when comparing azoCm cis to azoCm trans elution. 
Elution with 1x SELEX buffer always showed lower RNA elution than elution with azoCm 
cis, however, indicating that a percentage of aptamers could still be eluted with azoCm cis. 
 
 
4.12 Next generation sequencing (NGS) of SELEX  
In order to get a deeper understanding of the development of the affinity and light SELEX, 
and to see which aptamers families would get enriched or lost during the SELEX process, 
Illumina next generation sequencing was performed on samples from every affinity SELEX 
round (round 1 to round 9) and comparable light SELEX round (LS-7 to LS-9), as shown in 
Figure 31. 
Deep sequencing analysis of the selections was performed [198]. A total of 820000 sequences 
was obtained, from which identical sequences were summed up and the total read count was 
normalized for each round to reads per million (RPM). 
First, an analysis was carried out, whether specific sequence motifs or families were enriched 
in the course of the different selections rounds. For this, the sum of RPM of the 100 most 
enriched sequences (Top100, Figure 35) was calculated for each SELEX round. 
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Figure 35: Deep sequencing analysis of the most 100 most enriched sequences in affinity and light SELEX 
rounds Enrichment of the 100 most enriched sequences (Top100) in each round is shown. Marked in black are 
the sums of the RPM for affinity SELEX and marked in violet are the ones for light SELEX. 
 
As can be seen in Figure 35, the sum of the Top100 was enriched until round 6 (particularly 
between round 4 and round 6). Starting from round 7, both SELEX approaches, more 
stringent affinity SELEX and light SELEX, did not lead to a drastic enrichment of the Top100 
anymore. In the light SELEX rounds, the enrichment continues to climb slightly, while in the 
affinity SELEX R7, first a drop in the enrichment of the Top100 occurs, after which 
enrichment starts to increase again. This was interpreted as an indication that enrichment of 
azoCm specific aptamers during SELEX did indeed take place as derived from the increasing 
amounts of eluted RNA measured during the different SELEX rounds (Figure 31). Also, the 
results seemed to stress that the stringency process introduced in the affinity SELEX rounds 
(more washes etc., Table 18) was comparably stronger than the introduction of the light 
SELEX protocol in the light SELEX rounds. Both ways of increasing selective pressure seem 
to be able to enrich a certain group of sequences in the Top100 group. 
In order to identify the sequence families that were enriched using one or the other form of 
SELEX starting in round 7, sequences from affinity SELEX round 9 and light SELEX  round 
LS-9 were compared using the software MEME suite (Table 12). In the light SELEX rounds, 
a 13 nt motif was found that showed enrichment in the light-selection rounds compared to the 
affinity SELEX rounds, in which the occurrence of the motif was decreased (Figure 36). 
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Figure 36: Light motif The depicted 13 nt DNA motif was discovered to be particularly enriched using the light 
SELEX protocol. Numbered in blue are the nucleotide positions. 
 
Plotting the sum of sequences containing the discovered motif against the SELEX rounds 
showed a distinct distribution of the motif starting after round 6. 
 
 
Figure 37: Deep sequencing analysis of the sequences containing the identified motif in affinity and light 
SELEX rounds Occurrence of the identified light motif (shown as the sum of sequences in RPM) within each 
selection round displays enrichment in the light SELEX compared to the affinity SELEX. 
 
As can be seen in Figure 37, the sum of all sequences containing the motif (allowing one nt 
mismatch for sequencing errors) in the affinity SELEX round 6 was 1.05x 10
5 
RPM. In the 
final light SELEX round LS-9, the sum of motif-containing sequences reaches 
1.55x 10
5 
RPM, while in the affinity round 9, it is decreased to 8.95x 10
4 
RPM. This 
distribution of the motif indicated that it might be part of a light-selectivity conveying feature 
of aptamers. 
After clustering the sequences into families for each round by comparing their sequence 
identities by Levenshtein distance. Levensthein distance (Lv dist) measures the difference 
between two strings of characters, e.g. sequences, by so-called single character edits, 
numbering the insertions, deletions or substitutions needed to change one sequence into 
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another [238]. In bioinformatics it is a measure on how closely related one sequence is to 
another. The smaller the Lv dist between two sequences is, the more closely related they are. 
Grouping the sequences from SELEX by comparing their Lv dist, it could be shown, that a 
Lv dist of five (5-fold, Figure 38) is ideal to split the sequence distribution into distinct 
families (clustering process adapted from Groher et al. [133]). This distribution is shown in 
Figure 38. 
 
 
Figure 38: Scatter plot of the families found by deep sequencing in affinity and light SELEX. Shown in 
violet are aptamer families which are enriched during light SELEX rounds. Shown in blue are aptamer families 
enriched during affinity SELEX rounds. Aptamer families showing no changed behavior are shown in black. 
Aptamer families corresponding to previously tested aptamers in vitro binding assays are marked. Aptamer 
families which were previously tested in binding assays and contained the light motif are marked with an arrow. 
 
The detailed analysis of the families enriched by light SELEX revealed 132 unique sequence 
families, for affinity SELEX, 243 families were identified, and 123 families could not be 
attributed to one or the other group (unchanged, Figure 38). Marked in Figure 38 are also 
aptamers, which were tested in previous binding studies (4.5), and which could be found 
again as enriched families in light SELEX (1, 7, 10, 12, 14, 16). Interestingly, also aptamers 
A and E could be found as enriched light SELEX families, even though sequence A was 
identified from round 6 aptamers, and sequence E was found in aptamers stemming from 
affinity SELEX round 9 (4.5). Notably, sequence A was identified as the same sequence 
family as sequence 5 (Lv dist of 5 or less, Figure 38). 
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Aptamer sequence 1 as well as 12 (families marked with arrows in Figure 38), which were the 
only aptamers tested in previous binding studies showing more than 33% reduced elution with 
azoCm cis than with azoCm trans, were found to contain the light motif (Figure 37). 
Comparing their sequences with the previously described aptamer 42 discovered in the 
SELEX by Rudolph [196], revealed that aptamer 42 contained the light motif as well (Table 
24).  
 
Table 24: Comparison of aptamers containing the light motif  
Aptamer Sequence 
Light motif 5’ CCUACGGGAAAGG 3’ 
Aptamer 1 
5’ GUGUUCCGACACGUGAACUCCAGCCCCCUUAAUAACGCUGUC
GACCCUUGCGCUGUUACCUACGGGAAAGGGGU 3’ 
Aptamer 12 
5’ CCCCUCCCUACUGUGACUGAACGAACCCACAGUAGGGCCUAC
GGGAAAGGGGAGUGACCUGGCCCAAAGCCACC 3’ 
Aptamer 42 
5’ GGUUGACCCUACUGCUUCGGCAGGCCUACGGGAAAGGUAA 
CA  3’ 
 
Shown is the sequence of the light motif in violet and its position in sequences of the tested aptamers (aptamers 
1, 12, 42). 
 
Two aptamers containing the light motif (12, 42) contained two additional G’s in front of the 
13 nt light motif, making it unclear whether they were important or not (marked bold and 
underlined in Table 24). 
The discovered light motif might play a role in binding the ligand, as it turned up in two 
entirely independent SELEX processes from two very different pools. In order to test if the 
motif could yield more azoCm binding aptamers, a new pool for a new SELEX approach was 
designed. 
 
 
4.13 Development of a motif doped pool 
To see whether the light motif discovered (Figure 36) was indeed relevant in binding the 
ligand azoCm, a new pool for a new SELEX was generated, called the motif-doped pool, or 
“pool 3” (Figure 39). This pool should help to generate small, highly specific aptamers able to 
selectively and reversibly bind to only the trans isoform of azoCm. As the light motif always 
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occurred towards the 3’ end of the three discovered aptamers 1, 12 and 42 (Table 24) a pool 
was designed consisting of 30 randomized nucleotides followed by two G’s, then the 13 nt 
light motif and finally, 5 more randomized nucleotides. The total size of the generated 
aptamers should accordingly be 50 nt. In order to find potentially better variations of the 
motif, a 6% mutation rate was allowed for the 13 core nucleotides of the light motif. As it was 
not clear whether the two G’s in front of the motif were a necessary or helpful addition to the 
motif (see Table 24), they were added on the 5’ side of the motif but were allowed to mutate 
with a possibility of 50% (Figure 39). As described before, the 30 and 5 nt flanking the motif 
were randomized entirely (probability for every nucleotide per position should be 25%). 
 
 
Figure 39: Motif-doped SELEX pool (pool 3) The newly designed pool for SELEX consists of a partially 
structured library containing a 15 nt sequence motif ((gg)cctacgggaaagg) derived from aptamers of the first and 
second affinity SELEX. The motif is flanked by 30 randomized nt on the motifs 5’ end, and 5 randomized nt on 
its 3’ end. The motif was partially randomized, with a 50% chance of a nucleotide exchange for the first two nt 
(GG), and a 6% chance for the remaining 13 nt. This partially structured library is flanked by the constant primer 
binding regions P1 and P2. 
 
This oligonucleotide for this new, “motif-doped” pool was synthesized by the company 
Seqlab. For large scale maximum efficiency amplification by PCR (using primer pair “Library 
doped fwd” and “Library doped rev”, Table 6), protocols were tested and optimized. 
 
 
4.13.1 Motif-doped pool PCR optimization 
Optimization of the PCR conditions was carried out according to (4.3.1). PCR was carried out 
according to the PCR protocol described in table (Table 16). Figure 40 shows a distinct band 
at the expected size of 127 bp on a 3% agarose gel. 
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Figure 40: Agarose gel of pool 3 scout PCR Shown is a 3% agarose gel with PCR-reactions performed with 
different amounts of cycles to test amplification of pool 3 via the PCR program described in (Table 16). Shown 
from left to right in the lanes are: Marker (M), 5, 6, 8, 10 and 12 cycles and the negative control sample 
containing no template (-). 
 
After PCR cycles 5, 6, 8, 10 and 12, 5 µL of the reaction were taken from each PCR sample 
and applied on a 3% agarose gel, together with a negative control reaction containing no 
template DNA (- , Figure 40). As can be seen in Figure 40, after 10 cycles, overamplification 
bands start to appear.  
In order to further optimize PCR conditions, different annealing temperatures were tested, 
parallel to a range of amplification cycles determined before. Temperatures tested were 54, 58 
and 62°C, the different amount of cycles tested were 6, 7, 8, and 9, as a control. Samples were 
checked on a 3% agarose gel (Figure 41).  
 
 
Figure 41: Agarose gel of pool 3 scout PCR Shown are details of a 3% agarose gel with PCR-reactions 
performed with different amounts of cycles to test amplification of pool 3 via the PCR program described in 
(Table 16). Shown from left to right in the lanes are: Marker (M), 6 cycles: 6a (54°C), 6b (58°C) 6c (62°C); 7 
cycles: 7a (54°C), 7b (58°C) 7c (62°C); 8 cycles: 8a (54°C), 8b (58°C) 8c (62°C); 9 cycles: 9a (54°C), 9b (58°C) 
9c (62°C) ; negative control sample containing no template (-, 54, 58, 62°C). 
 
Figure 41 shows the strongest and cleanest results at 54°C and after 7 cycles of amplification. 
PCR efficiency was calculated according to Hall et al. [234]. The final optimized PCR 
program can be found in Table 17, as it is identical to the one previously used (4.3.1). 
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4.13.2 Motif-doped pool generation 
The optimized PCR protocol was applied in a 40 mL PCR reaction carried out in 96 well 
plates, using the entire remaining synthesized pool sample as template. The resulting DNA 
pool was precipitated using sodium acetate precipitation (3.2.12) and resuspended in a total 
volume of 2 mL water. From this pool DNA solution with a concentration of 1.51 µg/µL (or 
3.6x 10
-11
 mol/µL), 215 µL were used in a 10 mL transcription sample used to transcribe the 
pool (3.2.8). The transcribed pool was precipitated using sodium acetate precipitation and 
purified using PAA gels (3.2.11). Resuspended in 2 mL of RNase free water, the RNA pool 
had a concentration of 189 pmol/µL. This pool RNA stock solution was used for motif-doped 
SELEX experiments.  
Applying the same calculations as in 4.3.2, 4.8x 10
14
 molecules were used in the motif-doped 
SELEX (Equation 6, Equation 7). Assuming a totally randomized nucleotide pool of 50 nt, 
the possible sequence space would still contain 1.27 x 10
30
 sequences and could not be 
covered with the pool applied in the SELEX. As before, all of the synthesized pool oligo had 
been used in the large-scale PCR and
 
a bigger sequence space could not be achieved. The 
motif-doped SELEX was carried out using the developed pool. 
 
 
4.14 Doped SELEX 
The generated motif-doped pool was used for SELEX against azoCm. azoCm Amino 
derivatized sepharose gel was used as column material, like in the previous affinity and light 
SELEX. The SELEX protocol was carried out using the protocol for affinity SELEX as 
described chapter 3.4.3. After loading the RNA and incubating it for 30 min on the columns at 
RT, 10 washing steps of CV=500 µL with 1x SELEX buffer were carried out. For elution, a 
1 mM azoCm trans solution was used in 4 elution steps (1 CV each) starting in SELEX 
round 1. This process was repeated for several consecutive rounds to generate an RNA pool 
enriched with ligand binding aptamers.  
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Figure 42: Summary of motif-doped SELEX against azoCm (pool 3) Shown is the fraction of loaded RNA 
that could be eluted from azoCm-derivatized columns after each selection round. RNA was eluted with 1 mM 
azoCm (Doped SELEX (DS) round 1-5).  
 
As shown in Figure 42, the SELEX was quickly enriched, reaching 38% RNA elution within 
five rounds of SELEX. This rapid enrichment coupled with the fact that elution was achieved 
with 1 mM of ligand solution (1/5
th
 of the concentration used in affinity SELEX) indicated 
that the motif was indeed relevant for ligand binding.  
To analyze the development of the motif doped pool, 96 aptamers generated by TOPO TA 
cloning (Table 4) each for doped SELEX (DS) rounds DS2 to DS5 were sequenced. Within 
these sequences, no sequence was found more than twice, and even those doublets were found 
only 11 times in all sequenced aptamers together (Table 25). Particularly in round 5 with 38% 
ligand-eluted RNA from the total applied RNA at least one dominant aptamer sequence would 
have been expected. The failure to find one or several dominant sequences in the SELEX, 
while at the same time the SELEX displayed strong enrichment over the progression of 
rounds seemed to indicate one single factor as the determinant on how well the RNA could 
bind azoCm. 
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Table 25: Summary of double sequences in motif-doped SELEX rounds 2-5  
Round RNA elution 
Number of doubled 
sequences in round 
Number of doubled sequences 
between rounds 
DS2 0.5% 6 1 
DS3 2% 1 - 
DS4 11.1% 2 - 
DS5 38.1% 1 1 
 
Shown are the SELEX rounds DS2 to DS5 and their respective RNA elution in percent. The amounts of 
sequences found twice within one round are listed, as well as the amounts of sequences found identical between 
one round and another. 
 
Reducing the analysis of the aptamer sequences to the light motif alone, while disregarding 
the randomized regions flanking it, showed a re-enrichment of the original motif sequence 
(see Figure 43). 
 
 
Figure 43: Enrichment analysis of the sequence motif of the doped selection in DS5. Shown is the nucleotide 
distribution over the different motif positions. In the first line, the original light motif is displayed. Below, the 
chance of one nucleotide occupying this position is listed in percent (A, C, G, T). Some positions show a 97 to 
100% probability of recovering their original nucleotide after round 5 of the doped SELEX (blue markings). 
Other nucleotides, like the very first position (originally a G) do not show a preference for one particular 
nucleotide in this position (green markings). Nucleotide positions showing a 0 to 3% probability lead to the 
conclusion that this position does not play a role in ligand binding (yellow and white markings). In the last line, 
the consensus sequence of the motif region after doped SELEX round 5 (DS5) is displayed, with larger letters 
describing higher nucleotide conservations. Marked in red are nucleotides which occur in 100% of the tested 
sequences 
 
Over the course of the doped SELEX, the initially partly randomized motif re-evolved mostly 
back to its original sequence (Figure 43), thus indicating the nucleotides relevant to ligand 
binding. Sequence positions marked in blue show a 97 to 100% probability of recovering their 
original nucleotide after round 5 of doped SELEX. Sequence positions marked in green, like 
the very first position (originally a G), do not show a preference for one particular nucleotide 
in this position, leading to the conclusion that this position does not play an important role in 
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ligand binding.  Sequence positions marked in yellow and white markings show a 0 to 3% 
probability of being a certain nucleotide. Typically, this marks a position where another 
nucleotide is highly probable to occupy this position. Thus, these markings display a 
“negative control” on which nucleotides would be detrimental for ligand binding on this 
position. 
For the light motif, it can be observed that a specific nucleotide is not relevant at the first 
position and should therefore not be involved in ligand binding (X, Figure 43). Position two 
of the motif is highly probable a purine base (A or G, probability sum of 96%). As it was 
unclear if these two positions were necessary in ligand binding (found in 2 out of 3 tested 
aptamers, Table 24), these results indicated that the first position plays a negligible role. The 
second position seems more important, however, allowing this position to be randomized with 
a 50% chance to either A, C or T leading to a clear preference for the nucleobase A, next to G. 
This indicated that position 2 of the motif plays a role in ligand binding, or potentially in 
stabilizing the binding pocket surrounding the ligand binding nucleotides of the aptamer. 
Motif positions 3 to 14 are highly conserved, with 7 out of 12 positions displaying a 100% 
chance of one specific nucleotide in this position. Of the 12 positions, the lowest probability 
observed for the original nucleotide of the motif was 97%. Therefore, the entire sequence can 
be considered as crucial for ligand binding or ligand binding pocket formation, as DS5 
displayed 38% RNA elution in the SELEX and can be considered highly enriched as well. 
Position 15 of the motif shows the same behaviour as position two, with a clear preference for 
purine bases in this position (probability sum of 96%). 
The observation of a re-enrichment of twelve nucleotides of the motif, with two purine 
nucleotides flanking this conserved region indicated that the light motif itself is the core 
binding region on which the ligand binding solely depends. It seems that the 30 (or 31) nt 
upstream and 5 nt downstream of the motif only serve the purpose to stabilize the aptamer in 
itself, whereas the motif is responsible for the binding on its own.  
As no single aptamers seeming to indicate enrichment could be extracted from this SELEX, 
an in vivo screening approach able to screen higher number of aptamer sequences was 
planned. 
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4.15 Preparation of libraries and controls for FACS screening 
To discover whether the motif-doped SELEX (Figure 42) did contain aptamers functioning as 
riboswitches in S. cerevisiae, in vivo screening was carried out. As previous in vivo screenings 
did not yield any functional riboswitches, which could be due to the method employed, a new 
screening approach was designed. As screening is a laborious, time- and material-consuming 
method, but still only a small part of the potential sequence space of the SELEX rounds can 
be tested, a FACS based in vivo screening method seemed appropriate. Adding FACS sorting 
steps before the manual in vivo screening would significantly reduce the amount of cells to 
test. Cell sorting was carried out at AG Kolmar by Dr. Andreas Christmann and Dr. Doreen 
Könning.  
To set up the cell sorter and adjust the fluorescence photomultiplier for GFP accordingly, 
S. cerevisiae cells containing the control plasmid pCBB006 (Table 8) grown with and without 
azoCm were measured. As the plasmid contains no start codon (ATG) in front of the GFP 
encoding gene gfp, no GFP protein should be generated, thus the cells should not show any 
fluorescence. For the next measurement, S. cerevisiae cells containing the control plasmid 
pCBB005 (Table 8) grown with and without azoCm were used. As this construct contained a 
start codon in front of the gfp gene, the cells should show continuous expression of GFP, 
leading to the maximum fluorescence intensity output the genetic construct pCBB005 should 
be able to produce. 
These two measurements were set as the high and low threshold of the experiment, 
respectively, representing the minimum and maximum fluorescence intensity of S. cerevisiae 
cultures containing the control plasmid pCBB with any variation of GFP expression controls 
(no GFP expression, continuous GFP expression, aptamer/ riboswitch regulated GFP 
expression). 
The baseline measurements regarding cell fluorescence intensity are shown in Figure 44, with 
minimal differences between minimum and maximum fluorescence intensity values grown 
with or without azoCm in the area above 10
1 
units. These differences can be regarded as 
background noise, according to Christmann (pers. comm.). Any differences below the value 
of 10
1 
fluorescence units can, therefore, be neglected.  
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Figure 44: First measurement of FACS controls Shown are the fluorescence intensities of yeast cells of grown 
with and without azoCm in the media. The cells contained the following plasmids. Orange line: pCBB005, green 
line: pCBB005+azoCm, violet line: pCBB006, blue line pCBB006+azoCm. On the X-axis, the fluorescence 
intensity is given in units after 488 nm excitation with a fluorescence emission detection between 530 ± 20 nm 
which is annotated as 530/40(488). The Y-axis gives the cells counted for a specific fluorescence intensity. 
 
To generate large S. cerevisiae aptamer libraries, large PCR amplifications of the aptamers 
from the doped SELEX pools DS3 and DS4 were ligated with digested pCBB005 plasmid 
backbone (3.2.4, 3.2.5). The ligations were butanol-purified (3.2.12) und transformed into 
commercially available E. coli 10-beta cells (3.3.2, Table 4). To avoid losing any transformed 
aptamer sequences, the entire transformation reaction was grown in a volume of 8 mL 
LB-medium, except for a few microliters of the reaction, which were used for dilution plating, 
so transformation efficiency could be quantified according to Equation 8 (an example for 
library DS3 is given in Equation 9). 
 
Equation 8: Calculation of transformation efficiency To calculate transformation efficiency (TE), cells are 
transformed with circularized plasmid DNA using optimal conditions and plated on solid media. After growth, 
colonies per plate are counted (colony forming units, cfu). Divided by the amount of plasmid used for 
transformation and the final dilution of the plated cells, TE in cfu/amount plasmid can be calculated. 
𝑐𝑓𝑢 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑝𝑙𝑎𝑡𝑒)
𝑛𝑔 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑
𝑓𝑖𝑛𝑎𝑙 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 𝑖𝑛 𝑚𝑒𝑑𝑖𝑎
= 𝑇𝐸 [
𝑐𝑓𝑢
𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑖𝑑
 ] 
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Equation 9: Calculation of transformation efficiency of library DS3 Transformation efficiency (TE) of cells 
transformed with circularized plasmid DNA of pool DS3 is calculated. Number of colonies counted on the plate 
was 2040 (cfu) and divided by the amount of plasmid used for transformation and the final dilution of the plated 
cells (1:115). TE was calculated as 234600 cfu per ng plasmid. 
 2040 𝑐𝑓𝑢
1 𝑛𝑔 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑
(1: 115)
=  𝑇𝐸 234600
𝑐𝑓𝑢
𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑖𝑑
  
 
Calculation of the transformation efficiency yielded a library size of 2.35x 10
5
 for library DS3 
(generated from aptamers of the doped SELEX round DS3) and 3.96x 10
4
 for library DS4 
(from aptamers from doped SELEX round 4). After growing the cells overnight, the plasmids 
were extracted and butanol-purified (3.2.12). The entire pool of aptamer-containing plasmids 
was then transformed into electrocompetent yeast cells (3.3.5). Thus, S. cerevisiae libraries 
were generated, containing the aptamers from DS3 or DS4 in a riboswitch set-up. They were 
kept in culture for immediate use or frozen in glycerol stocks at -80°C for later experiments. 
 
 
4.15.1 Yeast library segregation and first FACS sort 
To prepare the libraries for fluorescence-activated cell sorting, the S. cerevisiae libraries had 
to be grown in a segregation set-up, a method that is employed to reduce the number of 
plasmids that one S. cerevisiae cell carries (3.3.5 [228]). After segregation, the cells were 
strained through cell strainers (Table 3) to remove budding cells, or cells stuck to each other, 
and kept on ice until sorting. In parallel to the libraries, S. cerevisiae cells transformed with 
pCBB005/006/007 were inoculated in 4 mL samples. They were strained through filters as 
well, chilled on ice, and used as daily control measurements for the FACS sorting. 
Figure 45 shows the distribution of fluorescense in the DS4 S. cerevisiae library as a green 
line. In comparison, the parallel control values of pCBB005 (blue line) and pCBB006 (brown 
line) show that the established FACS protocol and its thresholds are suitable for the 
experiment, as there are almost no cells of DS4 that lie outside of the established minimum 
and maximum fluorescence values. The fluorescence intensity of DS4 is almost equally 
distributed over the range of 10
1
 to10
3
 fluorescence units, with a decreasing number of cells 
that shift towards the minimum and maximum fluorescence values. Overall, 75% of the cells 
were above the values of the negative control. Figure 45 shows the two gates which were set 
to sort the cells, a high gate (“DS 4 high”, green gate, 25% of the cells) and a low gate (“DS 4 
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low”, blue gate, 42% of the cells). Cell sorting was carried out until 2 millions cells per gate 
were isolated. 
 
 
Figure 45: First measurement of yeast cells containing DS4 aptamers Shown are the fluorescence intensities 
of yeast cells containing the following plasmids: Orange line: pCBB006, green line: DS4 aptamer library, blue 
line: pCBB005. 2 million cells were sorted into each of the two gates, one showing low fluorescence intensity 
(green gate, “P1”) and one showing high fluorescence intensity (blue gate, “P2”). On the X-axis, the 
fluorescence intensity is given in units after 488 nm excitation with a fluorescence emission detection between 
530 ± 20 nm which is annotated as 530/40(488). The Y-axis gives the cells counted for a specific fluorescence 
intensity. 
 
The same procedure was carried out for cells of the library DS3 (data not shown). The 
distribution of the cells was similar to DS4 prior to sorting, with 84% of the cells above the 
negative control. For DS3, the same gates as for DS4 were used, sorting 2 million cells into 
the high gate (32% of the total cells) and 2 million into the lower gate (40% of the total cells).  
All sorted cells were grown in 50 mL SCD-URA medium for 48h at 30°C. The cultivated 
cells were then diluted 1:100 in fresh 50 mL SCD-URA medium, grown for 24h, and then 
diluted 1:100 in 10 mL of medium with and without 100 µM azoCm, and grown for 24h. 
Parallel controls of S. cerevisiae cells containing pCBB005 and pCBB006 were inoculated in 
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4 mL again. All libraries and controls were strained through cell strainers (Table 3) and kept 
on ice until sorting. 
 
 
4.15.2 Second FACS sort  
The second FACS sorting consisted of the two libraries with their previously sorted two 
fluorecence groups, DS3 low, DS3 high, DS4 low and DS4 high, all cultivated with and 
without azoCm resp. 
 
 
Figure 46: Measurement of yeast cells containing sorted DS3 and DS4 cells from the “low” gate (see Figure 
45) A Shown are the fluorescence intensities of yeast cells from the previous DS3 low sort: green line: grown 
with azoCm, pink line: grown without azoCm. B Shown are the fluorescence intensities of yeast cells from the 
previous DS4 low sort: blue line: grown with azoCm, brown line: grown without azoCm. On the X-axis, the 
fluorescence intensity is given in units after 488 nm excitation with a fluorescence emission detection between 
530 ± 20 nm which is annotated as 530/40(488). The Y-axis gives the cells counted for a specific fluorescence 
intensity. 
 
Figure 46A shows the distribution of fluorescent cells of DS3 low grown without azoCm 
(green line) and with 100 µM azoCm (pink line). Figure 46B shows the cells of DS4 low 
without azoCm (brown line) and with 100 µM azoCm (blue line). As there was barely a 
difference between the cells grown with or without azoCm, the cells of DS3 low and DS4 low 
were not sorted and were discarded. Figure 47B shows the distribution of fluorescent cells of 
DS4 high grown without azoCm (pink line) and with 100 µM azoCm (blue line). At a 
fluorescence intensity of around 10
2
 units there are fewer fluorescent cells in the sample 
grown with azoCm present as in the one without. This indicated that in this region, an azoCm 
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dependent regulation of GFP production could have taken place. A gate (P2) was set, and 
50000 cells of the gated population (making up 11% of all cells) were sorted. 
 
Figure 47: Measurement of yeast cells containing sorted DS3 and DS4 cells from the “high” gate (Figure 
45). A Shown are the fluorescence intensities of yeast cells from the previous DS3 high sort: brown line: grown 
with azoCm, black line: grown without azoCm. B Shown are the fluorescence intensities of yeast cells from the 
previous DS4 high sort: blue line: grown with azoCm, pink line: grown without azoCm. Cells were sorted into 
one gate (blue gate, “P2”). On the X-axis, the fluorescence intensity is given in units after 488 nm excitation with 
a fluorescence emission detection between 530 ± 20 nm which is annotated as 530/40(488). The Y-axis gives the 
cells counted for a specific fluorescence intensity. 
 
Figure 47A shows the cells of DS3 high without azoCm (black line) and with 100 µM azoCm 
(brown line). The same shift in fluorescence around an intensity of 10
2
 as in DS4 high could 
be observed, even though it was less pronounced. Overall, 50000 cells of gate P2 were sorted 
(making up 2% of all cells).  
The sorted cells were diluted to a density of 200 cells/µL and plated on 20 SCD-URA plates, 
for DS3 high and DS4 high, each. The remaining cells were grown in 8 mL of SCD-URA for 
48 h at 30°C, then harvested and frozen in glycerol at -80°C for later use. 
 
 
4.16 In vivo screening of doped SELEX aptamers from FACS sorted pools 
To find out whether the generated aptamers in the doped SELEX (DS) rounds DS3 and DS4 
contained some functioning as riboswitches, in vivo screening with the previously FACS 
sorted yeast cells was carried out. The cells were grown on SCD-URA plates and single 
colonies were inoculated into 96 well plates. Screening was carried out according to (3.3.8). 
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Figure 48: In vivo screening of doped SELEX rounds DS3 and DS4 after FACS sorting This boxplot shows 
the summarized in vivo screening of S. cerevisiae cultures for the doped SELEX rounds DS3 and DS4. For each 
investigated clone, the regulatory activity was calculated as the ratio of GFP fluorescence with and without 100 
µM azoCm (x-fold). The numbers written above the boxplot indicate the number of clones analyzed. The median 
of all analyzed clones was 0.98. 
 
The median regulatory activity of analyzed clones at in vivo screening of rounds DS3 and 
DS4 was 0.98. There were clones showing regulatory activity above 1.0 on the upper antenna 
of Figure 48. In a second and third screening, four aptamers with regulatory function could be 
validated, called B1, B2, C3 and D1 (Table 26).  
 
Table 26: Aptamer sequences with regulatory function discovered in DS3 and DS4 in vivo screening  
Ribos
witch 
Sequence 
B1 CCCTTAGCACGACGAACTAGATGCCGTTGCTACCTACGGGAAAGGACGGT 
B2 GCTCCCTTTAGATGTTAGTCGAAGACATCTAACCTACGGGAAAGGAGACC 
C3 CTCAGCCCCTCAGTCGAGTGGATTCACGGCTGCCTACGGGAAAGGGTGAG 
D1 CCCTTTGGTTAGAATACAGTGCTCTAGCCAACCTACGGGAAAGGACGGT 
 
Shown are the sequences of the four aptamers from doped SELEX rounds DS3 and DS4 (B1, B2, C3, D1) 
showing regulatory function regarding gene expression. Marked in green is the original light motif sequence. 
 
These regulatory aptamers were analyzed in triplicates using cytometry (3.3.7), as well as 
fluorimetry (3.3.6), to exclude methodical bias (Figure 49). Controls were measured as well. 
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Figure 49: Cytometric and fluorimetric measurements of regulatory aptamers from doped SELEX rounds 
DS3 and DS4. Shown are the measurement of the median regulatory factors of azoCm dependent aptamers B1, 
B2, C3 and D1 using a cytometer (left, 3.3.7) or a fluorimeter (right, 3.3.6). As controls, cells with plasmids 
showing constant (+ control, pCBB005) or no GFP production (- control, pCBB006) were measured, as well as a 
sample containing the Neomycin riboswitch (Neo, pCBB007). A dotted line marks a regulatory factor of 1.0. All 
samples were measured in triplicates and with azoCm or Neomycin as ligand. 
 
Aptamers B1, B2, C3 and D1 all show a regulatory factor of GFP expression of 1.25 to 1.35. 
The controls showed no influence on their fluorescence by addition of azoCm (+ and – 
control, Figure 49). Growing and measuring yeast cells containing plasmid pCBB007 insured 
that growth conditions were fitting for riboswitch activity.  
As neither of the aptamers in Figure 49 showed a regulating activity of more than 1.35-fold, 
new pools for doped in vivo screening were designed. In order to be able to generate a 
riboswitch out of one of the aptamers showing a slight regulatory function, the aptamer B2, 
showing the highest and most consisted regulatory factor, was chosen as a basis for a new 
pool design. Randomized mutagenesis of the aptamer sequence of B2 were designed and 
screened in vivo to find a functional riboswitch.  
 
 
4.17 Development of doped in vivo screening pools 
To find azoCm dependent riboswitches with a higher regulatory factor (x-fold), four new 
pools for in vivo screening based on the B2 riboswitch were designed. The variants were 
based on the supposed 2D structure of the B2 riboswitch (Figure 50A), which was derived 
from the way the aptamer 42 was folded (Figure 14B), as the riboswitch and the aptamer 
contain the same core motif of 13 nucleotides (Table 26).  
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Figure 50: Structure of B2-derived pools A Shown is the via mfold predicted structure of riboswitch B2 (Table 
12, Table 26). For B2-derived pools B2-10 and B2-5, the entire sequence was allowed a 10 or 5% nucleotide 
permutation rate. Marked in a dotted red line is where the sequence was truncated to generate the structural bases 
shown in B (pools B2-N6 and B2-6N6) B Shown is the mfold predicted structure of riboswitch B2-derived pools 
B2-N6 and B2-6N6. For pool B2-N6, the upper left loop allows for total randomization of 6 nucleotides. B2-6N6 
allows for total randomization of 6 nucleotides in the left upper loop, while allowing a 6% nucleotide 
permutation rate in the remaining sequence. 
 
Two variants allowed for a 5% and 10% nucleotide permutation rate of the sequence of 
riboswitch B2, respectively (Figure 50A). To reduce the size of the riboswitch, the two other 
pool variants were composed of a truncated version of B2 by removing parts of the upper arm 
of the structure, where no ligand binding should take place. In one pool variant, 15 nt of the 
upper arm of B2 (Figure 50A) were replaced with a short loop containing 6 randomized 
nucleotides (B2-N6, Figure 50B). In the other variant, B2-6N6, the upper arm was replaced 
with a N6 loop as well, with the remaining nucleotides of the sequence being allowed a 
nucleotide permutation rate of 6% (Figure 50B). 
 
 
4.17.1 Doped in vivo screening pool generation 
The DNA templates for the designed pools were ordered from Seqlab, as described 
previously. As pools for this in vivo screening did not undergo a SELEX experiment prior to 
in vivo screening, a smaller sequence space was acceptable. Therefore, PCR condition 
optimization was only carried out regarding the amount of amplification cycles used. As PCR 
primers, for every in vivo pool its forward template oligo (e.g. “Library B2-10 fwd”, Table 6) 
was used in combination with their common reverse oligo “Libraries B2 rev” (Table 6). The 
PCR products were gel purified using the Qiagen kit (Table 4). Figure 51 shows a 
representative 3% agarose gel of the amplification of pool B2-10, using 35, 37, and 40 cycles 
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of amplification (protocol see Table 16). Figure 51 shows a distinct band at the expected size 
of 97 bp on a 3% agarose gel. 
 
 
Figure 51: Agarose gel of the PCR amplification-results of pool B2-10 Shown are Marker (M), and results of 
40, 37 and 35 cycles of amplification on a 3% agarose gel. For each PCR, 5 µL of the PCR reaction (a) and the 
gel purified PCR product (b) were applied on the gel, as well as a negative control containing no template (-). 
 
As can be seen in Figure 51, only the protocol with 35 cycles of PCR amplification does not 
show overamplification bands. Therefore, 35 cycles were used in the finalized PCR reaction 
using the protocols shown in Table 27 and Table 28. 
All four amplified DNA pools were used as aptamer templates. The DNA was cleaved using 
restriction enzymes AgeI and NheI (Table 5) and ligated into the plasmid pCBB006 (Table 8), 
which was linearized using the same enzymes, previously (3.2.4, 3.2.5). The ligation reaction 
was butanol-purified (3.2.12) after 16 h of incubation. The commercial cells E. coli 10-beta 
(Table 4) were transformed with the generated plasmid library, to ensure high transformation 
yields. The transformed cells were grown in 8 mL LB-Amp medium per library and the 
plasmids were extracted after 16 h of growth using the plasmid extraction kit from QIAgen 
(Table 4). These generated plasmid-libraries were butanol-purified again and could be used 
for subsequent yeast transformation. 
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Table 27: Finalized doped in vivo screening pool PCR amplification protocol  
 
Shown are the temperature (T) applied in each PCR step, as well as the time (t) the temperature is applied. The 
marked three steps are repeated for 35 cycles. 
 
 
Table 28: Finalized doped in vivo screening pool PCR amplification composition  
 
Shown are the reagents applied in each pool PCR reaction, as well as the volumes used. 
 
 
4.18 Motif-doped in vivo screening 
To find azoCm dependent riboswitches with a higher regulatory factor (x-fold) than 
riboswitch candidate B2 (Table 26), four new plasmid pools containing randomized aptamers 
based on B2 were generated (4.17). 
For in vivo screening, competent S. cerevisiae cells were transformed with the three pools 
B2-10, B2-N6 and B2-6N6, using the lithium acetate protocol (3.3.4). The transformed cells 
were plated on SCD-URA plates and grown for 3 d. Transformation efficiency (TE) was 
calculated as shown in Equation 8. As transformed plates with 1 ng plasmid diluted in 110 µL 
volume for the pools B2-10, B2-N6 and B2-6N6 yielded 56, 30 and 32 colonies, respectively, 
calculation efficiencies varied between 3330 to 6160 cfu/µg plasmid. 
T t  PCR steps 
98°C 2 min  Initial melting 
98°C 10 s  Melting 
58°C                                 30 s    repeat for 35 cycles Primer annealing 
72°C 30 s  Elongation 
72°C 5 min  Elongation 
98°C 2 min  Melting 
58°C 5 min  Primer annealing 
72°C 20 min  Final elongation 
Reagent Volume in µL 
Pool DNA template, diluted in MQ 295 
Pool fwd oligo  15 
Pool rev oligo 75 
dNTPs 10 
Q5 reaction buffer (5x) 100 
Q5 polymerase 5 
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Single clones were inoculated in 96 well plates and in vivo screening was carried out 
according to chapter 3.3.8.  
 
 
Figure 52: In vivo screening of B2-derived pools B2-10, B2-N6 and B2-6N6 These boxplots show the 
summarized in vivo screening in S. cerevisiae cultures for the pools B2-10, B2-N6 and B2-6N6. For each 
investigated clone, the regulatory activity was calculated as the ratio of GFP fluorescence with and without 
100 µM azoCm (x-fold). The numbers written above the boxplot indicate the number of clones analyzed. The 
median of all analyzed clones in B2-10 was 1.01, in B2-N6 0.96 and in B2-6N6 1.05.  
 
In vivo screening of these pools showed no riboswitches with an improvement of the 
regulatory factor of B2, as shown in Figure 52. The median of all 3 pools lay between 1.05 
and 0.96. Regarding pools B2-N6 and B2-6N6, this seemed to indicate that removal of the 
long upper left stem with its terminal loop destroyed any regulatory function. Regarding the 
pool B2-10, the in vivo screening results seemed to indicate that the degree of nucleotide 
permutation chosen was too high to yield any functional riboswitches, let alone some with a 
higher regulatory factor than B2.  
 
For in vivo screening of the pool B2-5, S. cerevisiae cells were transformed with the protocol 
described in 3.3.5, in order to increase transformation efficiency. Transformed cells were 
plated on SCD-URA plates and grown for 3 d. Transformation efficiency (TE) was calculated 
according to Equation 8 and Equation 9, and yielded a TE of 2.29x 10
5
 cfu/ng plasmid. This 
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showed that the transformation efficiency could be two orders of magnitude higher using 
yeast electroporation, making this transformation method useful, if large amounts of colonies 
should be screened.  
Single clones were inoculated in 96 well plates and in vivo screening was carried out 
according to chapter 3.3.8.  
 
 
Figure 53: In vivo screening of B2-derived pool B2-5 This boxplot shows the summarized in vivo screening in 
S. cerevisiae cultures for pool B2-5. For each investigated clone, the regulatory activity was calculated as the 
ratio of GFP fluorescence with and without 100 µM azoCm (x-fold). The number written above the boxplot 
indicates the number of clones analyzed. The median of all analyzed clones in B2-5 was 0.98. 
 
In pool B2-5, seven functional aptamers with a regulatory factor of 1.25 to 1.3 were found. 
Sequence analysis of them showed, that more than 50% of them were actually the 
parent-switch B2. The other switches consisted of only two sequences, 8C8 and G3 (Figure 
54 and Table 29). Their regulatory factors are shown in Figure 54 and were measured using a 
cytometer (Table 3, 3.3.7). 
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Figure 54: Cytometric measurement of the aptamers B2, G3 and 8C8 Shown are the median regulatory 
factors of azoCm dependent regulatory aptamers B2, G3 and 8C8. As controls, cells with plasmids showing 
constant (+ control, pCBB005) or no GFP production (- control, pCBB006) were measured, as well as a sample 
containing the Neomycin-riboswitch (Neo, pCBB007). A dotted line marks a regulatory factor of 1.0. Four 
samples were measured for every construct and azoCm or Neomycin was added as a ligand. Measurements were 
performed on a cytometer (Table 3). 
 
Figure 54 shows aptamers G3 and 8C8 to have comparable regulatory factors as B2 (1.28 for 
G3, 1.3 for 8C8, 1.33 for B2). Four samples of each aptamer were measured. Table 29 shows 
their sequences compared to sequence of B2, highlighting the base differences. As no other 
riboswitch was found, a composite sequence of the three aptamers was designed, shown in 
Table 29 (B2-1).  
 
Table 29: Development of potential riboswitch B2-1  
Riboswitch Sequence 
B2 
GCTCCCTTTAGATGTTAGTCGAAGACATCTAACCTACGGGAAAGG
AGACCAAAATG 
G3 
GCTCCCTTTAGAGGTTAGTCGAAGACCTCTAACCTACGGGAAAGG
AGACCAAAATG 
8C8 
GCTCCCTTTAGATGTTTGTCGAAGACATCTAACCTACGGGAAAGGA
GACCAAAATG 
B2-1 
GCTCCCTTTAGAGGTTTGTCGAAGACCTCTAACCTACGGGAAAGG
AGACCAAAATG 
 
Shown are the sequences of the three aptamers B2, G3 and 8C8. In G3 and 8C8, the nucleotides differing from 
the sequence of B2 are marked in red. Changing all three nucleotides in the sequence of B2 lead to the composite 
sequence B2-1, shown below with the changed nucleotides marked again in red. 
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This rationally designed riboswitch candidate B2-1 was synthesized via hybridization and 
amplification of two oligonucleotides (Table 6). Designing the oligonucleotides in a way that 
5’ and 3’ single stranded DNA overhangs were generated, allowed the direct ligation of the 
gel-purified PCR product (Table 4) in a restriction enzyme linearized plasmid pCBB006 
(Table 8). The generated plasmid containing the putative riboswitch B2-1 was sequenced. 
Yeast cells were transformed with it using the EZII protocol (3.3.3), and it was used in further 
in vivo analysis. 
 
 
4.19 Validation of the riboswitch B2-1 
In order to test whether the rationally designed riboswitch candidate B2-1 did show regulative 
activity, yeast cells containing the putative riboswitch B2-1, its parent switch B2, as well as 
the control plasmids pCBB005, pCBB006 and pCBB007 (Table 8) were inoculated in 
doublets in a 24 well plate. Measurements were performed as described in 3.3.7.  
 
 
Figure 55: Cytometric measurement of the riboswitch candidates B2 and B2-1 A Shown are the median 
regulatory factors of azoCm dependent aptamers B2 and B2-1. As controls, cells with plasmids showing constant 
(+ control, pCBB005) or no GFP production (- control, pCBB006) were measured, as well as a sample 
containing the Neomycin-riboswitch (Neo, pCBB007). A dotted line marks a regulatory factor of 1.0. All 
samples were measured in duplicates and with azoCm or Neomycin as ligand using a cytometer (Table 3). B To 
better compare the riboswitch candidates B2 and B2-1, they are shown separately with another scale. The 
regulatory factor of B2 amounts to 1.319 (±0.055), while the regulatory factor of B2-1 is 1.322 (±0.031).  
 
Figure 55 displays a comparable regulatory factor for the putative riboswitches B2-1 and B2 
(B2-1 shows a regulatory factor of 1.32 (±0.03), and B2 1.32 (±0.05)), showing that the 
rationally designed riboswitch candidate did function in an azoCm dependent manner. As the 
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regulatory factor of B2-1 was considered very low, it was tested whether B2-1 could function 
in a dose-dependent manner, which would confirm that it could act as a riboswitch. To this 
end, yeast cells containing the riboswitch candidate B2-1 were inoculated in duplicates on a 
24 well plate and incubated with different azoCm concentrations. Two independent 
measurements were carried out. 
 
 
Figure 56: Dose dependence of the regulatory factor of B2-1 riboswitch Shown is the regulatory factor of the 
riboswitch B2-1 at increasing concentrations of its ligand azoCm. A Shown are ligand concentrations in the 
range of 10 nM to 1000 nM ligand. Shown is the mean value of two independent measurements. B Shown are 
ligand concentrations in the range of 10 nm to 316 nm. Shown is the mean value of two independent 
measurements. The coefficient of determination (R
2
) of the linear regression is given. 
 
Figure 56A shows a dose-dependent behavior for the riboswitch candidate B2-1 in the range 
of 10 nm to 360 nm ligand. The coefficient of determination (R
2
) of the linear regression is 
0.99, indicating a linear dose dependency (Figure 56B). Due to this dose-dependency, B2-1 is 
in the following referred to as “riboswitch B2-1”. Application of 1000 nM ligand 
concentration to the yeast cell medium (SCD-URA, Table 11) lead to precipitation of the 
ligand into a visible residue at the incubation wells’ bottom, therefore concentration of ligand 
in the solution was not reliable. Precipitation started upon addition of the ligand to the 
medium but seemed to increase at the end of the growth period, according to visual 
observation. It was concluded that the pH value of the yeast medium was conductive to this 
[239]. Due to this, Figure 56B depicts the dose dependence of the riboswitch B2-1 in the 
range from 10 nM to 316 nM, which shows exponential development. Starting at 10 nM, B2-1 
shows a regulatory factor of 1.05 (±0.015), which climbs to 1.45 (±0.01) at a ligand 
concentration of 316 nM. This ligand dose-dependency of B2-1 seemed to indicate that B2-1 
did in fact act as a riboswitch, albeit one with a low regulatory factor. 
A B 
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4.20 B2-1 based pools  
To increase the regulatory factor of riboswitch B2-1, two new pools for in vivo screening 
based on the mfold-predicted structure of B2-1 were designed (Table 12). It was considered, 
that the plasmid region between the riboswitch and the promoter (5’ UTR upstream of B2-1, 
Figure 57) might be involved in the formation of the riboswitches aptamer domain. Therefore, 
randomization of this region might yield a riboswitch displaying a better regulatory factor 
than B2-1. 
 
 
Figure 57: Mfold predicted secondary structure of B2-1 with its 5’ UTR region Marked in red is the 
sequence of B2-1 stemming from the random region of the doped SELEX, marked in yellow is the light motif, 
and marked in blue are parts of the 5‘ UTR upstream of B2-1. 
 
Based on this structure, pools 7 and 8 (Table 30) were designed, allowing either only the 
5’ UTR upstream of B2-1 to be randomized (pool 7), or the entire 5’ UTR, including B2-1 
itself (pool 8). 
The pools were ordered from Seqlab, and were amplified using the PCR protocol and 
composition described in chapter 4.17.1 (Table 27, Table 28) using the primers “Library 7/8 
fwd” and “Library 7/8 rev” (Table 6). 
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Table 30: B2-1 based pools for in vivo screening  
Riboswitch Sequence 
B2-1 7 
5’ AGCTATACCAAGCATACAATCAACTCCAAGCTAGATCTACCGG
TGCTCCCTTTAGAGGTTTGTCGAAGACCTCTAACCTACGGGAAAG
GAGACC 3’ 
B2-1 8 
5’ AGCTATACCAAGCATACAATCAACTCCAAGCTAGATCTACCGG
TGCTCCCTTTAGAGGTTTGTCGAAGACCTCTAACCTACGGGAAAG
GAGACC 3’ 
 
Shown are the sequences of the two developed B2-1 derived pool for in vivo screening. Marked in red is the 
sequence of B2-1, marked in blue are the last nucleotides of the adh1 promoter on the plasmid pCBB. In the 
underlined region of the sequences, 2 nucleotides were randomized. 
 
PCR protocol optimization was carried out regarding the amount of amplification cycles used. 
Figure 58 shows a distinct band at the expected size of 307 bp on a 3% agarose gel. 
 
 
Figure 58: Agarose gel of the PCR amplification-results of B2-1 derived pools for in vivo screening Shown 
is a 3% agarose gel of the different amount of cycles tested to amplify the B2-1 riboswitch derived pools 7 and 8. 
The PCR program described in Table 27 was used. Shown from left to right in the lanes are: Marker (M), 7, 9, 
11, 13, and 15 cycles and the negative control sample containing no template (-). 
 
Figure 58 that 15 cycles of PCR amplification of pools 7 and 8 yielded strong bands on a 3% 
agarose gel without any overamplification. Therefore, the large-scale PCR amplification of 
the pool template DNA was carried out using the protocol described in chapter 4.17.1 but 
with only 15 cycles of amplification.  
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4.20.1 In vivo screening of B2-1 based pools 
For in vivo screening of the pools B2-1 7 and 8, S. cerevisiae cells were transformed with the 
protocol described in chapter 3.3.5. 50 µL of transformed cells were plated on SCD-URA 
plates and grown for 3 d. Transformation efficiency (TE) was calculated according to 
Equation 8 and yielded a TE of 1.27x 10
5
 cfu/ng plasmid for pool 7 and 1.4x 10
5
 cfu/ng 
plasmid for pool 8. The remaining transformed cells were grown in a segregation approach, as 
described in chapter 4.15.1, to generate yeast cells containing only one plasmid each. After 
the final segregation step, cells were sorted on a cell sorter as described in chapter 4.15.1, the 
same two gates were used for sorting. 100000 cells per gate and pool were sorted, diluted to a 
density of 200 cells/µL, and plated on 20 SCD-URA plates for each pool and gate (7 high and 
low, 8 high and low). The remaining cells were grown in 8 mL of SCD-URA medium for 
48 h at 30°C, then harvested and frozen in glycerol at -80°C for later use.  
The plates were incubated for 3 d at 30°C. From them, single clones were inoculated in 96 
well plates and in vivo screening was carried out according to 3.3.8 using a cytometer.  
 
 
Figure 59: In vivo screening of B2-1 derived pools These boxplots show the summarized in vivo screening of 
S. cerevisiae cultures of the pool B2-1 derived pools 7 and 8. For each investigated clone, the regulatory activity 
was calculated as the ratio of GFP fluorescence with and without 100 µM azoCm (x-fold). The numbers written 
above the boxplot indicate the number of clones analyzed. The median of the analyzed clones from the pools was 
1.02 (7hi), 1.05 (7lo), 1.26 (8hi) and 1.33 (8lo).  
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In vivo screening of the sorted cells from pools 7 and 8 showed no riboswitches with an 
improvement of the regulatory factor compared to B2-1, as shown in Figure 59. The median 
of pools 7high and 7low (7hi and 7lo, Figure 59) was 1.02 and 1.05. This seemed to indicate 
that allowing nucleotide randomization in the 5’ UTR upstream of B2-1 destroyed all 
riboswitch function. Regarding the pools 8 high and low (8hi and 8lo, Figure 59), the in vivo 
screening results seemed to indicate that the degree of nucleotide permutation chosen was 
yielding functional riboswitches, but none with a higher regulatory factor than B2-1 was 
discovered. With medians of 1.26 and 1.33 (pools 8hi and 8lo, respectively), plenty of 
riboswitches with nucleotide permutations could be found. However, results from in vivo 
screening of pools 7hi and 7lo suggest that all those permutations take place in the B2-1 
region of the randomized 5’UTR.  
 
 
4.21 Determination of the binding constant of B2-1 aptamers using ITC 
As the riboswitch B2-1 could not be improved regarding its regulatory factor using partially 
randomized in vivo screening approaches, more about the binding affinity of the RNA 
aptamer B2-1 should be found out. To this end, two RNA constructs were designed, based on 
the mfold predicted structure of B2-1 (Figure 57). The sequence of B2-1 was folded, and 
regions of the 5’ UTR and the sequence of GFP were included, as they would be present in 
the mRNA transcript within yeast cells. To gather information by ITC which could reflect the 
behavior of the B2-1 riboswitch in vivo, these sequences were included. ITC construct B2-1 
was a 102 nt long sequence (Figure 60, left). To see whether the 5’ UTR and the GFP gene 
regions (marked in blue) were necessary for ligand binding, the truncated version B2-1 short 
was designed, consisting only of the sequence of B2-1 (marked in red, with the light motif 
marked in yellow), as well as 9 nt of the 5’ UTR allowing the RNA to fold into the predicted 
stem formation shown in Figure 60 (right). B2-1 short was 59 nt long. The sequences for B2-1 
and B2-1 short are shown in Table 31. 
 
 Results 136 
 
Figure 60: Sequences and mfold predicted secondary structures of B2-1 and B2-1 short used in ITC Shown 
are the mfold predicted structures of the sequences based on aptamers B2-1 which were designed for ITC. B2-1 
is 102 nt, B2-1 short is 56 nt long. Marked in red is the sequence of B2-1, marked in yellow is the light motif, 
and marked in blue are parts of the 5‘ UTR upstream of B2-1, as well as parts of GFP gene, including Kozak 
sequence and ATG, downstream (3‘) of B2-1.  
 
Table 31: Sequences of B2-1 aptamers  
Apta
mer 
Length 
in nt 
Sequence 
B2-1 102 CCAAGCTAGATCTACCGGTGCTCCCTTTAGAGGTTTGTCGAAGA
CCTCTAACCTACGGGAAAGGAGACCAAAATGGCTAGCAAAGGA
GAAGAACTTTTCACT 
B2-1 
short 
59 TCTACCGGTGCTCCCTTTAGAGGTTTGTCGAAGACCTCTAACCTA
CGGGAAAGGAGACC 
 
Shown are the aptamers B2-1 and short, and their respective length in nucleotides (nt), as well as their sequence. 
As shown in Figure 60, sequences from the 5’ and 3’ UTR of B2-1 are displayed in blue, the 50 nt core region 
from the doped SELEX pool (chapter 4.13, Figure 39) is shown in red, and the light motif is marked in yellow. 
 
The shown sequences in Table 31 were generated by designing oligonucleotides compatible 
to each other and containing a T7 promoter (Table 6). RNA was generated by in vitro 
transcription as described in chapter 3.2.8 and purified using 8% PAA gels (3.2.11). 
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First, RNA B2-1full was measured according to the protocol described in chapter 3.2.13. For 
the measurement, the RNA aptamers were subjected to the folding program used in SELEX 
(3.4.3). The RNA was dissolved in 1x SELEX buffer, yeast tRNA was not added, as opposed 
to during SELEX. The DMSO concentrations in the RNA and ligand solution were adjusted 
to the same value to prevent unspecific dilution effects. B2-1 was measured with a 200 µM 
azoCm trans and azoCm cis solution, in the latter case the ligand was first irradiated with UV 
light (λ=365 nm), and the entire ITC measuring device (3.2.13) was covered with aluminum 
foil during the duration of the measurement. This should prevent the ligand from switching 
back to its trans state during the measurement. Results are shown in Figure 61 and Table 32. 
Using a two-site binding model (Figure 61), the kD for the first binding site yielded a mean 
kD of 23.5 ± 2.44 nM. The second binding site showed a mean kD of 3.375 ± 0.087 µM, two 
orders of magnitude lower binding than the first binding site. No binding to azoCm cis could 
be detected. 
 
 
Figure 61: Results of ITC of aptamer B2-1 with 200 µM azoCm trans (left) and 200 µM azoCm cis (right), 
two-site binding model. The upper graphs show the raw data of the titration in µW. The lower graphs show the 
heat conversions in kJ/mol per injection obtained by integrating the peaks, plotted against the molar ratio of 
ligand/RNA. The solid line shows the curve adapted to the measurement points according to a two-site binding 
model (Table 12). Two measurements for every RNA-ligand combination were carried out. The mean kD can be 
found in Table 32. 
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B2-1 short was measured with a 100 µM azoCm trans and azoCm cis solution, the 
measurement of the cis compound was carried out under exclusion of light, again. Shown in 
Figure 62 are the ITC results for B2-1 short. 
 
 
Figure 62: Results of ITC of aptamer B2-1 short with 100 µM azoCm trans (left) and 200 µM azoCm cis 
(right), one-site binding model. The upper graphs show the raw data of the titration in µW. The lower graphs 
show the heat conversions in kJ/mol per injection obtained by integrating the peaks and plotted against the molar 
ratio of ligand/RNA. The solid line shows the curve adapted to the measurement points according to a two-site 
binding model (Table 12). Two measurements for every RNA-ligand combination were carried out. The mean 
kD can be found in Table 32. 
 
Measurements of B2-1 short with azoCm trans showed a value of n =0.667 ± 5.45x 10
-2
 
binding sites. Fitting with a one-site binding model yielded a mean kD of 1.24 ± 222.5 µM of 
two measurements (Table 32). No binding to azoCm cis could be detected.  
The summary of the mean kDs of all B2-1 derived RNA aptamer measurements are shown in 
Table 32.  
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Table 32: Mean kD of ITC measured aptamers.  
Aptamer 
Mean predicted ligand 
binding sites (n) 
Mean kD azoCm trans 
Mean kD 
azoCm cis 
B2-1  
(two-site model) 
n1 = 1.8 ± 1.6x10
-2
 
n2 = 9.46 ± 0,224 
 
kD1: 23.5x 10
-9
 ± 2.44x 10
-9
 
kD2: 3.375 x 10
-6
 ± 87.4x 10
-9
 
N/A 
 
B2-1 short  
(one-site model) 
 
n = 0.667 ± 5.45x 10
-2 
 
1.24x 10
-6
 ± 222.5x 10
-9 
 
N/A 
Shown are the aptamers and the fitting model used to determine the mean kDs for binding azoCm trans and 
azoCm cis. Two measurements were carried out for each azoCm enantiomer. If no kD could be determined, N/A 
(not applicable) is given as a value. 
 
The results from Table 32 make it clear, that B2-1 aptamer is able to bind azoCm in an 
isoform selective manner. While the trans isoform can be bound with a nanomolar to low 
micromolar dissociation constant (kD), the cis isoform does not show any binding affinity to 
B2-1, neither to its full or short version. This indicates a kD greater than 1 mM for azoCm cis, 
and therefore a discrimination between azoCm trans and cis for B2-1 of at least 5 orders of 
magnitude, and for B2-1 short of at least 3 orders of magnitude.  
 
 
4.22 Summary of Results 
In the course of this thesis, a successful SELEX against the ligand azoCm was carried out. A 
light SELEX protocol was developed and applied, as well. NGS analysis of the SELEX 
rounds yielded a 13 nt sequence motif which was enriched in the light SELEX rounds, but 
decreased in number in the affinity SELEX rounds. Using this light motif as a core sequence, 
a motif-doped SELEX was successfully performed, which showed a fast increase of RNA 
elution over the rounds. Using a FACS sorting based approach, aptamers from this motif-
doped SELEX have been analyzed in an in vivo screening, which yielded a functional 
riboswitch called B2. Further in vivo screening approaches based on the sequence of 
riboswitch B2 could not increase its regulatory factor but lead to a more stable variant of B2 
called B2-1. Riboswitch B2-1’s regulatory factor could not be increased using randomized in 
vivo screening; however, a dose dependent regulation could be demonstrated. Using ITC 
measurements, the isoform selective binding of B2-1 could be verified and a kD in the 
nanomolar range could be determined.  
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5 Discussion 
5.1 Aptamer libraries and SELEX 
5.1.1 Aptamer libraries  
The choice of an aptamer library lies at the beginning of every SELEX experiment. Different 
approaches to the choice of library exist, often depending on the application scenarios of the 
aptamers to be developed. Thus, pre-structured RNA libraries have been described, which 
convey a certain feature to the developed aptamers, e.g. inherent increased stability [112, 
233]. Such a library, mixed 1:1 with an unstructured one, was formerly used in the research 
group to conduct a SELEX against azoCm [196]. As the results show, most aptamers from the 
final round of SELEX contained the pre-formed stem loop. The pre-structuring of the 
aptamers seemed to lead to a dominance of the enriched aptamers containing the stem-loop, 
potentially due to a greater inherent stability that the pre-formed stem loop conveys. 
The aptamer library initially used in this work did not contain any pre-structuring elements. 
Aptamers resulting from the performed SELEX did not show an overbearing trend towards 
sequence or structural motifs, as the next generation sequencing (NGS) analysis of the 
SELEX demonstrated. However, round 6 and 9 of the SELEX have shown to contain 
dominant aptamer sequences, as 12 out of 20 tested sequences from rounds 6 and 9 were 
identical (aptamer “A”, see chapter 4.5). As singling out individual aptamers, sequencing 
them and afterwards producing them in vitro to test individual binding properties is a time- 
and material consuming effort, but can provide limited information, high-throughput methods 
like NGS have come into the focus of aptamer researchers when studying SELEX [240]. 
Sequence motifs becoming enriched or losing prevalence in the pool can be tracked using 
NGS more easily and in a much greater sample size than using random samples. The NGS 
used in this work was particularly useful to compare influences of stringency enhancing 
methods, like introducing more wash steps, or starting a light elution protocol (see chapters 
4.4, 4.9 and 4.12). 
NGS analysis has shown itself to be an important tool to judge the success of a performed 
SELEX, because previous to the use of NGS methods, the SELEX process itself has been 
considered a black box [166]. As experiments using random samples from SELEX rounds in 
this work show (see chapters 4.5 and 4.11), selectively binding aptamers can be found using 
the described method. However, the tracking of the enrichment process of the light motif 
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through the rounds would not be possible using random samples, except for major single 
clone sequencing efforts for every round individually. NGS becomes a worthwhile tool here, 
because bias introduced by the researcher in such a hypothetical, alternative large-scale 
cloning and sequencing effort can be eradicated, and the information content gathered from 
NGS will always be higher than what can be achieved from manual single clone analysis. 
 
A particular significant role in the selections carried out in this work seems to be played by 
the constant regions of the aptamer libraries. The ITC analysis of aptamer B2-1 indicate, that 
there is a dependence of the ligand binding on at least the 5’ UTR of the aptamer, which was 
part of the constant regions of the doped SELEX library (see chapters 4.13, 4.21). While a 
majority of selected aptamers in literature bind their target independently of the constant 
regions [241], there are examples where the latter are part of the ligand binding regions [242-
244]. In these cases, standard truncation experiments are not possible [245, 246]. While the 
truncated version of B2-1 (B2-1 short) shows isoform selective binding towards azoCm, the 
kD is two orders of magnitude lower and the amount of ligand binding sites (n) indicates that 
the stoichiometry towards azoCm has lessened (from n = 1.8 for B2-1 to n = 0.67 for B2-1 
short). Further analysis of the aptamer B2-1 would be feasible to preclude attempts to truncate 
the aptamer, like structural analysis of the aptamer, or identification of the exact binding 
regions and stability conferring regions of the aptamer. As the binding regions might play a 
major role here, in future SELEX experiments it might be recommendable to choose a 
SELEX method that does not necessitate the inclusion of primer binding sites on the aptamer 
pool. Such primer-less SELEX methods exist, most of them relying on the enzymatic removal 
of the primer binding sites used for amplification prior to the RNA transcription step [109, 
247, 248]. Application of primer-less SELEX methods could lead to shorter RNA aptamers 
from the beginning. This is particularly worth considering, as aptamer B2-1 was generated 
from a partly randomized pool containing a N50 sequences at its core, but B2-1 is 102 nt 
long, and its truncated version is 59 nt long, due to the constant regions of the aptamer.  
 
 
5.1.2 Light-SELEX development 
Some aptamers showing isoform selective binding against azoCm were generated during 
SELEX even without the introduction of a light SELEX method (see chapters 2.2.3, 2.2.4 and 
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4.5, as well as [196, 198]). To increase the dominance of the isoform selective aptamers, and 
to introduce a variation of a counter-SELEX step [65], a light SELEX was developed. In 
classical counter-SELEX, RNA is incubated with structurally similar targets in an additional 
SELEX step to remove those RNAs (unspecifically binding aptamers) able to bind the desired 
target and these decoy molecules. Light SELEX makes use of this method, by first letting the 
RNA bind to the real target azoCm trans, immobilized on the column, and then switching the 
conformation of azoCm to cis. RNAs which cannot bind to azoCm cis anymore are washed 
out of the column by the flow of buffer, making light SELEX similar to a “one-step” 
counter-SELEX. As counter-SELEX has been effective in yielding highly specific aptamers 
previously [249-251], it was thought to be a useful method, particularly when applied to the 
goal of generating isoform selective aptamers. 
While literature shows examples of development of reversible light-selective aptamers, the 
protocols described stay very vague. Lee et al. [203], who developed a hammerhead ribozyme 
isoform selectively binding a dihydropyrene compound [252], described their light SELEX 
protocol as follows: 
 
 …“were then irradiated with either visible (see above) or UV light (280–375 nm, 
from a Spectroline model EB-280C hand-held lamp, 46 W, with peak emission at 
308 nm until the color of the bead-bound photo-switch either disappeared or appeared 
to its fullest extent.” 
 
Young & Deiters, having developed an aptamer selectively binding the closed spiropyran 
isoform and not the corresponding open merocyanin form of their compound [204], describe 
their light SELEX protocol as follows: 
 
“After binding had been detected, the gold slide was irradiated with UV light of 
365 nm for approximately 10 min, dissociation and adsorption were monitored in real 
time, and the switching was repeated to demonstrate the reversibility of the aptamer 
binding [… ] using fiberoptics connected to a UV LED system (Prizmatix BLCC-02).” 
 
While in Lee et al. the power and the wavelength of the UV light used are described, distance 
from the irradiated sample and irradiation time are not. Young & Deiters mention wavelength 
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of the used UV light and the producer of their light-source, but neither the distance from light-
source to sample, nor the power of the light source are described [204].  
According to the inverse square law, distance from a light-source affects energy uptake by the 
sample, as increased distance “dilutes” the amounts of photons reaching the irradiated object 
[253, 254]. To describe irradiation precisely, either the power of the light source and its 
distance from the object need to be given, or the photon density (power per surface area, 
typically W/m
2
) needs to be determined and described. Therefore experiments cannot be 
reproduced accurately without this information. 
 
The light SELEX protocol described in this work is much more detailed and can be followed 
easily by other researchers. The finalized light SELEX procedure will be published in Lotz et 
al. (see below) and tries to unite the maximum information possible to enable a reproduction 
of the experiment [198]:  
 
“RNA was eluted by irradiating the column with light (λ=365 nm, UVLED-365-1000-
SMD, 0.15 A, 13.5 V, 16 x 1s) under exclusion of other light sources (distance from 
column to light source = 10 cm), while washing the column with 6 CV of 1x SELEX 
buffer” 
 
Exact irradiation time, distance of the light-source to the sample and treatment of the sample 
during irradiation are described. The described procedure is considered complete, compared 
to the protocols described in literature previously, which were missing key information 
elements needed for reproduction of the experiments. 
Further selections carried out against light-selective molecules might benefit from the here 
described process of protocol development. Also, it would be possible to adapt the finalized 
protocol to the needs of another SELEX procedure, as the materials used are low-tech and can 
be incorporated into existing processes quite easily.  
An important pre-requisite for light-sensitive SELEX needs to be solved in every light 
SELEX process, however: exclusion of light of all undesired wavelengths is not a trivial 
matter when a researcher carries out the SELEX manually. Automated SELEX might be a 
solution to that, however, while several approaches have been described already, some as 
early as in 2005, they bring along their own limitations [255-257]. When carrying out a light-
selective SELEX, all these considerations and technical necessities need to be weighed 
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carefully. Therefore, the detailed development of the light SELEX protocol described in this 
work was considered relevant to the SELEX community in general, and was included in the 
submitted publication Lotz et al. [198]. 
 
 
5.1.2.1 SELEX and NGS 
NGS of SELEX has been first described in literature in 2011 [258]. While other nucleic acid 
libraries or genomes have been analyzed using this technique before [259-261], the first 
implications regarding the SELEX process itself have been described by the Glökler group 
[258]. Since then, with NGS methods becoming commercially available and easier to afford, 
various NGS based SELEX analysis have been published [133, 260, 262].  
NGS has been used in this work, to compare light SELEX and affinity rounds, and to discover 
whether a motif is enriched using one method and not the other. It could be shown, that the 
discovered 13 nt sequence motif behaved differently in R7 to R9 as opposed to LS-7 to LS-9 
(see chapter 4.12, Figure 37). Introduction of increased stringency steps in the affinity SELEX 
(chapter 4.4) did lead to a drastic decrease of the prevalence of the light-selective motif, while 
it was further enriched in the light SELEX rounds.  
Using NGS to study the effect of stringency compared to the application of a light SELEX 
protocol on the SELEX was relevant in the course of this thesis to discover the light motif and 
track its enrichment. In future SELEX experiments time and resources could be saved by 
applying NGS early in the SELEX and planning the SELEX progress or the downstream 
experiments after SELEX according to the results from NGS. This would generate a better 
understanding of the SELEX progression, and could help identify factors that impact selection 
[263]. Also, being able to stop the SELEX early, due to earlier possible identification of 
enriched aptamer or motif families, could help avoid bias in the later SELEX rounds 
introduced e.g. during the PCR amplification steps between selection rounds [264]. 
More detailed analysis of the NGS data generated from this SELEX was published in Blank et 
al. [96]. They developed a secondary structure prediction algorithm based on the NGS data of 
the SELEX performed, allowing the discovery of secondary structure motifs by comparing 
aptamer sequences to each other. 
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5.2 Light-selective aptamers 
5.2.1 Aptamer B2-1 and the light motif 
The aptamer developed in this work, B2-1, shows a kD of 23 nM, and no binding to the cis 
isoform of its target molecule (determined using ITC, see Table 32). 
ITC measurements could not detect any binding to the cis ligand, up to a final ligand 
concentration of 37.7 µM after titration of the ligand to the RNA. Hence, a kD of at least 
1 mM is assumed. 
Aptamer B2-1 contained a 13 nt sequence motif (“light motif”, Figure 36), which was 
discovered by comparing aptamer sequences from different SELEX approaches (affinity 
SELEX Rudolph and light SELEX) to each other which showed the best discriminatory 
abilities between the trans and cis conformation of azoCm (Table 24). That this common 
motif was found in two different SELEX experiments using two different RNA pools strongly 
indicated that the light motif might be the optimal sequence for binding to azoCm. The 
analysis of the development of the partly randomized light motif during the doped SELEX 
(chapter 4.14) showed a strong re-orientation of several nucleotide positions, with seven 
positions of the light motif reaching a 100% nucleotide retention in all sequences in the last 
doped SELEX round. 
As aptamer 42 contained the light motif as well, the structural analysis by in-line probing not 
only allowed improved secondary structure prediction for aptamer 42 by mfold, but also 
delivered indications towards the nucleotides involved in binding azoCm (see chapter 4.1) 
within the light motif. In-line probing results showed stabilization of two or three adenosine 
nucleotides at aptamer positions A33 to A35 (Figure 14), corresponding to positions 9 to 11 
of the light motif (Figure 36). As these adenosines were part of the strongly retained 
nucleotides during the doped SELEX as well, the conclusion was drawn that these two to 
three nucleotides were mainly involved in azoCm binding in all aptamers containing the light 
motif. A comprehensive 3D structure of the aptamer B2-1 could be generated using NMR, or 
kinetic analysis of the aptamer could be carried out using smFRET (see chapter 2.1.14) to 
give more detailed information regarding the binding pocket of aptamer B2-1 and the role of 
the light motif in azoCm binding. 
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5.2.2 Light-switchable molecules and their potential applications  
Next to aptamer B2-1developed in this work, another characteristic of the developed aptamer 
system needs to be discussed, namely the target molecule of the aptamer itself. Three 
published aptamers against light-switchable molecules have been published to date to the 
knowledge of the author. Lee et al. generated an aptamer binding to a dihydropyrene 
compound, called BDHP [203]. Young & Deiters carried out a SELEX against a spiropyran 
derivative (Spiropyran 1) [204], while Hayashi et al. carried out a SELEX against a small 
peptide containing an azobenzene group (KRAzR) [205, 206].  
 
Table 33: Listing of light-switchable molecules against which aptamers have been developed 
Ligand Light-switchable 
ligand class 
Specifications Reference 
BDHP-COOH 
 
Dihydropyrene Water soluble Lee et al. [203] 
Spiropyran 1 Spiropyran Low water 
solubility, racemate 
Young & Deiters 
[204] 
KRAzR Azobenzene Water soluble Hayashi et al. [205, 
206] 
azoCm Azobenzene Water soluble  Lotz et al. [198] 
 
Apart from the spiropyran compound developed by Young & Deiters, all light-switchable 
compounds show good water solubility, a necessity when a biological application is 
considered. azoCm displays outstanding photochemical and biological stability even when 
tested in HeLa cell extract, as shown in Lotz et al. [198]. While all publications of aptamers 
binding to light-switchable molecules discuss potential applications in a biological setting, no 
data regarding toxicity of their compound in vivo have been published to the knowledge of the 
author. 
Accordingly, for azoCm toxicity tests for bacteria (E. coli, Bacillus subtilis), yeast 
(S. cerevisiae) and human cell lines (HeLa) were performed. They showed that azoCm had no 
significant influence on cell growth [198]. Therefore, the aptamer-ligand-set B2-1 and azoCm 
would be well suited for biological applications. 
Notably, the ligand concentrations used in the binding studies as well as the ITC experiments 
were in a range that would be applied in biological applications of the aptamer. These binding 
studies combined with the gathered toxicity data would allow a future application of the 
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developed aptamers and their switching system in genetic regulation systems like engineered 
riboswitches or biosensors. 
 
 
5.2.3 Comparison of aptamer B2-1 to light-selective aptamers in literature 
As previously described (see chapters 2.2.3 and 2.2.4), aptamers binding to one of two 
isoforms of a light-switchable molecule have been selected before [196, 203-206]. Lee et al. 
generated an aptamer with a 2 µM binding constant to its target (12 µM for the hammerhead 
ribozyme construct), while discriminating 35-fold against the undesired target isoform [203]. 
The most affine aptamer from Young & Deiters displayed a 14-fold discrimination between 
the two isoforms of their target molecule, with an approximate kD of 10 µM [204]. The 
aptamers developed by Hayashi et al. against an azobenzene peptide compound showed kDs 
in the range of 0.8 to 1.8 µM, with a 10-fold discrimination between the two isoforms [205, 
206].  
 
Table 34: Listing of aptamers developed against light-switchable molecules 
Aptamer 
name 
Ligand Binding affinity 
of aptamer (kD) 
Discrimination 
between isoforms 
Reference 
C8 BDHP-COOH 2 µM 35-fold Lee et al. [203] 
SP3 Spiropyran 1 10 µM 14-fold Young & Deiters 
[204] 
Aptamer 66 KRAzR 0.8 µM 10-fold Hayashi et al. 
[205, 206] 
42 azoCm 3.6 µM >10
3
-fold Lotz et al. [198] 
B2-1 azoCm 24 nM >10
5
-fold Lotz et al. [198] 
B2-1 short azoCm 1.24 µM >10
3
-fold see chapter 4.21 
 
Lee et al. impressively demonstrated the coupling of their developed aptamer C8 to a 
communication module and successfully generated an in vitro functional ribozyme with a 
900-fold regulation factor [203]. Such a system could well be an alternative strategy for the 
development of an in vivo functional RNA regulatory device instead of a riboswitch. 
However, no in vivo functional application by Lee et al. has been published to date. 
The aptamer developed by Young & Deiters showed the weakest kD value of app. 10 μM 
when comparing all aptamers binding light-switchable molecules [204]. Because of the low 
solubility of the spiropyran in aqueous solutions, the comparatively weak affinity of its 
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aptamer, and its presence as a racemic mixture, a biological application of this system is not 
feasible. 
The aptamer generated by Hayashi et al. is the most comparable to the aptamers described in 
this work, as the ligand was also an azobenzene compound [205, 206]. Selection was carried 
out in a similar manner, too, by immobilizing the peptide azobenzene on Affi-gel (Table 1) 
and generating ligand-derived columns. The most affine aptamer in the study of Hayashi et al. 
showed a 10-fold discrimination between the trans and cis compound with a kD of 0.8 µM. 
Hayashi et al. developed this aptamer without the application of a light SELEX protocol. 
Comparing the aptamer generated by Hayashi et al. to aptamer 42 which selectively binds 
azoCm, shows a comparable range of binding affinity. The kD of aptamer 42 against azoCm 
lay at 3.6 µM. The advantage of aptamer 42 over the aptamers developed by Hayashi et al. 
was its discrimination against azoCm cis. Comparing aptamer B2-1 to the light-selective 
aptamers described in literature shows B2-1 aptamer as the most affine aptamer to its intended 
target isoform to date, as its binds only to the trans isoform of its target molecule with a kD of 
23 nM. Even the truncated version of B2-1, B2-1 short, displays a kD of 1.24 µM, which can 
compete with most described light-selective aptamers (see Table 34). Like aptamer 42, no 
binding to azoCm cis could be determined in the course of this work, leading to an assumed 
discrimination ability of B2-1 between azoCm trans and cis of more than 100000-fold. 
 
As KRAzR, the molecule Hayashi et al. selected against, is also an azobenzene compound, it 
was considered whether the aptamers developed against azoCm (B2-1, Table 31 and 42, Table 
24) showed any sequence homology to aptamer 66 (Table 34). A motif search using the 
software MEME was carried out (Table 12). A sequence homology region between the 
aptamers could be discovered, as shown in Table 35 (yellow marked nucleotides). Six 
conserved nucleotides could be found in an eight nt stretch which were identical in all three 
compared aptamers. As these nucleotides were located within the light motif (included in 
Table 35 for comparison), it was concluded that azobenzene-specific binding was taking place 
in this region, particularly because the three aptamers compared originate from three different 
SELEX experiments. 
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Table 35: Sequence comparison of aptamers binding to azobenzene derivatives (including the light motif) 
Aptamer Sequence 
  
Light motif 
azoCm 
5’ CCUACGGGAAAGG 3’ 
Aptamer 
B2-1 
5’ CCAAGCUAGAUCUACCGGUGCUCCCUUUAGAGGUUUGUCGAA
GACCUCUAACCUACGGGAAAGGAGACCAAAAUGGCUAGCAAAG
GAGAAGAACUUUUCACU 3’ 
Aptamer 42 5’ GGUUGACCCUACUGCUUCGGCAGGCCUACGGGAAAGGUAA 
CA  3’ 
 
Aptamer 66 5’ GGGAAUUCCGCGUGUGCACACCUCAACAACAAAAGGAUAAGC
UAGGCGAGCCUUACCGAACGCGUCCGUUCGGAUCCUCAUGG 3’ 
 
Aptamers are shown in 5’ to 3’ orientation, sequence homologies between aptamers B2-1, 42 and 66 discovered 
by MEME (Table 12) are marked in yellow.  
 
A notable characteristic for aptamers B2-1 and 42 is, that there are A and G rich sequences 
stretched in and after the light motif, which are largely missing in aptamer 66. As 
chloramphenicol (Cm) was used as a substituent for one side of the azoCm molecule, it was 
expected to find aptamers binding to azoCm readily. Cm has been shown to bind to a variety 
of aptamers, both RNA and DNA, without a defined sequence or structure motive contained 
in all of the examined sequences [265, 266]. While A-rich sequences in RNA and G-rich 
sequences in DNA have been reported as common in the analyzed aptamers, no fixed motif 
for the binding of Cm was described to date. As in nature, Cm work as an antibiotic in 
prokaryotes by binding to a rRNA segment in the large ribosomal unit of (50S), it has been 
inferred that Cm might show a tendency to bind to a variety of RNA sequences, and therefore 
can often interact unspecifically with RNA [265]. Therefore, aptamer 42 and B2-1 fit to the 
hypothesis, that chloramphenicol binds preferentially to purine-bases in RNA and DNA. 
 
 
5.2.4 Comparison of light-selective aptamers recognizing azoCm 
One aptamer developed in this thesis, B2-1, was analyzed regarding its binding affinity (kD) 
towards azoCm. Similar to aptamer 42, no binding to azoCm cis could be detected. Using a 
two-site binding model, a binding affinity of 23 nM on one binding site and 3.38 µM on the 
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second site was determined (Table 32). Therefore the full-length aptamer B2-1 is two orders 
of magnitude more affine to azoCm trans than aptamer 42 (kD = 3.6 µM). These results could 
be due to the application of a light SELEX step, as well as carrying out a motif doped SELEX 
afterwards. For aptamer 42, no light SELEX protocol was performed, similar to Hayashi et al. 
[206]. The double approach to first identify a light-selective motif, and then continuing with a 
motif doped SELEX, as carried out in this work, seems to have led to highly specific aptamers 
for the trans isoform of azoCm. As the binding to the target itself does not define the 
specificity in this work, but more importantly the discrimination of the aptamer between the 
trans and cis isoforms of azoCm, the aptamer B2-1 described here is the most specific 
aptamers for a light-switchable molecule to date to the knowledge of the author. A kD of 
23 nM for the trans isoform, and no detectable binding to the cis isoform of azoCm indicate a 
kD of B2-1 to azoCm cis of at least 1 mM. The discrimination between the two isoforms 
would therefore be 10
5
-fold.  
Further evidence, that the aptamer B2-1 not only binds to trans azoCm specifically but also 
releases the ligand upon irradiation to its cis form, was generated by circular dichroism (CD) 
experiments carried out by Christoph Kaiser of the Wachtveitl group of the 
Goethe-University, Frankfurt [198, 267, 268]. He could show that no different behavior of 
aptamer 42 was observable, when azoCm was switched from its trans to its cis conformation 
in its presence. This indicated that, once bound by aptamer 42, azoCm was not released by the 
aptamer, whichever conformation the ligand presented. Aptamer B2-1, however, showed a 
reproducible difference in the CD measurement, depending on the conformation of the ligand. 
Reversible switching of the ligand from cis to trans and back led to correspondingly changing 
CD signals, indicating a change in aptamer structure as a response to the changed ligand 
conformation. These results, published in Lotz et al., strongly indicate a release of azoCm 
from the aptamer, once it switches to its cis form, as well as a new binding once it is present 
in its trans form again [198]. 
With a kD of 23 nM, aptamer B2-1 would be more affine to its ligand than most in vitro 
selected aptamers described in literature to date, including the flavin mononucleotide aptamer 
(kD = 500 nM [269]), the malachite green aptamer (kD = 117 nM [151]), and the extremely 
well studied theophylline aptamer (320 nM [65, 270]). The comparison to the theophylline 
aptamer is particularly interesting, because a synthetic riboswitch working in vivo in 
B. subtilis was developed from it [271]. While the kD of natural aptamers (stemming from 
natural riboswitches) is typically much lower (e.g. TPP riboswitch thiM: kD = 0.21 nM [272]; 
 Discussion 151 
c-di-GMP class II: kD = 0.2 nM [273]), the construction of a synthetic riboswitch from an 
aptamer with a similar kD makes the successful construction of a riboswitch out of B2-1 
feasible. 
Summarily, the aptamers developed in the course of this work represent a novel set of an 
aptamer with its corresponding light-selective molecule. Advantages of the aptamer 
developed are its high binding affinity to its trans target molecule and no binding at all to the 
respective cis isoform. The target molecule azoCm itself has the advantages to show good 
switching capabilities and high water solubility, while showing no influence on cell growth.  
The characteristics of the aptamer-ligand-set developed in this work make it a basis for further 
research in this field and classify it as a potential tool in future biological applications. 
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5.3 Light-selective riboswitches 
5.3.1 In vivo screening methods and potential optimizations 
As already emphasized in literature [129, 152, 229], in vivo screening methods of aptamers 
derived from SELEX should be employed if the aptamers are to be used as riboswitches in 
cells. An example for this is the neomycin riboswitch. Derived from a SELEX, none of the 
abundant riboswitches in the final SELEX rounds could show regulation of gene expression 
in vivo, even though highly affine aptamers for neomycin could be found [132]. Only the 
application of an in vivo screening step could yield functional riboswitches. Detailed NMR 
studies of the neomycin riboswitch made it clear, that the defining difference between 
neomycin binding aptamers and neomycin dependent riboswitches lay in the structural 
dynamics rather than an affine binding of an in vitro selected aptamer [274, 275].  
As in vivo screening by hand is an extremely laborious and time-consuming endeavor, high-
throughput methods are desirable [129, 152]. The primary method used for in vivo screening 
in this work was a manual one. Therefore, a limited number of clones can be screened per 
day, which could be significantly increased, if robotics platforms could be included in the 
methodology. Using a robotics platform e.g. to split cell cultures could also reduce 
experimental bias introduced by the researcher [276].  
It should be mentioned however, that functional riboswitches have been discovered using 
manual in vivo screening with less clones screened than done in this thesis. An example for 
this is the ciprofloxacin riboswitch recently developed in our laboratory. Screening of the 
aptamers from two different SELEX rounds yielded two riboswitch candidates with 1.5- and 
1.7-fold regulation factors in only app. 1100 tested S. cerevisiae colonies [133]. During this 
work, about 4300 S. cerevisiae colonies were tested from azoCm SELEX rounds (see chapters 
4.2, 4.7, 4.10) without finding one aptamer showing regulatory function. Only the 
implementation of the FACS based screening allowed the discovery of aptamers with low 
regulatory function (1.25- to 1.35-fold) from 375 tested S. cerevisiae colonies (see chapter 
4.16). While for the ciprofloxacin riboswitch, motif doped screening of app. 2400 
S. cerevisiae colonies was sufficient for the generation of a riboswitch with 7.5-fold 
regulation factor, app. 5900 screened colonies in this work were not able to increase the 
regulation factor of B2-1 beyond 1.45-fold.  
While some potentially functional riboswitches could be lost during a FACS sorting based in 
vivo screening, these pre-sorts could drastically improve the chances to find functional 
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riboswitches from SELEX. Further optimizations of the method could be carried out in the 
future, e.g. using a FACS sorter able to sort individual cells into medium well plates directly, 
without the need to plate and grow and inoculate cells manually [277-279]. Coupled to a 
robotics platform, this method could drastically improve the yield of synthetic riboswitches 
generated from aptamers, as the work of the researcher could be reduced to the scientifically 
relevant parts, like designing the pool used for SELEX, or designing the synthetic riboswitch 
platform by choosing strategies on where to insert the aptamer into the genomic context. 
While the machinery necessary for such an almost fully automated in vivo screening 
(potentially even coupled with automated SELEX) is to date still expensive and not easily 
integrated with each other, advances in these fields could provide a giant leap forwards in the 
field of synthetic riboswitch design as well. 
Until robotics based screening methods are widely available, the two-pronged in vivo 
screening approach presented in this work, which combines FACS screening with classical in 
vivo screening, therefore seemed to yield results faster and in a more reliable manner than 
purely manual in vivo screening (see chapters 4.15 and 4.16) and could be applied in other 
riboswitch developments as well. 
 
 
5.3.2 Riboswitch B2-1 
The riboswitch B2-1 developed in this thesis is the first riboswitch known to date to bind a 
light-switchable target molecule to the knowledge of the author. Nevertheless, its regulatory 
factor was considered too low for testing a light-induced difference in gene expression (see 
chapter 4.19, Figure 55, Figure 56). As azobenzenes typically only show a 70-90% 
isomerization towards their cis isoform [280], testing the regulation of gene expression was 
considered too early in the development of the riboswitch itself during this thesis. Any effects 
measured could easily be considered “background noise”, therefore an increase of the initial 
regulation factor of the riboswitch was considered necessary. In vitro analysis of the aptamer 
derived from the riboswitch B2-1 did show affine binding to azoCm in the low nanomolar 
range and a high discrimination between azoCm trans and cis. However, the low regulation 
factor of riboswitch B2-1 was determined using the standard ligand concentration for in vivo 
screening in this work (100 µM). Dose dependency experiments have shown, that riboswitch 
B2-1 responds to azoCm in a dose dependent manner, confirming its functionality in 
 Discussion 154 
dependence of azoCm concentration (chapter 4.19, Figure 56). This indicated the possibility 
to improve this riboswitch to a switching factor allowing further experiments, particularly 
regarding the light-induced activation of gene expression.  
Truncation experiments leading to B2-1 short showed a heavy reliance of the aptamers on 
their genetic context. Structural analysis of the aptamers could help to provide better 
knowledge regarding the binding of azoCm by B2-1, as well as regarding the design of a 
better regulating riboswitch B2-1. Several in silico design approaches for the development of 
riboswitches are described, which could be employed alternatively or additionally to any 
structural analysis gathered for B2-1 [140, 141, 281, 282]. For example, Wachsmuth et al. 
have used an in silico approach combined with additional optimization steps, to develop 
synthetic riboswitches that control transcription termination using the theophylline and  
tetracycline aptamers [142]. Borujeni et al. have developed a statistical thermodynamic model 
predicting the sequence-structure-function relationship for translation-regulating riboswitches 
that activate gene expression [281]. The secondary structure prediction software SICOR 
developed using the NGS data derived from the selections performed in this work could be 
another tool in the future development of synthetic riboswitches [96].  
Summarily, riboswitch B2-1 can be viewed as fulfilling the first of two steps in constructing a 
light-responsive riboswitch: Ligand binding and the subsequent structural change of the 
riboswitch inhibiting gene expression has been proven for the trans form of azoCm (compare 
to chapter 2.1.11) using CD spectroscopy (see chapter 5.2.4) [198]. The reversibility of this 
binding has been verified in vitro, but still needs to be verified in vivo, once an optimized 
variant of B2-1 riboswitch exists. Then, the re-activation of gene expression upon irradiation 
of azoCm treated S. cerevisiae cells could be tested. A functional light-dependent riboswitch 
based on riboswitch B2-1 would be the first light-dependent riboswitch described in literature 
to date. 
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6 Outlook 
In the course of this work, a new method for the selection of light-switchable aptamers has 
been developed. While several SELEX experiments were carried out, future variations of this 
SELEX method using automated techniques could improve results. Particularly the 
development of an experimental environment without light “noise” (light of other 
wavelengths) would make advanced methods possible, e.g. the selection of aptamers against 
the cis isoform of azobenzene ligands. For this, the entire SELEX would need to be carried 
out in an environment with only UV light present, which was technically impossible in the 
course of this thesis. The developed light SELEX protocol, however, is easily adaptable to 
other experimental set-ups and could benefit the scientific community in future experiments. 
Aptamer B2-1 developed in this thesis shows light-selective binding to the trans isoform of 
azoCm, while selectively discriminating against its cis isoform, which has been shown in 
several individual experiments. Present knowledge shows, that B2-1 is more affine to its 
ligand as all published aptamers against light-switchable compounds to date, including 
aptamer 42 from a previous SELEX against azoCm. Experiments showed a dependence of the 
aptamer on its 5’ and 3’ UTR regions. While this has been reported for aptamers in literature 
previously, it makes application scenarios in vivo more difficult, as the aptamer could not be 
used as an exchangeable regulation element relying only on its core aptamer sequence. 
Optimization of the aptamer would need to begin with structural analysis, from which variants 
with changed or shortened sequence regions could be developed. These analysis results and 
engineering approaches could also translate to the in vivo functionality of the riboswitch B2-1 
developed in this work. While regulation of gene expression in dependence of azoCm 
concentration in yeast medium has been demonstrated in this work, the regulation factor 
remained low. Further knowledge about the in vitro structure of B2-1 could improve its 
functionality in vivo, as rational design methods could be applied to improve the riboswitch. 
Useful for this would also be novel in silico design approaches for riboswitches, which are 
currently being developed in the Suess group [283].  
A new SELEX strategy against azoCm could be considered as well, using a SELEX method 
under development in the Suess group at the moment (manuscript in preparation). This 
so-called “capture SELEX” includes a structural switching step in its selection process, which 
could be beneficial if aptamers with structural switching properties for the development of 
synthetic riboswitches are desired [284]. It would be possible, for example, to include the 
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light motif discovered in this work in the SELEX library, so SELEX with a motif doped pool 
could be carried out. 
In summary, the first steps towards a light-regulated riboswitch have been successfully carried 
out in the course of this work. An aptamer-ligand set could be developed, which shows 
excellent properties for future applications, like high affinity between aptamer and ligand, as 
well as reversible ligand binding upon irradiation. The chosen ligand also shows low toxicity 
in several tested organisms and good switching properties in aqueous solution. The developed 
riboswitch is the first described riboswitch against a light-switchable compound to the 
knowledge of the author, even if its regulatory factor might be improved by further studies. In 
the course of this work, several methods to improve the in vitro and in vivo characteristics of 
the aptamer and the riboswitch B2-1 have been discussed, and strategies for future 
experiments have been developed.  
The results generated from this work are expected to support the generation of a broad range 
of light-selective aptamers in the future. A basis for the development of a light-selective 
riboswitch has been established, and future experiments and strategies to achieve this goal 
have been laid out.  
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7.2 Abbreviations and units 
Table 36: Abbreviations and units 
Abbreviation or unit Meaning 
  
% percent 
°C degree Celsius 
∆ATG-gfp no start codon (ATG) in front of gfp gene 
(e)GFP (enhanced) green flurorescent protein 
[α-32P] UTP Uridine triphosphate, labeled on the alpha phosphate 
group with [
32
P] 
[γ-32P] ATP Adenosine triphosphate, labeled on the gamma 
phosphate group with [
32
P] 
λ wavelenght 
μc s−1 units of power used in ITC 
µg microgram 
µL microliter 
µM micromolar 
µW micro-watt 
µΩ micro-ohm 
3’ UTR three-prime untranslated region 
32
P Phosphorus-32, radioactive isotope of phosphorus 
5’ UTR five-prime untranslated region 
A, C, G, U, T Nukleotides in DNA and RNA sequences 
A Ampère 
adh1 promoter alcohol dehydrogenase 1 promoter 
AP Antarctic phosphatase 
app. approximately 
asRNA antisense RNA 
ATG start codon 
ATP, CTP, GTP, UTP (NTPs) Adenosine (-cytosin, guanin- thymidin) triphosphate 
(nucleoside triphosphates) 
bp base-pairs 
B. subtilis Bacillus subtilis 
cDNA complementary DNA 
CE capillary electrophoresis 
cfu Colony forming units 
cm centimeter 
Cm chloramphenicol 
cpm counts per minute 
CRISPR/ Cas9 Clustered Regularly Interspaced Short Palindromic 
Repeats‚ CRISPR-associated 
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CV Column volume(s) 
d day(s) 
dATP, dCTP, dGTP, dTTP 
(summarized as dNTP) 
desoxy-adenosin(-cytosin, guanin- thymidin) 
monophosphate 
de novo For the first time, from the beginning (latin: “of 
new”) 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DS Doped SELEX 
DTT Dithiothreitol 
E. coli Escherichia coli 
e.g. for example (latin: exempli gratia) 
EDTA Ethylenediaminetetraacetic acid 
etc.  
F Forward primer (oligo-nucleotide) 
FACS fluorescence activated cell sensing/sorting 
g gram 
G Guanidine nucleotide 
gDNA genomic DNA 
g-force? zuviele Gs 
GFP  green fluorescent protein 
gfp  green fluorescent protein gene 
GOI Gene of interest 
h hours 
HR homologous recombination 
i.e. for example (latin: in exemplia) 
IgG IgG Antibody 
IR Infrared 
ITC Isothermal titration calorimetry 
k kilo 
kb kilobasepairs 
kCPM kilo counts per minute (radioactivity) 
kD dissociation constant 
kDa kilodalton  
kJ kilojoule 
kV kilovolt 
L liter 
LED light-emitting diode 
LiOAc Lithiumacetat 
lnc RNA long non-coding RNA 
LS Light SELEX 
m
2 
square meter 
mCherry mCherry fluorescene protein 
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mCherry mCherry fluorescene protein gene 
MCS multiple cloning site 
min minutes 
miRNA micro RNA 
mL milliliter 
mM millimolar 
MQ MilliQ (purified water) 
mRNA messenger RNA 
ncRNA Non-coding RNA 
N/A not applicable 
N Number of randomized nucleotides 
Nmean Arithmetic mean number of randomized nucleotides 
N=N Nitrogen double bond 
n number 
NEB New England Biolabs 
Neo Neomycin riboswitch gene 
Neo neomycin 
ng nanogram 
NHS N-Hydroxysuccinimid 
nm nanometer 
nM nanomolar 
NMR nuclear mangnetic resonance 
nt nucleotide(s) 
mg milligram 
mL milliliter 
mM millimolar 
OD600 Optical density at 600 nm 
oligo oligonucleotide 
ORI Origin of replication 
P Primer binding site 
PAA polyacrylamide 
PCR polymerase chain reaction 
pers. comm. personal communication 
pH acidity or basicity of an aqueous solution 
pmol picomole 
PNK polynucleotide kinase 
pre-mRNA primary transcript of RNA (unprocessed) 
resp. respective 
R Reverse primer (oligo-nucleotide) 
R
2
 (R square) coefficient of determination 
RNA ribonucleic acid 
RNAi RNA interference 
Rnase Ribonuclease 
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rpm rounds per minute (incubation or plate shakers) 
rRNA ribosomal RNA 
RT Room temperature, 25 °C 
RT-PCR Reverse transcription polymerase chain reaction 
s Second(s) 
S. cerevisiae Saccharomyces cerevisiae 
SAM S-Adenosyl methionine 
SAXS Small-angle X-ray scattering 
SELEX Systematic evolution of ligands by exponential 
enrichment 
sRNA small RNA 
siRNA small interfering RNA 
smFRET Single molecule fluorescence resonance energy 
transfer 
SPR surface plasmon resonance 
SSC saline-sodium citrate 
ssDNA single-stranded DNA 
T temperature 
t time 
TAE Tris base, acetic acid and EDTA buffer solution 
TE Transformation efficieny 
TK Transcription  
TPP thiamine pyrophosphate 
tRNA transfer RNA 
TSS transcription start site 
UTP Uridine-5'-triphosphate 
UTR untranslated region 
UV Ultra violet 
V Volt 
v/v  Volume per volume 
VIS Visible light 
W Watt 
w/v weight per volume 
x  x-fold 
x G times g-force (e.g. 17000 x G) 
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